

## AN ABSTRACT OF THE THESIS OF

Yi Lu for the degree of Doctor of Philosophy in Chemistry presented on August 6, 2018.

Title: Strategies for the Synthesis of Nitrogenous Compounds:  
Aminal Radical Reactions and Pyridinium Oxide Cycloadditions

Abstract approved:

---

Christopher M. Beaudry

Pharmaceuticals, molecular catalysts, and secondary metabolites often contain nitrogen. The problems faced synthesizing compounds which contain nitrogen was because of the Lewis base reactivity of nitrogen lone pairs, and the acidic protons of some nitrogenous functional groups. We developed two methods for the synthesis of nitrogenous compounds. Additionally, we successfully constructed the heterotetracyclic core of himgaline.

The amination radicals were generated by reduction of the corresponding amidine or amidinium ion. The intermediate radicals participate in C–C bond-forming reactions to produce fully substituted amination stereocenters. No toxic additives or reagents are required.

The regioselectivity and diastereoselectivity was investigated in pyridinium oxide cycloadditions using complex substrates. The reaction is reversible under the reaction conditions. High levels of diastereoselectivity and regioselectivity are observed, which can be attributed to minimization of *syn*-pentane interactions in the products.

The stereo- and region-selective intramolecular pyridinium oxide cycloaddition successfully forms two bonds and builds four stereocenters in a single step. These key cycloaddition reactions are particularly suitable to the challenge of preparing multiple rings with control of stereochemistry. It has been shown that the new methodology replacing acid-base strategy would enhance the efficiency of alkaloid synthesis.

©Copyright by Yi Lu  
August 6, 2018  
All Rights Reserved

Strategies for the Synthesis of Nitrogenous Compounds:  
Aminal Radical Reaction and Pyridinium Oxide Cycloadditions

by  
Yi Lu

A THESIS

submitted to

Oregon State University

in partial fulfillment of  
the requirements for the  
degree of

Doctor of Philosophy

Presented August 6, 2018

Commencement June 2019

Doctor of Philosophy thesis of Yi Lu presented on August 6, 2018

APPROVED:

---

Major Professor, representing Chemistry

---

Head of the Department of Chemistry

---

Dean of the Graduate School

I understand that my thesis will become part of the permanent collection of Oregon State University libraries. My signature below authorizes release of my thesis to any reader upon request.

---

Yi Lu, Author



## ACKNOWLEDGEMENTS

I would like to express my thanks to my wife, Wanyu, for all of her support to complete my degree. I would also like to thank my family for the encouragement during my time in Oregon. I would like to thank my mentor, Cem Celik, for all of the help from first to the end. I would like to thank David Schiedler for teaching me in lab and helping with the chapter 1 and 2. I would also like to thank the members of the Beaudry research group, both past and present for their support. I am appreciated for all my friends here. In the end, I would like to thank my advisor, Professor Chris Beaudry, for his guidance over the last six years. Professor Beaudry led me to the field of chemistry, taught me to think critically about chemistry.

## CONTRIBUTION OF AUTHORS

David A. Schiedler assisted with the data collection for chapter 2 and the writing of chapters 2.

## TABLE OF CONTENTS

	<u>Page</u>
1 Introduction.....	2
2 Reductive Synthesis of Amino Radicals for Carbon–Carbon Bond Formation.....	14
2.1. Radicals in the Synthesis of Nitrogen Containing Molecules .....	14
2.2. Result .....	17
3 Cycloadditions of Pyridinium Oxide .....	21
3.1. Intramolecular Pyridinium Oxide Cycloadditions: Regioselectivity and Diastereoselectivity .....	21
3.2. Application of cycloaddition of pyridinium oxide in total synthesis: Progress towards the total synthesis of himgaline .....	29
4 Conclusion .....	41

## LIST OF FIGURES

<u>Figure</u>	<u>Page</u>
1.1 Well-known natural products containing nitrogen .....	2
1.2 Racemic strychnine syntheses over the course of time. ....	12
1.3 Enantioselective strychnine syntheses over the course of time.....	12
2.1 Nitrogen-rich pharmaceuticals which contain aminal.....	16
3.1 Polycyclic architecture featuring bridgehead nitrogen atoms. ....	21
3.2 Representative Galbulimima alkaloids by class.....	31

## LIST OF TABLES

<u>Table</u>	<u>Page</u>
2.1 Development of the amidine reduction reaction .....	18
2.2 Scope of the amidine and amidinium reduction reaction.....	19
3.1.1 Development of the intramolecular pyridinium oxide cycloaddition reaction.....	24
3.1.2 Scope of the intramolecular pyridinium oxide cycloaddition reaction.....	26

## LIST OF SCHEMES

<u>Table</u>	<u>Page</u>
1.1 Alkaloid synthesis utilizing the protecting group strategies.....	3
1.2 Alkaloid synthesis utilizing the strategy of unreactive nitrogenous groups..	3
1.3 Alkaloid synthesis utilizing the strategy of late stage nitrogen installation...	4
1.4 Woodward's retrosynthetic analysis of strychnine.....	5
1.5 Overman's retrosynthetic analysis of strychnine.....	6
1.6 Rawal's retrosynthetic analysis of strychnine.....	7
1.7 Kuehne's retrosynthetic analysis of strychnine. ....	7
1.8 Vollhardt's retrosynthetic analysis of strychnine.....	8
1.9 Martin's retrosynthetic analysis of strychnine.....	8
1.10 Fukuyama's retrosynthetic analysis of strychnine.....	9
1.11 Reissig's retrosynthetic analysis of strychnine.....	9
1.12 Vanderwal's retrosynthetic analysis of strychnine.....	10
1.13 MacMillan's retrosynthetic analysis of strychnine.....	11
2.1 C-C bond formation of $\alpha$ -aminoalkyl radical.....	14
2.2 C-C bond formation of acetal radical.....	15
2-3 C-C bond formation of amination radical by our lab .....	16
2.4 Alternative method to generate amination radicals.....	17
2.5 Generate $\alpha$ -Amino radicals by single electron reduction of iminium ions ..	17
3.1.1 Retrosynthetic analysis of azatricyclo[4.4.1.0 <sup>2,7</sup> ]undecanes.....	22
3.1.2 Intramolecular pyridinium oxide cycloaddition.....	23
3.1.3 Conformation of the cycloaddition product.....	25

3.1.4	Structure conformation of <b>87</b> and <b>100</b> .....	27
3.1.5	Study of the minor product in the cycloaddition reaction.....	28
3.1.6	Study of the mechanism in the cycloaddition I.....	28
3.1.7	Study of the mechanism in the cycloaddition II.....	29
3.2.1	Retrosynthetic analysis of himgaline by Shah.....	32
3.2.2	Retrosynthetic analysis of ent-himgaline by Evans.....	32
3.2.3	Retrosynthetic analysis of ent-himgaline by Ma.....	33
3.2.4	The first generation of himgaline synthesis.....	34
3.2.5	Attempted amination by Mitsunobu reaction.....	35
3.2.6	Attempt to synthesize pyridinium oxide.....	36
3.2.7	Pyridinium oxide formation. ....	36
3.2.8	Study of the cycloaddition of the trisubstituted alkene I.....	37
3.2.9	Study of the cycloaddition of the trisubstituted alkene II.....	38
3.2.10	Study of the cycloaddition of the 2-substituted pyridinium oxide.....	38
3.2.11	The second generation of himgaline synthesis.....	39
3.2.12	Synthesis of heterotetracyclic core of himgaline.....	39
3.2.13	Future work on the himgaline synthesis.....	40

Strategies for the Synthesis of Nitrogenous Compounds:  
Aminal Radical Reactions and Pyridinium Oxide Cycloadditions.

by

Yi Lu

August 6, 2018

LPSC 2pm



## 1. Introduction

Nitrogenous molecules are abundant in nature. Pharmaceuticals, molecular catalysts, and secondary metabolites often contain nitrogen.<sup>1</sup> Some examples of nitrogen containing natural products are morphine, saxitoxin, vallesine, noscapine, daphmanidin E, and strychnine (Figure 1.1).






Figure 1.1 Well-known natural products containing nitrogen.

It is difficult to synthesize nitrogen rich compounds. The problems faced synthesizing compounds which contain nitrogen are the Lewis base reactivity of nitrogen lone pairs and the acidic protons of some nitrogenous functional groups.<sup>2</sup> Solubility and reactivity can sometimes become the major difficulty in synthesizing nitrogen-containing compounds. Overcoming these challenges with the development and application of new methods for synthesis of nitrogen rich compounds is necessary and relevant to the improvement of human health. There are different ways to work with nitrogen in organic molecules. The most common way protection.<sup>3</sup> Examples in which nitrogen protection have been used are dinitrobenzene sulfonyl (DNs) of nitrogen in morphine synthesis of Fukuyama (Scheme 1.1, entry 1),<sup>4</sup> Woodward's nitrogen protection with toluenesulfonyl (Ts) in the strychnine synthesis (Scheme 1.1, entry 2),<sup>5</sup> or *tert*-butoxycarbonyl (Boc) protection of nitrogen in the vallesine synthesis by Movasaghi (Scheme 1.1, entry 3).<sup>6</sup>




Scheme 1.1 Alkaloid synthesis utilizing the protecting group strategies.

Another similar idea to protection is to incorporate unreactive nitrogenous groups and convert them to the final desired functional group later. These methods work well but take additional steps and cause lower yields. One example is daphmanidin E synthesis by Weiss and Carreira (Scheme 1.2), where a nitro group was used to install the nitrogen.<sup>7</sup>



Scheme 1.2 Alkaloid synthesis utilizing the strategy of unreactive nitrogenous groups.

Another common approach is to introduce the nitrogen in at a late stage of synthesis. This strategy usually limits flexibility of the synthetic route and might also increase step count. An example is sieboldine A synthesis by Mukai and co-workers. In this synthesis, it took 19 steps to reach the intermediate which had the nitrogen atom, and only took 5 steps to finish this synthesis (Scheme 1.3).<sup>8</sup>




Scheme 1.3 Alkaloid synthesis utilizing the strategy of late stage nitrogen installation.

Alkaloids are difficult to synthesize due to the mentioned properties of nitrogen atom(s) found in the molecule. Therefore chemists have pursued different strategies to overcome this challenge. The earliest and most followed strategy is based on Lewis acid-base reactions. Recently developed and frequently used strategies are radical- and pericyclic reactions, which have proven to reduce the number of Lewis acid-base manipulations and step count because it forms C-C bonds directly. This outcome requests the need for the development of new methodologies to decrease the step count and improve the yield further. The relevant support is provided by the study of strychnine done by famous synthetic chemists.

The application and importance of radical and pericyclic reactions in the alkaloid syntheses is elaborated in the strychnine synthesis. The first racemic synthesis of strychnine was published by Woodward et al in 1954.<sup>9</sup> The retrosynthetic analysis is shown in Scheme 1.4. Strychnine has hexacyclic ring system with two nitrogen atoms and six stereocenters. At that time it was thought that it is extremely difficult to synthesize an alkaloid such as strychnine's structural complexity. By the standards of the time, the first synthesis is impressive, with a longest linear step count of 28 and an overall yield of 0.0002 %. To overcome the difficulty of alkaloid synthesis, Woodward has used Lewis acid-base type reactions in the strychnine synthesis. The


rings needed to be fused consecutively in Woodward's synthesis, because there were no reactions involved that form multiple C-C bonds in the single step. It is noticeable that Woodward did not use any reactions belonging to the radical or pericyclic reaction type which could have probably decreased the step count and led also to a higher yield. According to their analysis, ( $\pm$ )-strychnine could be obtained from compound **1** via alkylation and allylic rearrangement. The hexacyclic ring system in compound **1** could be yielded from compound **2** by oxidative cyclization which closes ring E and the Dieckmann condensation which forms ring D. The spiro tetracyclic compound **2** should be formed from indole **3**, by which ring F would form by a oxidative veratryl cleavage and the spiro cycle C should be obtained via a Pictet-Spengler cyclization.



Scheme 1.4 Woodward's retrosynthetic analysis of strychnine.


The Overman group reported their enantioselective synthesis of strychnine in 1993.<sup>9</sup> The retrosynthetic analysis of Overman's strychnine synthesis is outlined in Scheme 1.5. The strategy that Overman used to overcome the difficulty of alkaloid synthesis was to set the radical and pericyclic reactions as their key step and to avoid Lewis acid-base reactions. For this purpose, Overman made use of aza-cope rearrangement / Mannich cyclization reactions as their key step. The use of the radical and pericyclic reactions in their synthesis resulted in a decrease of the step count and increased yield. Based on Overman's retrosynthetic analysis, the hexacyclic Wieland-Gumlich aldehyde should be obtained from the tricyclic compound **4**, installing rings B and G by indole synthesis and carbonylation respectively. Tricyclic compound **4** would be yielded from bicyclic compound **5** through a sequential aza-cope rearrangement and

Mannich cyclization accordingly forming ring C and D. Compound **5** would be obtained from cyclopentene **6** via an epoxide opening reaction which could form ring E.




Scheme 1.5 Overman's retrosynthetic analysis of strychnine.

In 1994, Rawal et al published their racemic synthesis of strychnine.<sup>9</sup> Their retrosynthetic analysis of strychnine is depicted in Scheme 1.6. Rawal's strategy to overcome the challenge linked with alkaloid synthesis was also to employ the radical and pericyclic reactions as a key step in order to avoid Lewis acid-base reactions. The further improvement in yield and decrease in the overall step count in Rawal and coworkers synthesis was due to their Diels-Alder key step, belonging to the category of pericyclic reactions. More and more well-known chemists are using radical and pericyclic reaction in their strategies for the syntheses of alkaloids, to avoid the Lewis acid-base reaction disadvantages. Considering Rawal's retrosynthetic analysis, ( $\pm$ )-isostrychnine would be yielded from pentacyclic compound **7** by a Heck reaction which installs ring E. The pentacyclic compound **7** should be obtained from diene **8** via Diels-Alder reaction that installs ring B and D. Pyrroline **8** could be obtained from construction of ring C via ring expansion of cyclopropane **9**.



Scheme 1.6 Rawal's retrosynthetic analysis of strychnine.


Kuehne's group reported their strychnine synthesis in 1998.<sup>9</sup> Their retrosynthetic analysis is shown in Scheme 1.7. They also avoided Lewis acid base reactions and have used in their key step Mannich / Cope / Mannich cyclization to improve yield and step count. According to Kuehne's analysis, Wieland-Gumlich aldehyde would be generated from tetracyclic compound **10** through a nucleophilic cyclization to close ring E and a Wittig reaction to form ring G. Compound **10** could be yielded from compound **11**. This tetracyclic compound **11** should be obtained from iminium ion **12** by Mannich / Cope / Mannich cyclization reactions thereby forming ring C and D.



Scheme 1.7 Kuehne's retrosynthetic analysis of strychnine.


In 2000, Vollhardt and coworkers published their strychnine synthesis (Scheme 1.8).<sup>9</sup> The group used the radical and pericyclic reaction strategy as a key step. Their key step involved a Co-mediated cycloaddition reaction, which is a pericyclic reaction. Vollhardt's retrosynthesis indicates (±)-isostrychnine could be obtained from compound **13** via a Heck reaction with the formation of ring E. The pentacyclic

compound **13** should be obtained through an N-alkylation conjugate addition from tetracyclic compound **14**, which in turn would be yielded from indole **15** by a Co-mediated cycloaddition reaction whereby rings D and F are installed.



Scheme 1.8 Vollhardt's retrosynthetic analysis of strychnine.


Martin and coworkers synthesized strychnine in 2001.<sup>9</sup> Their retrosynthesis is shown in Scheme 1.9. The same trend in favoring radical and pericyclic reactions over Lewis acid-base reactions is also recognizable in their work. Martin group's choice of pericyclic reaction was the hetero Diels-Alder reaction. Considering Martin's retrosynthetic analysis, the Wieland-Gumlich aldehyde could be obtained from pentacyclic compound **16** via functional group manipulations, which could be yielded from biomimetic rearrangement that results in the C and D ring formation from tetracyclic compound **17**. Compound **17** should result diene **18** via a hetero Diels-Alder reaction which installs ring E.



Scheme 1.9 Martin's retrosynthetic analysis of strychnine.


Fukuyama et al. published their strychnine synthesis in 2004.<sup>9</sup> The retrosynthetic analysis is outlined in Scheme 1.10. Their analysis indicates that the Wieland-

Gumlich aldehyde could be obtained from iminium ion **19** via a Mannich reaction that forms ring C and D. Compound **19** should yield from aldehyde **20** through an iminium ion formation which closes ring E. Amine **20** would result from alcohol **21** by a Mitsunobu reaction that installs the amine. The interesting feature about Fukuyama's synthesis is that no radical or pericyclic reaction was used.



Scheme 1.10 Fukuyama's retrosynthetic analysis of strychnine.


In 2010 Reissig et al. reported their strychnine synthesis.<sup>9</sup> Scheme 1.11 depicts their retrosynthetic analysis. Similarly, a radical reaction, SmI<sub>2</sub> induced cyclization cascade reaction, was involved as a key step instead of a Lewis acid-base reaction. Reissig's retrosynthetic analysis indicates that (±)-isostrychnine could be obtained from pentacyclic compound **22**, which should be yielded from tetracyclic compound **23** by installation of ring C through a reductive amination reaction. The tetracyclic compound **23** would be obtained from indole **24** via SmI<sub>2</sub> induced cyclization cascade which results in the formation of ring D and F.



Scheme 1.11 Reissig's retrosynthetic analysis of strychnine.




Vanderwal's strychnine synthesis was published in 2011,<sup>9</sup> and Scheme 1.12 shows the retrosynthetic analysis. The group used an intramolecular Diels-Alder reaction to avoid the Lewis acid-base reaction to obtain a better yield and shorter route. In Vanderwal's analysis, the Wieland-Gumlich aldehyde could be obtained from tetracyclic compound **25** via an intramolecular Diels-Alder reaction which installs rings C and D. Compound **25** should be yielded from Diels-Alder precursor **26**, which should be formed from indole **27** and pyridinium **28** through a Zincle pyridine ring opening reaction.



Scheme 1.12 Vanderwal's retrosynthetic analysis of strychnine.

MacMillan and coworkers published their strychnine synthesis in 2011.<sup>9</sup> The retrosynthetic analysis is outlined in Scheme 1.13. The latest trend of favoring radical and pericyclic reactions over Lewis acid-base reactions is also the case in MacMillan's synthesis. To shorten the route and increase the yield their choice was to employ the enantioselective organo-catalytic alkyne Diels-Alder reaction as their key step, which belongs to the pericyclic reactions. According to MacMillan's retrosynthetic analysis, the Wieland-Gumlich aldehyde should be yielded from tetracyclic compound **29**, which would be obtained from compound **30**. Tetracyclic compound **30** could result diene **31** and alkyne **32** via an enantioselective organocatalytic alkyne Diels-Alder reaction, thereby forming ring C and D.



Scheme 1.13 MacMillan's retrosynthetic analysis of strychnine.

As elaborated on the strychnine example, the total synthesis has gradually been improved over the past 65 years. The first synthesis of strychnine was reported in 1954 with overall 28 steps and 0.0002 % yield. Whereas, the last outlined synthesis was made in 2011 with overall 12 steps and 6 % yield. The strategy to overcome the challenge linked with alkaloid synthesis was also in to use more radical and pericyclic reactions which decreased the step count and increased the yield. Essentially, for the further improvement in yield and decrease in the overall steps, more and more chemists are using radical and pericyclic reaction in their strategies for the syntheses of alkaloids with the aim to avoid the disadvantages of Lewis acid-base reaction. The first strychnine syntheses used more strategies based on Lewis acid-base reactions, whereas the recent strychnine syntheses have avoided this strategy by using more radical or pericyclic reactions.

Figure 1.2 shows the racemic strychnine synthesis made by different research groups. The diagram shows the synthesis step count over the course of time, the red numbers show the amount of newly formed C-C sigma bonds resulted from a single radical or pericyclic reaction step. The figure shows clearly how the step count decreases as the amount of C-C bonds formed by radical or pericyclic reaction increases.




Figure 1.2 Racemic strychnine syntheses over the course of time.

Figure 1.3 shows the enantioselective strychnine synthesis published by different research groups. The racemic and enantioselective syntheses were analyzed separately to obtain a better comparison. The diagram shows the synthesis step count over the course of time, the red numbers show the amount of newly formed C-C sigma bonds resulted from a single radical or pericyclic reaction step. The figure gives the same conclusion as the racemic strychnine synthesis and confirms that the step count decreases as the amount of C-C bonds formed by radical or pericyclic reaction increases.




Figure 1.3 Enantioselective strychnine syntheses over the course of time.


In conclusion, alkaloids have been known for many years as difficult targets. The difficulty in synthesizing them is mainly due to the properties of the nitrogen atom(s) in the compound. Therefore, the common strategies that chemists have pursued to overcome this challenge was to use Lewis acid-base strategy. This approach to the alkaloid syntheses either involved the protection of nitrogen atoms, or the employment of unreactive nitrogen groups, or the installation of the nitrogen atom in the late stage of the total synthesis. This approach resulted in high step counts and low yields. Better solutions were provided by the use of radical or pericyclic reactions instead of Lewis acid-base reactions, which led to shorter synthesis and higher yields.

In addition, the reduction in step count and improvement in yield is due to the development of new methodologies and reagents by organic chemists such as the radical and pericyclic reactions. These new C-C bond formation reactions, based on radical and pericyclic reactions, made the cascade possible and enabled the installation of two rings in one step. Besides the traditional ways to overcome alkaloid syntheses the new methodologies have enriched the toolbox with more alternatives. Therefore, it is worthwhile to discover new methodologies or expand on existing strategies that can overcome the limitations and difficulties in the synthesis of alkaloids.

## 2. Reductive Synthesis of Amino Radicals for Carbon–Carbon Bond Formation

### 2.1. Radicals in the Synthesis of Nitrogen Containing Molecules


In order to mask the Lewis acid-base reactivity of nitrogen while progressing towards the target compound, synthetic chemists often resort to the use of protecting groups. One efficient way to avoid this is single-electron processes, such as radical reactions, which can be used to prevent the interference of the acid–base reactivity of nitrogen.<sup>10</sup> Radical reactions are generally tolerant of N–H bonds, O–H bonds, and heteroatom lone pairs; they are ideally suited to the synthesis of heteroatom-rich substrates. The method of incorporating carbon-centered radicals containing heteroatoms to C–C multiple bonds was introduced more than 50 years ago.<sup>11</sup> Hart and coworkers reported that N,S acetal was converted to the  $\alpha$ -amido radical intermediate, which subsequently formed the bicycle through a 5-exodig radical reaction yielding the formal synthesis of (–)-dehydrohastanecine (Scheme 2.1).<sup>12</sup> The effect of the lone pair on the adjacent nitrogen is to increase the stability of  $\alpha$ -aminoalkyl and  $\alpha$ -amido radicals and forming C–C bonds with the unsaturated carbon atoms.<sup>9</sup> The advantage of this approach is the key disconnection of bonds that would be challenging to be formed with classic cationic or anionic reaction conditions and it has already been demonstrated in the synthesis of heterocycles and alkaloid natural products.



Scheme 2.1 C–C bond formation of  $\alpha$ -aminoalkyl radical.

It is known that carbon-centered radicals having two adjacent heteroatoms form C–C bond after reacting with C–C multiple bonds. The acetal radical **34** was obtained from

acetal **33** by a homolytic C-H bond cleavage with photosensitized benzophenone. Compound **35** forms after the propagation step in which the radical **34** adds across the unsaturated enone system (Scheme 2.2, entry 1). The reaction between 2-bromobenzoyl enamides **36** and AIBN and Bu<sub>3</sub>SnH is thought to form via N,S- and N,O- acetal radical intermediates **37** while the C-C bond forms to yield the ring fused compound **38** (Scheme 2.2, entry 2).<sup>12</sup>



Scheme 2.2 C-C bond formation of acetal radical.

Since the reactivity of acetal and  $\alpha$ -aminoalkyl radicals are well known, the observation of a new reaction was thought to be formed in which the aminoradical adds to alkenes yielding a C-C bond. Based on findings of computational chemistry the aminoradicals are 1–2 kcal/mol lower in energy compared to the analogous  $\alpha$ -aminoalkyl radicals.<sup>13</sup> This result suggested a promising selectivity in favor of aminoradical formation over carbon atoms containing a single nitrogen atom.

Carbon-centered radical reactions of nitrogen-rich functional groups, such as the aminoradical, would enjoy useful application in synthesis. Aminoradicals can be conveniently prepared from condensation reactions, and also can functionalize several nitrogen atoms in the same step of carbon-centered radical reactions. Thus, the aminoradical functional group was identified as a particularly attractive substrate for radical-based bond-forming reactions. It illustrates some biologically active pharmaceuticals

bearing amination (Figure 2.1), that are in the focus of many synthetic organic chemists.<sup>14</sup> Additionally, quinethazone and metolazone are some commercial pharmaceuticals that contain the amination functionality.





Figure 2.1 Nitrogen-rich pharmaceuticals which contain amination.


Previously, our lab reported the formation of C–C bonds using amination radical intermediates.<sup>15</sup> The hydrogen atom abstraction of iodobenzyl-substituted amines **39** undergo radical translocation **40** to generate amination radical intermediates **41**. The amination radicals add to a radical acceptor, such as an electron poor alkene to give products **42** with carbon–carbon bond formation (Scheme 2.3). It demonstrates a new methodology to construct an amination group by forming a carbon–carbon bond allowing new strategies for synthesizing nitrogen-rich compounds.



Scheme 2.3 C–C bond formation of amination radical by our lab

Despite the effectiveness of the radical translocation method to obtain amination radical intermediates, it requires foul smelling or toxic reagents, leading us to develop alternative methods. Ideally, the starting materials should be easy to be obtained and should not need a 2-iodobenzyl substituent. Due to the success of starting material **39** in the radical translocation reaction product **41** should be formed if amination radical **41** is obtained through an alternative radical acceptor (Scheme 2.4). It was expected that


the reaction of known<sup>16</sup> amidine **43** by protonation and single electron reduction should yield intermediate **41**.



Scheme 2.4 Alternative method to generate aminal radicals.

For many years,  $\alpha$ -amino radicals have been formed from iminium ions by single electron reduction with the aid of a proton source.<sup>17</sup> Iminium ion **44** was converted by Martin to the fused bicyclic compound **46** via  $\alpha$ -amino radical **45** (Scheme 2.5).

This strategy had the potential to be widened for the formation of aminal radicals because it was an alternative way to obtain an aminal radical in a regioselective fashion without a poor atom economy in contrast to the C–X bond homolysis method.




Scheme 2.5 Generation of  $\alpha$ -amino radicals by single electron reduction of iminium ions

## 2.2. Result

Searching different conditions for this conversion, amidine **43** was produced with reductive condition in the presence of acrylonitrile (Table 2.1). The use of Zn metal yielded no reaction and LiDBB induced the decomposition (entries 1–4). We found that aminal radical **41** could be generated by protonation and single electron reduction




of **43** with samarium(II) iodide and camphor sulfonic acid (entry 5). Although the reaction worked in the absence of a proton source, yields were significantly lower and some starting material remained unreacted (entry 6). Ammonium chloride was the best choice as proton source because it is mild, cheap, and provided high yields (entry 7). In comparison, the amidine reduction strategy had several advantages over the translocation strategy; it formed quickly at room temperature, no toxic or foul smelling additives were necessary, easy to handle, and higher yields were obtained.



entry	conditions	result
1	Zn (2.2 equiv), HOAc (0.1 M), rt	no reaction
2	Zn (2.2 equiv), HOAc (0.1 M), 118 °C	no reaction
3	LiDBB (2.5 equiv), CSA (1.1 equiv), THF (0.3 M), rt	decomposition
4	LiDBB (2.5 equiv), THF (0.3M), rt	decomposition
5	Sml <sub>2</sub> (2.5 equiv), CSA (1.1 equiv), THF (0.3 M), rt	90%
6	Sml <sub>2</sub> (2.5 equiv), THF (0.3 M), rt	57%
7	Sml <sub>2</sub> (2.5 equiv), NH <sub>4</sub> Cl (1.1 equiv), THF (0.3 M), rt	99%

Table 2.1 Development of the amidine reduction reaction.

After determining the optimal reaction conditions, different substrate combinations were investigated. Quinazolinones which have the N-acyl amidine incorporated in the structure, show interesting biological activities,<sup>18</sup> and can be obtained from the corresponding aminobenzamide derivatives. The reaction between amidine, methyl and tertbutyl acrylates yielded **47b** and **47c** (Table 2.2). The quinazolinone containing a tethered alkene would still react with acrylonitrile **49a**, tert-butyl acrylate **49b**, and methyl acrylate **49c** in a bimolecular radical fashion disfavoring the unimolecular 5-exo-trig radical cyclization that contained the tethered alkene.



<sup>a</sup>CSA was used as the proton source

Table 2.2 Scope of the amidine and amidinium reduction reaction.

The execution of the amidine reduction strategy does not require a benzyl substituent and substrates that contain N-alkyl **54a,b**, N-aryl **54a-c**, and unprotected nitrogen **54a-c** all participated in the reaction. However, for the translocation alternative, completely substituted aminals needed to be formed in high yield through a reductive alkylation of the relevant amidines (**51a-c**, **52a-c**). Interestingly, the amidine containing an even more sterically demanding tert-butyl moiety reacted also to form the desired aminal (**53**). The reaction of dihydroquinazolinone-derived amidinium ion gave an excellent yield with methyl acrylate **55a**, tert-butyl acrylate **55b**, and acrylonitrile **55c**, and this condition also reacted perfectly with amidinium ion to produce fully substituted aminal **56**.

In summary, amination radicals are obtained through the reduction of the relevant amidine and amidinium ions with the employment of a proton source. The C–C bonds are formed by the reaction of radical intermediates and radical acceptors in good yields, without using heavy metal hydrides or thiols. The reaction is versatile and can be used inter- and intramolecularly with high yields. Moreover, this methodology enables fully substituted amination stereocenters formation in good yields.

### 3. Cycloadditions of Pyridinium Oxide

#### 3.1. Intramolecular Pyridinium Oxide Cycloadditions: Regioselectivity, and Diastereoselectivity.

Polycyclic nitrogenous architectures are widespread in biologically active natural products. For example, the tropane alkaloids, exemplified by cocaine, are characterized by a 8-aza-bicyclo[3.2.1]octane structure,<sup>19</sup> **57**. Amaryllidaceae alkaloids such as siculine display a topologically distinct 1-azabicyclo[3.2.1]octane (**58**) core.<sup>20</sup> Homopumiliotoxin 223G is a quinolizidine (**59**) alkaloid isolated from poison dart frogs.<sup>21</sup> Finally, the intriguing structure of the galubalimima alkaloid,<sup>22</sup> himgaline, displays all of these component aza-bicyclic fragments in a 2-azatricyclo[4.4.1.0<sup>2,7</sup>]undecane architecture (**60**) (Figure 3.1.1).





Figure 3.1.1 Polycyclic architecture featuring bridgehead nitrogen atoms.

Such bridged polycyclic alkaloids represent enduring challenges for synthetic chemists. A notable difficulty associated with the synthesis of the natural products shown are the stereogenic carbons bearing nitrogen; the himgaline structure displays stereogenic carbon atoms at all three adjacent positions. Many synthetic strategies have appeared to access nitrogenous bicycles, and particularly successful approaches create multiple rings in a single transformation with control of stereochemical configuration of the substituents.


Cycloaddition reactions are particularly well-suited to the challenge of preparing multiple rings with control of stereochemistry, and we wondered if such polycyclic nitrogenous frameworks could be prepared using a suitable cycloaddition. We decided to focus on the tricyclic motif found in himgaline, complete with the equatorial methyl substituent (**60**). Any method capable of preparing this tricyclic architecture could, at least in principle, be used to construct any of the component bicyclic structures (**57–59**).

We envisioned tricyclic molecules such as **61** arising from a molecule such as enone **62**, which contains functional handles suitable for the construction of additional C–C bonds. Consideration of the topology of **62** suggested that an intramolecular dipolar cycloaddition of a pyridinium oxide with a tethered alkene dipolarophile (**63**) would give the required molecular connectivity. Moreover, it appeared that the diastereoselectivity of the cycloaddition may be controlled by a favored orientation of the molecular tether, which positions the methyl substituent in an equatorial position. The starting material for this cycloaddition would be the relatively simple pyridinium oxide **64** (Scheme 3.1.1). One question was the regiochemistry of the cycloaddition; specifically, regioisomeric tricycle **65** would arise from cycloaddition of conformer **66**, and it was unclear to us which pathway would be favored.




Scheme 3.1.1 Retrosynthetic analysis of azatricyclo[4.4.1.0<sup>2,7</sup>]undecanes.

Pyridinium oxide cycloadditions are well known in the literature. Since the first report by Katrizky in 1988,<sup>23</sup> there have been dozens of intermolecular examples. Intermolecular pyridinium oxide cycloadditions require electron-poor alkene dipolarophiles (e.g. acrylonitrile, maleamide) for successful reactivity. Conversely, intramolecular pyridinium oxide cycloadditions are much fewer in number (Scheme 3.2). Simple *N*-pentenyl pyridinium oxide **67** and tolyl-substituted substrate **68** react to form **69** and **70**, respectively (Scheme 3.2, entry 1).<sup>23</sup> Substrate **71** featured a substituted tether between the dipole and dipolarophile (Scheme 3.2, entry 2).<sup>24</sup> Pyridinium oxide **72** featured a tethered dipolarophile linked to the pyridinium ring, rather than the nitrogen atom (Scheme 3.1.2, entry 3).<sup>25</sup> It is notable that these intramolecular examples do not require a polarized dipolarophile, and simple terminal alkenes participate in the reaction. Gin published an intramolecular cycloaddition where stereochemistry in the tether lead to good diastereofacial discrimination of the dipolarophile (Scheme 3.2, entry 4).<sup>26</sup> However, there has been no systematic study of substitution in such systems.




Scheme 3.1.2 Intramolecular pyridinium oxide cycloaddition.

We began our investigations by preparing cycloaddition substrate **74**. There are multiple synthetic strategies for preparing pyridinium oxides; however, we found the most convenient method was the substitution of alkyl mesylates with 3-hydroxypyridines. The pyridinium oxides was subjected under the published cycloaddition reaction conditions with no reaction in refluxing toluene, while heating to 210°C in different solvents resulted in either no reaction or decomposition (Table 3.1.1, entry 1-3). Under the catalytic acid and base condition, there was no consumption of the starting material (Table 3.1.1, entry 4, 5). With the strong base, substrate was decomposed, and no desired product was obtained in the reaction with Lewis acid. (Table 3.1.1, entry 6,7). Under the condition which was heat the IRX-78 (OH form), we were able to yield cycloaddition product **75** in 60% yield with dr=4:1 (Table 3.1.1, entry 8). The major product of the reaction was the anticipated product, which positions the tether methyl substituent in an equatorial orientation. The structure of the major and minor diastereomers was confirmed by 2D-NMR methods (Scheme 3.1.3). This result is consistent with our prediction, in which substrate control arises from the methyl substituent in an equatorial position. After screening basic reaction conditions, we found that K<sub>2</sub>CO<sub>3</sub> is a suitable reagent in this cycloaddition reaction to give the 83% yield dr=5:1, whereby the decomposition may happen because of the basicity of Cs<sub>2</sub>CO<sub>3</sub> (Table 3.1.1, entry 9-13). Sequestration of the potassium counterion had no effect on the reaction yield (Table 3.1.1, entry 14). The reaction was largely insensitive to the carbonate counter-cation, and both Ag<sub>2</sub>CO<sub>3</sub> (93% yield dr=6:1) and K<sub>2</sub>CO<sub>3</sub> were effective in promoting the reaction (Table 3.1.1, entry 16,17). We found that polar solvents such as acetonitrile gave the best reaction rates, limited the formation of unwanted by products, and gave good selectivities for the major product. The best yields were obtained in butyronitrile at 130 °C, and we settled on these as our standard conditions.



Entry	Reagent	Solvent	Temperature	Result
1	-	Toluene	210°C	no Reaction
2	-	ACN	210°C	no Reaction
3	-	DMSO	150°C	decomposition
4	cat. HCl	ACN	160°C	no Reaction
5	cat. NaOH	ACN	160°C	no Reaction
6	NaOH	ACN	130-150°C	decomposition
7	TiCl <sub>4</sub>	ACN	130-150°C	no Reaction
8	IRX-78 OH form	ACN	130°C	60%, dr=4:1
9	TBAI	ACN	130°C	57%, dr=4:1
10	NEt <sub>3</sub>	ACN	130°C	38%, dr=4:1
11	K <sub>2</sub> CO <sub>3</sub>	ACN	130°C	83%, dr=5:1
12	Cs <sub>2</sub> CO <sub>3</sub>	ACN	130°C	decomposition
13	K <sub>2</sub> HPO <sub>4</sub>	ACN	130°C	82%, dr=5:1
14	K <sub>2</sub> CO <sub>3</sub> , 18-C-6	ACN	130°C	75%, dr=5:1
15	K <sub>2</sub> CO <sub>3</sub> , AgOAc	ACN	130°C	88%, dr=5:1
16	Ag <sub>2</sub> CO <sub>3</sub>	ACN	130°C	93%, dr=6:1
17	Ag <sub>2</sub> CO <sub>3</sub>	BuCN	130°C	87%, dr=7:1

Table 3.1.1 Development of the intramolecular pyridinium oxide cycloaddition reaction.



Scheme 3.1.3 Conformation of the cycloaddition product

We next evaluated additional substrates to investigate the ability of the intramolecular cycloaddition to create other complex bicyclic products. Substitution on the dipolarophile and the pyridinium oxide dipole was well tolerated (Table 3.1.2). Halogen substituents as well as alkyl substitution are tolerated on the pyridinium oxide. Substrate **77** features an additional carbocycle and leads to polycyclic product **78**. Moving the methyl substituent on the tether was possible, and **76** reacted to give good yields of the major product resulting from positioning of the methyl equatorial in the product. Substrate **92** includes two methyl substituents on the tether and cycloaddition leads to product **93**, where both methyl groups are equatorial. In this



case the product ratio was very high, and we could not detect (NMR, TLC) a minor isomer. Conversely, diastereomeric substrate **94** reacts and is required to position one methyl group axial. The reaction was successful; however, as expected, the product isomer ratio was low (~3:1). These results demonstrate that the substitution on the molecular tether can control the stereochemistry of the cycloaddition. Unfortunately, cyclization of trisubstituted alkene dipolarophiles such as **96** and **98** were unsuccessful.






Table 3.1.2 Scope of the intramolecular pyridinium oxide cycloaddition reaction.

In all cases the product ratio was usually quite high, favoring a single major product with equatorial methyl substituent. All major products were separated and the isomer was characterized by 2D-NMR methods. In the case of **86**, we were able to obtain x-ray crystallographic confirmation of the major product structure **87** (Scheme 3.1.4). Additionally, we isolated the minor product of the reaction, and found that it was structure **100**, which is the result of the regioisomeric bond formation and positioning of the methyl substituent axial. Presumably, this avoids *syn*-pentane interactions between the halogen and methyl groups. Other than these two cases, we did not characterize the minor component of the product mixture.




Scheme 3.1.4 Structure conformation of **87** and **100**.

Our original hypothesis was that the stereochemical outcome of the reaction was a result of kinetic control. Specifically, we anticipated that the transition state leading to the major product would be favored if the tether methyl was equatorial. This follows from Katritsky's analysis in his seminal publication on the intermolecular reaction. However, we began to suspect the reaction may actually be under thermodynamic control. We noticed that the product ratios were somewhat variable, and more forcing conditions (higher temperatures, longer reaction times) generally gave superior product ratios. Finally, when the reaction was stopped prior to full consumption of the starting material, the product ratios tended to be lower.



Scheme 3.1.5 Study of the minor product in the cycloaddition reaction.


To unequivocally test whether the reaction was reversible, we isolated major product **87** and minor product **100**, and resubjected it to the reaction conditions respectively. Resubjecting compound **87** and compound **100** to the reaction conditions respectively resulted in equilibration to the same product ratio. This clearly demonstrates that this reaction is under thermodynamic control (Scheme 3.1.6).



Scheme 3.1.6 Study of the mechanism in the cycloaddition I.

We also wondered if the reaction was stereospecific with respect to dipolarophile substituents. We prepared geometrical isomers **101** and **103** and subjected them to our standard conditions (Scheme 3.7). *E*-Isomer **101** reacted to give product **102**, and *Z*-alkene isomer **103** gave **104**; the reaction is stereospecific with respect to the alkene substituents. This also suggests that although the reaction is reversible, it is likely proceeds with concerted bond formation. We observed that the cycloaddition of *E*-configured **101** was a smooth transformation that occurred under our normal conditions. However, *Z*-isomer **103** required longer reaction times. Moreover, the reaction yield was low, likely a result of the production of numerous other by

products. Analysis of crystal structure data for the related product **87** and models of **104** suggested that the pyrrolidine methyl substituent projects directly into the concave bicyclic structure leading to severe steric interactions. Such interactions would destabilize the transition state leading to this molecule, which in turn, would explain why more forcing conditions are required. Furthermore, these steric interactions would also explain the reluctance of trisubstituted alkenes in the cycloaddition reaction.



Scheme 3.1.7 Study of the mechanism in the cycloaddition II.

In conclusion, polycyclic nitrogenous architectures can be constructed by the regioselectivity and diastereoselectivity intramolecular pyridinium oxide cycloaddition reaction. In our investigation, the selectivity arises from the substrate control induced by the orientation of the molecular tether. Furthermore, this cycloaddition is concerted and under thermodynamic control. This methodology will be useful for the alkaloid synthesis to build up multiple bonds and control stereocenters in one step.

### 3.2. Application of cycloaddition of pyridinium oxide in total synthesis: Progress towards the total synthesis of himgaline

The rainforest tree *Galbulimima belgraveana* is distributed in Northern Australgonistia and Papua New Guinea. In Papua New Guinea, people used *Galbulimima* bark as a traditional medicine.<sup>27</sup> The bark was chewed and then swallowed with salt to reduce pain and fever, or it was mixed with leaves of *Homalomena* sp. to induce visions and a dream-like state. Likewise, people used *Galbulimima* bark in combination with tobacco leaves for the treatment of hair lice. The *Galbulimima* bark was found as a rich source of several complex alkaloids since 1965.<sup>22</sup> A total of 28 *Galbulimima*

alkaloids have been isolated, of which 22 have structures which have been elucidated.<sup>28</sup> According to their structural properties, Galbulimima alkaloids are divided into four classes (Figure 3. 2.1): (1) Class I can be represented by himbacine, which has shown potent muscarinic antagonist activity.<sup>29</sup> Based on series structure-activity relationships (SAR) studies, derivatives of himbacine have been developed.<sup>30</sup> Vorapaxar (SCH530348) was approved by FDA in 2014 as a treatment of acute coronary syndrome. Another class I compound (SCH205831) has shown strong antispasmodic activity.<sup>31, 32</sup> (2) Class II can be represented by himandrine (15 members). (3) Class III is represented by GB13 and himgaline. (4) Some miscellaneous compounds belong to Class IV, like GB17. Synthetic chemists are interested in class I began with the biological properties. Despite the potentially high activity of class I, the pharmacological properties of class II–IV remain unexplored. We speculate that the difficulty to screen bioactivity of class II–IV Galbulimima alkaloids was due to the trace amount of these compounds. Although the more structurally complex molecules of class II–IV have received attention from synthetic chemists, the number of steps leads to low yields of these alkaloids. Based on the high potential of class I, the pharmacological properties are possible to be explored if the efficient synthetic route of class II–IV can be found. Himgaline has one of the most complicated structures of the Galbulimima alkaloids. The challenges include a hexacyclic ring system, nine contiguous chiral centers, a tertiary amine attached to three chiral centers, and few functional groups; these features make it the most difficult synthetic target of the Galbulimima alkaloids.






Figure 3.2.1 Representative Galbulimima alkaloids by class.

Shah and co-workers reported the first total synthesis of (-)-himgaline in 2006 (Scheme 3.2.1).<sup>33</sup> Himgaline could be converted from GB13 by conjugate addition and hydrogenation. Hexacyclic intermediate **105** would be converted to GB13 via a decarboxylative intramolecular conjugate addition reaction, followed by a retro conjugate reaction. The intermediate **105** could be built from the pentacyclic intermediate **106**, which was from the tricyclic carboxylic acid **107**. Pentacyclic intermediate **106** was built from a diastereoselective intramolecular Diels-Alder reaction of precursor **108**. This route took 33 steps to finish and the overall yield was 0.3%.



Scheme 3.2.1 Retrosynthetic analysis of himgaline by Shah.


Evans and co-workers reported a total synthesis of ent-himgaline at about the same time (Scheme 3.2.2).<sup>34</sup> As in Shah's synthetic route, they converted ent-GB13 to ent-himgaline. The ent-GB13 was made from imine **109** by enamine aldol cyclization. Multiple steps were required to convert imine **108** from **110**, which was made by enantiopure *trans* decalin **111**. The Evans auxiliary controlled the enantioselective intramolecular Diels–Alder reaction to give *trans* decalin **111** from the triene **112**. Synthesizing the unnatural enantiomer, the Evans group was able to elucidate the absolute stereochemistry of himgaline, which was previously unknown. This route is still a beautiful synthesis, although it took them 32 steps to finish and the unnatural enantiomer of himgaline was obtained in 0.9% yield.



Scheme 3.2.2 Retrosynthetic analysis of ent-himgaline by Evans.

Ma and co-workers reported a racemic synthesis of himgaline in 2011 (Scheme 3.2.3).<sup>35</sup> As before, himgaline could be produced from GB13. Several steps including the key step, SmI<sub>2</sub>-mediated carbonyl–alkene reductive coupling reaction of ketone **113**, gave the GB13 from the pentacyclic intermediate. The carbonyl–alkene reductive coupling precursor **113** was made from silyl enol ether **115** and  $\alpha,\beta$ -unsaturated ketone **114**. This route took 25 steps to finish and the overall yield was 1.2%. It is a good strategy to build the pentacyclic intermediate by using a reductive coupling reaction.

The advantage of our strategy to synthesize himgaline is the use of our intramolecular oxide cycloaddition which could reduce the synthesis steps significantly.




Scheme 3.2.3 Retrosynthetic analysis of ent-himgaline by Ma.

Our first generation retrosynthetic plan is described in Scheme 3.2.4. Himgaline could be broken down to triketone **116** by global deoxygenation and deprotection. The hexacyclic ring **116** could be constructed by the keto enone ester **117** by Michael addition and reductive Claisen condensation. The intramolecular pyridinium oxide cycloaddition, which is the key step of this synthetic route, is expected to selectively give heterotricyclic intermediate **117**. Br<sub>2</sub>-mediated oxidative rearrangement of furanylamine **119** would form the 1,3-dipole **118**, which is the pyridinium oxide cycloaddition precursor. The linear product **119** could be made by Wittig reaction,




Mitsunobu reaction and the epoxide opening reaction. Minimization of A<sup>1,3</sup> strain would give the selective addition and condensation of the trisubstituted alkene. The only stereogenic center in the linear product **119** would be installed by Mitsunobu reaction of sulfonamide. 2,5- disubstituted furan could be installed by epoxide opening reaction.




Scheme 3.2.4 The first generation of himgaline synthesis.

According to our plan, we prepared the starting material for the Wittig reaction as depicted in Scheme 3.2.5. We reduced the lactone **120** to the acetal **121** with DIBAL. Bromination of methyl 2-methoxyacetate **122** by NBS gave bromide **123**, and followed by the Wittig reaction with acetal **121** yielded the Mitsunobu reaction precursor **124** as an alcohol. For the other Mitsunobu reaction partner, we took the Ns protected furanylamine in the acidic condition in presence of methyl vinyl ketone to functionalize the C5 position of the furanylamine to obtain ketone **125**. With this two reaction partners in hand, we tried this reaction with several Mitsunobu reaction conditions, but we did not identify suitable conditions.




Scheme 3.2.5 Attempted amination by Mitsunobu reaction.

Because of this result, we investigated other ways to form the C-N bond such as reductive amination. (Scheme 3.2.6) We treated alcohol **124** with Dess-Martin periodinane (DMP) to gain the corresponding ketone and followed by reductive amination with furanamine in the presence of sodium cyanoborohydride to generate the anime **126** as a pyridinium oxide formation precursor. We tried to set up pyridinium oxide formation using Gin's method,<sup>26</sup> but it only showed the brominated compound **127**. We thought that the second equivalent of bromine in Gin's conditions could cause this undesired reaction, so we changed the reaction condition to only 0.8 equivalents of bromine. However, we were not able to observe our desired product. We also suspected that the relative electron rich alkene in amine **126** causes the undesired bromination reaction, so we tried to start with the simpler alkene which is the vinyl ester. The reaction was set up with vinyl ester **129** under the same reaction condition as we installed the furanamine, but we obtained the undesired conjugated addition product **130** back. At this point, we were facing the problem that the previous chemists did not deal with, so it was important to find other ways to form the pyridinium oxide in our system.




Scheme 3.2.6 Attempt to synthesize pyridinium oxide.

Aggarwal mixed benzyl bromide with 3-hydroxypyridine to yield the pyridinium oxide bromine salt<sup>36</sup> (Scheme 3.2.7, entry 1). Coming up with a similar idea, we treated the alcohol **131** under mesylation condition to yield mesylate **132**. The mesylate was stirred with 3-hydroxypyridine in acetonitrile at 130°C to obtain the corresponding pyridinium oxide **133** successfully in good yield (Scheme 4.7, entry 2).




Scheme 3.2.7 Pyridinium oxide formation.

After having the pyridinium oxide **133** in hand, we started to run the key step of himgaline synthesis. The cycloaddition precursor **133** was treated under the standard reaction condition, but the starting material decomposed (Scheme 3.2.8). This result pushed us to investigate this intermolecular pyridinium cycloaddition reaction more in depth. First, we simplified the alkene and checked what the result was. The desired product was formed if the vinyl ester **137** was the starting material. This result showed that the diastereoselectivity and the regioselectivity of this intramolecular pyridinium oxide cycloaddition matched our expectations.




Scheme 3.2.8 Study of the cycloaddition of the trisubstituted alkene I.

In order to figure out the intramolecular pyridinium oxide cycloaddition, more cycloaddition reactions were attempted. The monosubstituted alkene reacted very well in this reaction in 93% yield (Scheme 3.2.9). The 1,2-disubstituted alkene under the cycloaddition reaction condition only gave 51% yield. The 1,1,2-trisubstituted alkene was decomposed slowly under reaction condition. These results indicated the hindrance of the alkene played a very important rule in the intramolecular pyridinium oxide cycloaddition, and also implied the 1,1,2-trisubstituted alkene might not work in this reaction.




Scheme 3.2.9 Study of the cycloaddition of the trisubstituted alkene II.

We found that the trisubstituted alkene does not generate the intramolecular dipolar pyridinium oxide cycloaddition product. We also found that the substitution of the pyridinium ring at position 2 does not yield cycloaddition product (Scheme 3.2.10). Based on these results we proposed our third generation retrosynthesis of himgaline. This new route has the tricyclic core structure of himgaline already installed and the end game is the functionalization of both  $\alpha$  ester  $\alpha$  keto-amino methynes.




Scheme 3.2.10 Study of the cycloaddition of the 2-substituted pyridinium oxide.

Our retrosynthetic analysis of himgaline is outlined in Scheme 3.2.11. Himgaline could be obtained from peroxide **138** through aldol reaction and directed C-H oxygenation. The peroxide **138** should be available from the  $\alpha$ -amino carbonyl **139** via a radical coupling reaction. Tetracyclic compound **139** should arise from hydroxypyridine and mesylate **140**.




Scheme 3.2.11 The second generation of himgaline synthesis.

After the core structure of himgaline was successfully installed by the key step, we tried to construct the heterotetracyclic core of himgaline through Claisen condensation. The first successful reaction was the methylcuprate conjugate addition to the enone followed by Claisen condensation to give the heterotetracyclic core of himgaline (Scheme 3.2.12).



Scheme 3.2.12 Synthesis of heterotetracyclic core of himgaline.

In the future, the functionalization of himgaline heterotetracyclic core to yield the natural product precursor is proposed in Scheme 3.2.13. The Claisen condensation will yield tetracyclic compound **139**, followed by the radical coupling with alkyne-enone to form dienone **141**.<sup>37</sup> The treatment of **141** with oxygen with Co catalyst would produce peroxide **138**<sup>38</sup> and the treatment with Cu catalyst should result in hydroxyenone **142**.<sup>39</sup> After its protection and reduction, we should obtain the aldol precursor **143** which would lead under basic condition to the hexacyclic compound **144**. After the Barton-McCombie deoxygenation and Wolff-Kishner reduction compound **145** would be obtained. The subsequent deprotection and oxidation should yield himgaline precursor **146**, whereas the conversion of it to himgaline is a known reaction.




Scheme 3.2.13 Future work on the himgaline synthesis.

If this route succeeds as we expect, we would be able to reduce the step count to 16. This is because of the methodology we discovered that belongs to a pericyclic reaction. The stereo and regio-selective intramolecular pyridinium oxide cycloaddition successfully forms two bonds and builds four stereocenters in a single step. This key cycloaddition reactions are particularly suitable to the challenge of preparing multiple rings with control of stereochemistry. It has been shown that the new methodology avoiding acid-base strategy would enhance the efficiency of the alkaloid synthesis.

#### 4. Conclusion


In conclusion, alkaloids have been known for many years as difficult targets. They are important for human health and are difficult to synthesize. The difficulty in synthesizing them is mainly due to the properties of the nitrogen atom(s) in the compound. Hence, the common strategies that chemists have pursued to overcome this challenge was to use Lewis acid-base strategy. This strategy to the alkaloid syntheses either involved the protection of nitrogen atoms, the employment of unreactive nitrogen groups, or the installation of the nitrogen atom in the late stage of the total synthesis. It resulted in high step counts and low yields. Better solutions were provided by the use of radical or pericyclic reactions instead of Lewis acid-base reactions, which led to shorter synthesis and higher yields. As supportive evidence, the investigation of development in the strychnine syntheses over the years clearly shows the conclusion that the step count decreases as the amount of C-C bonds formed by radical or pericyclic reaction increases. This application of this feature is noticeable in the latest alkaloid synthetic approaches made by well-known chemists, which have the following two common features. Using radical or pericyclic reactions (avoiding Lewis acid-base reactions) leads to shorter routes and higher yields. In addition, the reduction in step count and improvement in yield is due to the development of new methodologies and reagents by organic chemists such as the radical and pericyclic reactions. These new C-C bond formation reactions, based on radical and pericyclic reactions, made the cascade possible and enabled the installation of two rings in one step.




In order to further expand the synthetic strategies for the alkaloid syntheses, we also developed a methodology in which the reductive synthesis of aminal radicals were utilized for the Carbon-Carbon bond formation. In our methodology we showed that the C-C bond formation by aminal radicals were successfully obtained from amidine or amidinium. Besides the traditional ways to overcome alkaloid syntheses, the new



methodologies have enriched the toolbox with more alternatives. Hence, it is important to develop new methodologies based on radical and pericyclic reactions to expand the toolbox for synthetic organic chemists. It is worthwhile to discover new methodologies or expand on existing strategies that can overcome the limitations and difficulties in the synthesis of alkaloids even further.



Furthermore, we were also interested in another alkaloid known as himgaline. For its synthesis we developed a pyridinium oxide cycloaddition reaction. We investigated the intramolecular pyridinium oxide cycloaddition reactions on its regioselectivity and diastereoselectivity and were able to successfully showcase the cycloaddition of pyridinium oxide in the progress towards the total synthesis of himgaline core structure.



We have successfully installed the himgaline core, which is the aza-tetracyclic ring system, in four steps. Our key step of the himgaline synthesis is the intramolecular pyridinium oxide cycloaddition which controlled four new stereocenters and formed two bonds in a single step. In addition, polycyclic nitrogenous architectures can be constructed by the regioselectivity and diastereoselectivity intramolecular pyridinium oxide cycloaddition reaction. These intramolecular pyridinium oxide cycloadditions have proven to be a useful tool for the successful polycyclic architecture construction such as in azatricyclo[4.4.1.0<sup>2,7</sup>]undecanes. In our investigation, the selectivity arises from the substrate control induced by the orientation of the molecular tether. Furthermore, this cycloaddition is concerted and under thermodynamic control. This methodology will be useful for the alkaloid synthesis to build up multiple bonds and control stereocenters in one step. The facial diastereoselectivity and the

regioselectivity of the cycloaddition were described, and the cycloaddition was shown to be under thermodynamic control and stereospecific.

1. McGrath, N. A.; Brichacek, M.; Njardarson, J. T. "A Graphical Journey of Innovative Organic Architectures That Have Improved Our Lives" *J. Chem. Ed.* **2010**, *87*, 1348.
2. Hesse, M. *Alkaloid Chemistry*, Wiley, New York, **1981**, pp. 175–200.
3. Wuts, P. G. M.; Greene, T. W. *Protective Groups in Organic Synthesis*. 4th ed.: Wiley: Hoboken, NJ, **2007**, pp. 696–926.
4. Gates, M.; Woodward, R. B.; Newhall, W. F.; Künzli, R. *Org. React.* **1950**, *72*, 1141–1146.
5. Umihara, H.; Yokoshima, S.; Inoue, M.; Fukuyama, T. *Chem. Eur. J.* **2017**, *23*, 6993–6995.
6. Antropow, A. H.; Garcia, N. R.; White, K. L.; Movassaghi, M. *Org. Lett.* **2018**, *20*, 3647–3650.
7. Weiss, M.; Carreira, E. M. *Angew. Chem. Int. Ed.* **2011**, *50*, 11501–11505.
8. Abd El-Gaber, M. K.; Yasuda, S.; Iida, E.; Mukai, C. *Org. Lett.* **2017**, *19*, 320–323.
9. Cannon, J. S.; Overman, L. E. *Angew. Chem. Int. Ed.* **2012**, *51*, 4288–4311.
10. Selected recent examples of radical reactions in alkaloid synthesis: (a) Baran, P. S.; Hafensteiner, B. D.; Ambhaikar, N. B.; Guerrero, C. A.; Gallagher, J. D. *J. Am. Chem. Soc.* **2006**, *128*, 8678–8693. (b) Movassaghi, M.; Schmidt, M. A. *Angew. Chem., Int. Ed.* **2007**, *46*, 3725–3728. (c) Zhang, H.; Curran, D. P. *J. Am. Chem. Soc.* **2011**, *133*, 10376–10378. (d) Palframan, M. J.; Parsons, A. F.; Johnson, P. *Tetrahedron Lett.* **2011**, *52*, 1154–1156.
11. Walling, C.; Huyser, E. S. *Org. React.* **1963**, *13*, 91–149. 12. Zhou, A.; Njogu, M. N.; Pittman, C. U. *Tetrahedron* **2006**, *62*, 4093–4102.
12. Choi, J. K.; Hart, D. J. *Tetrahedron*. **1985**, *41*, 3959–3971.
13. Urry, W. H.; Juveland, O. O. *J. Am. Chem. Soc.* **1958**, *80*, 3322–3328.
14. a) Bhonde, V. R.; Looper, R. E. *J. Am. Chem. Soc.* **2011**, *133*, 20172–20174; (b) Iwamoto, O.; Shinohara, R.; Nagasawa, K. *Chem. Asian J.* **2009**, *4*, 277–285; (c) Fleming, J. J.; McReynolds, M. D.; Du Bois, J. *J. Am. Chem. Soc.* **2007**, *129*, 9964–9975; (d) Jacobi, P. A.; Martinelli, M. J.; Polanc, S. *J. Am. Chem. Soc.* **1984**, *106*, 5594–5598; (e) Tanino, H.; Nakata, T.; Kaneko, T.; Kishi, Y. *J. Am. Chem. Soc.* **1977**, *99*, 2818–2819; (f) Yang, J.; Wu, H.; Shen, L.; Qin, Y. *J. Am. Chem. Soc.* **2007**, *129*, 13794–13795; (g) Zuo, Z.; Xie, W.; Ma, D. *J. Am. Chem. Soc.* **2010**, *132*, 13226–13228; (h) Seo, J. H.; Liu, P.; Weinreb, S. M. *J. Org. Chem.* **2010**, *75*, 2667–2680; (i) Liu, P.; Seo, J. H.; Weinreb, S. M. *Angew. Chem., Int. Ed.* **2010**, *49*, 2000–2003; (j) Belmar, J.; Funk, R. L. *J. Am. Chem. Soc.* **2012**, *134*, 16941–16943; (k) Takano, S.; Sato, T.; Inomata, K.; Ogasawara, K. *J. Chem. Soc., Chem. Commun.* **1991**, 462–464; (l) Morales, C. L.; Pagenkopf, B. L. *Org. Lett.* **2008**, *10*, 157–159; (m) Simone, F. D.;

- Gertsch, J. *Angew. Chem., Int. Ed.* **2010**, *49*, 5767–5770; (n) Simone, F. D.; Gertsch, J.; Waser, J. *Angew. Chem., Int. Ed.* **2010**, *49*, 5767–5770; (o) Mizutani, M.; Inagaki, F.; Nakanishi, T.; Yanagihara, C.; Tamai, I.; Mukai, C. *Org. Lett.* **2011**, *13*, 1796–1799; (p) Xu, Z.; Wang, Q.; Zhu, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 3272–3276.
15. Schiedler, D. A.; Vellucci, J. K.; Beaudry, C. M. *Org. Lett.* **2012**, *14*, 6092–6095.
16. Qin, F.; Wang, L.; Xia, J.; Qian, C.; Sun, J. *Synthesis* **2003**, 1241–1247.
17. Martin, S. F.; Yang, C. P.; Laswell, W. L.; Rüger, H. *Tetrahedron Lett.* **1988**, *29*, 6685–6687.
18. (a) Chawla, A.; Batra, C. *Int. Res. J. Pharm.* **2013**, *4*, 49–58; (b) Rajput, R.; Mishra, A. P. *Int. J. Pharm. Pharm. Sci.* **2012**, *4*, 66–70; (c) Rajput, C. S.; Bora, P. S. *Int. J. Pharm. Bio Sci.* **2012**, *3*, 119–132.
19. Fodor, G.; Dharanipragada, R. *Nat. Prod. Rep.* **1994**, *11*, 443–450.
20. Jin, Z. *Nat. Prod. Rep.* **2013**, *30*, 849–868.
21. Michael, J. P. *Nat. Prod. Rep.* **2008**, *25*, 139–165.
22. (a) Binns, S. V.; Dunstan, P. J.; Guise, G. B.; Holder, G. M.; Hollis, A. F.; McCredie, R. S.; Pinhey, J. T.; Prager, R. H.; Rasmussen, M.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1965**, *18*, 469–573. (b) Mander, L. N.; Prager, R. H.; Rasmussen, M.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1967**, *20*, 1473–1491. (c) Mander, L. N.; Prager, R. H.; Rasmussen, M.; Ritchie, E.; Taylor, W. C. *Aust. J. Chem.* **1967**, *20*, 1705–1718. (d) Mander, L. N.; Willis, A. C.; Herlt, A. J.; Taylor, W. C. *Tetrahedron Lett.* **2009**, *50*, 7089–7092.
23. Sammes, P. G.; Watt, R. A. *J. Chem. Soc., Chem. Commun.* **1976**, *13*, 367–368.
24. Orlek, B. S.; Sammes, P. G.; Weller, D. J. *J. Chem. Soc., Chem. Commun.* **1993**, 1412–1413.
25. Bromidge, S. M.; Archer, D. A. *J. Chem. Soc., Perkin Trans. 1* **1990**, 353–359.
26. Peese, K. M.; Gin, D. Y. *Chem. Eur. J.* **2008**, *14*, 1654–1665.
27. Thomas, B. *PNG. Med. J.* **2006**, *49*, 57–59.
28. Rinner, U.; Lentsch, C.; Aichinger, C. *Synthesis* **2010**, *22*, 3763–3784.
29. Anwar-Ul, S.; Gilani, H.; Cobbin, L. B. *Naunyn-Schmiedeberg's Arch. Pharmacol.* **1986**, *332*, 16–20.
30. (a) Darroch, S. A.; Taylor, W. C.; Choo, L. K.; Mitchelson, F. *Eur. J. Pharmacol.* **1990**, *182*, 131–136. (b) Malaska, M. J.; Fauq, A. H.; Kozikowski, A. P.; Aagaard, P. J.; McKinney, M. *Bioorg. Med. Chem. Lett.* **1995**, *5*, 61–66.
31. Chackalamannil, S.; Xia, Y.; Greenlee, W. J.; Clasby, M.; Doller, D.; Tsai, H.; Asberom, T.; Czarniecki, M.; Ahn, H.; Boykow, G.; Foster, C.; Agans-Fantuzzi, J.; Bryant, M.; Lau, J.; Chintala, M. *J. Med. Chem.* **2005**, *48*, 5884–5887.
32. Siller-Matula, J. M.; Krumphuber, J.; Jilma, B. *Brit. J. Pharmacol.* **2010**, *159*, 502–517.
33. Shah, U.; Chackalamannil, S.; Ganguly, A. K.; Chelliah, M.; Kolotuchin, S.; Buevich, A.; McPhail, A. *J. Am. Chem. Soc.* **2006**, *128*, 12654–12655.
34. Evans, D. A.; Adams, D. J. *J. Am. Chem. Soc.* **2007**, *129*, 1048–1049.
35. Zi, W.; Yu, S.; Ma, D. *Chem. Asian. J.* **2011**, *6*, 573–579.
36. Aggarwal, V. K.; Grainger, R. S.; Newton, G. K.; Spargo, P. L.; Hobson, A. D.; Adams, H. *Org. Biomol. Chem.*, **2003**, *1*, 1884–1893.

37. P. J. Crick, N.S. Simpkins, A. Highton *Org. Lett.*, **2011**, Vol. 13, No. 24, 6472-6475.
38. P. C. Too, Y. L. Tnay, S. Chiba, *Beilstein J. Org. Chem.* **2013**, 9, 1217-1225.
39. K. Sugamoto, Y. Matsushita, T. Matsui, *J. Chem. Soc., Perkin Trans. 1*, **1998**, 3989-3998.
40. Tauber, J; Rohr M; Walter, T; Erkel, G; Opatz, Till, *Org. Biomol. Chem.*, **2015**, 13, 7813-7821.
41. Hay, M. B.; Hardin, A. R.; Wolfe, J. P.; *J. Org. Chem.*, **2005**, 70, 3099-3107
42. Commercially available
43. Stangeland, E. L.; Sammakia, T.; *J. Org. Chem.*, **2004**, 69, 2381-2385
44. Tannert, R.; Milroy, L. G.; Ellinger, B.; Hu, T. S.; Arndt, H. D.; Waldmann, H.; *J. Am. Chem. Soc.*, **2010**, 132, 3063-3077
45. Warner, M. C.; Backvall, J. E.; *Eur. J. Org. Chem.*, **2015**, 2388-2393
46. Paradine, S. M.; Whit, M. C.; *J. Am. Chem. Soc.*, **2012**, 134, 2036-2039

### General Experimental Details:

All reactions were carried out under an inert Ar atmosphere in oven-dried glassware. Flash column chromatography was carried out with SiliaFlash P60, 60 Å silica gel. Reactions and column chromatography were monitored with EMD silica gel 60 F254 plates and visualized with potassium permanganate, iodine, or vanillin stains. Toluene (PhMe) and methylene chloride (DCM) were dried by passage through activated alumina columns. Tetrahydrofuran (THF) was distilled from sodium and benzophenone and stored under an atmosphere of Ar. Butyl nitrite (BuCN) was distilled and stored under an atmosphere of Ar. Methyl acrylate and tert-butyl acrylate were purified by washing with aqueous NaOH, drying over MgSO<sub>4</sub>, and calcium hydride. These reagents were then distilled under vacuum prior to use. Acrylonitrile was distilled under vacuum prior to use. Samarium iodide solutions were prepared with THF distilled from sodium and benzophenone and were stored under an atmosphere of argon with vigorous stirring. The concentrations of the samarium iodide solutions were determined by iodometric titration. All other reagents and solvents were used without further purification from commercial sources.

Instrumentation: FT-IR spectra were obtained on NaCl plates with a PerkinElmer Spectrum Vision spectrometer. Proton and carbon NMR spectra (<sup>1</sup>H NMR and <sup>13</sup>C NMR) were recorded in deuterated chloroform (CDCl<sub>3</sub>) unless otherwise noted on a Bruker 700 MHz Avance III Spectrometer with carbon-optimized cryoprobe and Bruker 400 MHz DPX-400 spectrometer and calibrated to residual solvent peaks. Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sept = septet, br = broad, m = multiplet. FCC: flash column chromatography. Melting points were determined with a Cole-Parmer instrument and are uncorrected.

**3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (47b)** (general reductive alkylation procedure). To a solution of 3-benzylquinazolin-4(3H)-one **75** (0.0327 g, 0.1390 mmol), NH<sub>4</sub>Cl (0.0089 g, 0.166 mmol), and acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) was added a THF solution of SmI<sub>2</sub> (3.7 mL, 0.35 mmol) via syringe pump over a period of 1 hour. At this time, TLC indicated the consumption of 3-benzylquinazolin-4(3H)-one. The reaction mixture was diluted with half-saturated aqueous Rochelle salt. This biphasic mixture was extracted with ethyl acetate. The combined extracts were dried over MgSO<sub>4</sub> and concentrated to give known adduct **47b** (0.0403 g, 0.1383 mmol, 99%) as a colorless oil.

**methyl 3-(3-benzyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (47c).** Following the general reductive alkylation procedure, 3-benzylquinazolin-4(3H)-one **75** (0.0332 g, 0.141 mmol), CSA (0.0358 g, 0.154 mmol), methyl acrylate (0.065 mL, 0.70 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.45 mL, 0.35 mmol) to give known adduct **66** (0.0261 g, 0.080 mmol, 57%) as a colorless oil after purification by FCC (4:1 hexanes:EtOAc).

**3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (50a).**

Following the general reductive alkylation procedure, 3-phenylquinazolin-4(3H)-one **76** (0.0320 g, 0.144 mmol), NH<sub>4</sub>Cl (0.0086 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (4.4 mL, 0.36 mmol) to give **50a** (0.0375 g, 0.135 mmol, 94%) as a colorless oil.

Data for **50a**: R<sub>f</sub> 0.40 (1:1 hexanes:EtOAc); mp = 155–156 °C; IR (thin film) 2929, 2246, 1638, 1496, 1154, 757 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (dd, *J* = 7.7, 1.2 Hz, 1 H), 7.41 (m, 5 H), 7.33 (t, *J* = 7.7 Hz, 1 H), 7.01 (t, *J* = 7.7 Hz, 1 H), 6.84 (d, *J* = 8.1 Hz, 1 H), 5.20 (dt, *J* = 9.0, 4.5 Hz, 1 H), 4.72 (d, *J* = 4.5 Hz, 1 H), 2.36 (m, 2 H), 2.10 (m, 1 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, DEPT) δ C 161.8, 143.6, 140.1, 118.5, 118.2; CH 134.0, 128.9, 129.5, 129.2, 127.4, 127.0, 121.0, 117.0; CH<sub>2</sub> 28.5, 13.7; HRMS (EI) calcd for C<sub>17</sub>H<sub>15</sub>N<sub>3</sub>O [M<sup>+</sup>]: 277.1215, found 277.1227.

**Methyl 3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate (50c).**

Following the general reductive alkylation procedure, 3-phenylquinazolin-4(3H)-one **76** (0.0312 g, 0.140 mmol), CSA (0.0358 g, 0.154 mmol), methyl acrylate (0.07 mL, 0.70 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (4.6 mL, 0.35 mmol) to give **50c** (0.0195 g, 0.0629 mmol, 45%) as a colorless oil after purification by FCC (4:1 hexanes:EtOAc).

Data for **50c**: R<sub>f</sub> 0.44 (1:1 hexanes:EtOAc); mp = 79–80 °C; IR (thin film) 2951, 1732, 1634, 1496, 1169, 756 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.99 (d, *J* = 7.8 Hz, 1 H), 7.42 (m, 4 H), 7.34 (t, *J* = 7.6 Hz, 1 H), 7.29 (m, 1 H), 6.91 (t, *J* = 7.6 Hz, 1 H), 6.72 (d, *J* = 8.1 Hz, 1 H), 5.19 (dd, *J* = 8.5, 3.8 Hz, 1 H), 3.60 (s, 3 H), 2.35 (m, 2 H),

2.22 (m, 1 H), 2.13 (m, 1 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 173.3, 162.3, 144.8, 140.4, 117.4; CH 133.7, 129.3, 129.1, 127.1, 127.0, 119.8, 115.7, 71.3; CH<sub>2</sub> 29.7, 28.5; CH<sub>3</sub> 51.8; HRMS (ESI) calcd for  $\text{C}_{18}\text{H}_{18}\text{N}_2\text{O}_3$  [M+H]: 310.1318, found 310.1304.

***tert*-butyl 3-(4-oxo-3-phenyl-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 50b .**

Following the general reductive alkylation procedure, 3-phenylquinazolin-4(3H)-one (0.0313 g, 0.141 mmol),  $\text{NH}_4\text{Cl}$  (0.0083 g, 0.155 mmol), *tert*-butyl acrylate (0.11 mL, 0.71 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (4.3 mL, 0.35 mmol) to give **50b** (0.0367 g, 0.104 mmol, 74%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **50b**: *R<sub>f</sub>* 0.65 (1:1 hexanes:EtOAc); IR (thin film) 2977, 1724, 1685, 1495, 1152, 753  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.99 (dd,  $J$  = 7.7, 1.6 Hz, 1 H), 7.42 (m, 4 H), 7.34 (ddd,  $J$  = 8.1, 7.6, 1.6 Hz, 1 H), 7.29 (tt,  $J$  = 6.6, 2.1 Hz, 1 H), 6.91 (t,  $J$  = 7.8 Hz, 1 H), 6.73 (d,  $J$  = 8.1 Hz, 1 H), 5.18 (dd,  $J$  = 8.4, 4.2 Hz, 1 H), 2.28 (m, 2 H), 2.14 (m, 2 H), 1.37 (s, 3 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 172.1, 162.3, 145.0, 140.5, 117.2, 81.0; CH 133.7, 129.3, 129.1, 127.2, 127.0, 119.7, 115.5, 71.4; CH<sub>2</sub> 31.1, 28.5; CH<sub>3</sub> 28.0; HRMS (ESI) calcd for  $\text{C}_{21}\text{H}_{24}\text{N}_2\text{O}_3\text{Na}$  [M+Na]: 375.1685, found 375.1674.

**methyl 3-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 48b.**

Following the general reductive alkylation procedure, quinazolin-4(3H)-one (0.0218 g, 0.149 mmol), CSA (0.0381 g, 0.164 mmol), methyl acrylate (0.08 mL, 0.89 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (3.8 mL, 0.37 mmol) to give **48b** (0.0195 g, 0.083 mmol, 56%) as a colorless oil.

Data for **48b**: *R<sub>f</sub>* 0.25 (1:4 hexanes:EtOAc); IR (thin film) 2951, 1725, 1653, 1438, 1382, 1155, 756  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.88 (dd,  $J$  = 7.7, 1.4 Hz, 1 H), 7.30 (ddd,  $J$  = 8.1, 7.3, 1.5 Hz, 1 H), 6.85 (td,  $J$  = 7.5, 1.0 Hz, 1 H), 6.66 (d,  $J$  = 8.0 Hz, 1 H), 6.46 (s, 1 H), 5.05 (t,  $J$  = 4.6 Hz, 1 H), 3.71 (s, 3 H), 2.64 (dt,  $J$  = 17.1, 6.6 Hz, 1 H), 2.57 (dt,  $J$  = 17.1, 6.6 Hz, 1 H), 2.12 (m, 2 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 173.9, 165.3, 147.2, 115.6, 81.1; CH 133.9, 128.5, 119.4, 114.8, 64.7; CH<sub>2</sub> 29.9, 28.1, CH<sub>3</sub> 52.1; HRMS (EI) calcd for  $\text{C}_{12}\text{H}_{14}\text{N}_2\text{O}_3$  [M+]: 234.1005, found 234.1016.

***tert*-butyl 3-(4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 48c.**

Following the general reductive alkylation procedure, quinazolin-4(3H)-one (0.0238 g, 0.162 mmol),  $\text{NH}_4\text{Cl}$  (0.0096 g, 0.178 mmol), *tert*-butyl acrylate (0.12 mL, 0.81 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (5.0 mL, 0.41 mmol) to give **48c** (0.0289 g, 0.105 mmol, 65%) as a colorless oil after purification by FCC (1:3 hexanes:EtOAc).

Data for **48c**: *R<sub>f</sub>* 0.48 (1:2 hexanes:EtOAc); mp = 114–115 °C; IR (thin film) 2978, 2830, 1728, 1677, 1469, 1367, 1154, 757  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.86

(dd,  $J = 7.7, 1.4$  Hz, 1 H), 7.28 (td,  $J = 7.6, 1.6$  Hz, 1 H), 6.96 (s, 1 H), 6.82 (td,  $J = 7.5, 1.0$  Hz, 1 H), 6.64 (d,  $J = 8.0$  Hz, 1 H), 5.01 (t,  $J = 4.6$  Hz, 1 H), 4.56 (s, 1 H), 2.55 (dt,  $J = 17.0, 7.0$  Hz, 1 H), 2.45 (dt,  $J = 17.0, 6.7$  Hz, 1 H), 2.01–2.13 (m, 2 H), 1.44 (s, 9 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 172.8, 165.5, 147.4, 115.5, 81.1; CH 133.8, 128.4, 119.1, 114.7, 64.8; CH<sub>2</sub> 29.9, 29.6, CH<sub>3</sub> 28.3; HRMS (EI) calcd for  $\text{C}_{15}\text{H}_{20}\text{N}_2\text{O}_3\text{Na}$  [ $\text{M}+\text{Na}$ ]: 299.1372, found 299.1379.

**3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 49a.**

Following the general reductive alkylation procedure, 3-(but-3-en-1-yl)quinazolin-4(3H)-one (0.0276 g, 0.138 mmol),  $\text{NH}_4\text{Cl}$  (0.0086 g, 0.160 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (3.7 mL, 0.35 mmol) to give **49a** (0.0307 g, 0.120 mmol, 87%) as a colorless oil after purification by FCC (1:1 hexanes:EtOAc).

Data for **49a**:  $R_f$  0.31 (1:1 hexanes:EtOAc); IR (thin film) 2916, 2246, 1632, 1469, 1394, 759  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.92 (dd,  $J = 7.7, 1.4$  Hz, 1 H), 7.32 (td,  $J = 7.6, 1.5$  Hz, 1 H), 6.93 (t,  $J = 7.5, 1.0$  Hz, 1 H), 6.77 (d,  $J = 8.1$  Hz, 1 H), 5.84 (ddt,  $J = 17.0, 10.2, 6.8$  Hz, 1 H), 5.12 (dd,  $J = 17.1, 1.6$  Hz, 1 H), 5.07 (d,  $J = 10.3$  Hz, 1 H), 4.75 (dd,  $J = 9.2, 3.6$  Hz, 1 H), 4.20 (dt,  $J = 13.7, 6.9$  Hz, 1 H), 2.92 (dt,  $J = 14.0, 7.1$  Hz, 1 H), 2.50–2.36 (m, 1 H), 2.15 (m, 1 H), 1.94 (m, 1 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 162.0, 143.2, 118.5; CH 134.8, 133.5, 128.6, 120.9, 117.1; CH<sub>2</sub> 117.5, 44.9, 32.9, 28.5, 13.6; HRMS (ESI) calcd for  $\text{C}_{15}\text{H}_{18}\text{N}_3\text{O}$  [ $\text{M}+\text{H}$ ]: 256.1450, found 256.1446.

**methyl 3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 49c.**

Following the general reductive alkylation procedure, 3-(but-3-en-1-yl)quinazolin-4(3H)-one (0.0295 g, 0.147 mmol), CSA (0.0375 g, 0.162 mmol), methyl acrylate (0.07 mL, 0.78 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (3.6 mL, 0.37 mmol) to give **17** (0.0264 g, 0.0916 mmol, 62%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **49c**:  $R_f$  0.42 (2:1 hexanes:EtOAc); IR (thin film) 2976, 2926, 1733, 1632, 1468, 1370, 1168, 754  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.91 (dd,  $J = 7.8, 1.4$  Hz, 1 H), 7.28 (td,  $J = 7.6, 1.5$  Hz, 1 H), 6.87 (t,  $J = 7.5, 1.0$  Hz, 1 H), 6.65 (d,  $J = 8.1$  Hz, 1 H), 5.84 (ddt,  $J = 17.1, 10.2, 6.9$  Hz, 1 H), 5.12 (dd,  $J = 17.2, 1.6$  Hz, 1 H), 5.05 (d,  $J = 10.1$  Hz, 1 H), 4.72 (dd,  $J = 8.9, 3.8$  Hz, 1 H), 4.54 (brs, 1 H), 4.19 (dt,  $J = 13.9, 7.0$  Hz, 1 H), 3.67 (s, 3 H), 2.92 (dt,  $J = 13.7, 7.1$  Hz, 1 H), 2.40 (m, 4 H), 2.40 (m, 2 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 173.3, 162.2, 144.3, 117.5; CH 135.1, 133.2, 128.5, 119.6, 115.7, 68.4; CH<sub>2</sub> 117.0, 44.8, 32.7, 29.6, 28.5; CH<sub>3</sub> 51.8; HRMS (ESI) calcd for  $\text{C}_{16}\text{H}_{21}\text{N}_2\text{O}_3$  [ $\text{M}+\text{H}$ ]: 289.1541, found 289.1552.

**tert-butyl 3-(3-(but-3-en-1-yl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 49b.**

Following the general reductive alkylation procedure, 3-(but-3-en-1-yl)quinazolin-4(3H)-one (0.0289 g, 0.144 mmol), CSA (0.0368 g, 0.158 mmol), *tert*-butyl acrylate (0.11 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with

a THF solution of SmI<sub>2</sub> (3.5 mL, 0.36 mmol) to give **49b** (0.0364 g, 0.110 mmol, 77%) as a colorless oil after purification by FCC (3:2 hexanes:EtOAc).

Data for **49b**: R<sub>f</sub> 0.68 (1:1 hexanes:EtOAc); IR (thin film) 2977, 2930, 1726, 1631, 1470, 1367, 1152, 754 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.90 (dd, *J* = 7.8, 1.3 Hz, 1 H), 7.27 (td, *J* = 7.7, 1.4 Hz, 1 H), 6.85 (t, *J* = 7.7 Hz, 1 H), 6.65 (d, *J* = 7.9 Hz, 1 H), 5.84 (ddt, *J* = 17.1, 10.2, 6.9 Hz, 1 H), 5.11 (dd, *J* = 17.1, 1.5 Hz, 1 H), 5.05 (d, *J* = 10.7 Hz, 1 H), 4.70 (dd, *J* = 8.8, 3.9 Hz, 1 H), 4.59 (brs, 1 H), 4.20 (dt, *J* = 13.9, 7.0 Hz, 1 H), 2.90 (dt, *J* = 14.1, 7.2 Hz, 1 H), 2.41 (q, *J* = 7.4 Hz, 1 H), 2.28 (t, *J* = 6.9 Hz, 1 H), 2.09–1.91 (m, 2 H), 1.44 (s, 9 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, DEPT) δ C 172.0, 162.2, 144.5, 117.3, 81.0; CH 135.1, 133.2, 128.4, 119.4, 115.4; CH<sub>2</sub> 117.0, 44.7, 32.7, 31.0, 28.6; CH<sub>3</sub> 28.0; HRMS (ESI) calcd for C<sub>19</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub> [M+H]: 331.2022, found 331.2015.

### **3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 51a.**

Following the general reductive alkylation procedure, 2-methylquinazolin-4(3H)-one (0.0229 g, 0.141 mmol), NH<sub>4</sub>Cl (0.0085 g, 0.155 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.6 mL, 0.35 mmol) to give **51a** (0.0247 g, 0.115 mmol, 81%) as a white solid.

Data for **51a**: R<sub>f</sub> 0.26 (1:2 hexanes:EtOAc); mp = 113–114 °C; IR (thin film) 2927, 2249, 1655, 1486, 754 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86 (dd, *J* = 7.8, 1.4 Hz, 1 H), 7.66 (s, 1 H), 7.33 (td, *J* = 7.6, 1.5 Hz, 1 H), 6.85 (t, *J* = 7.5 Hz, 1 H), 6.66 (d, *J* = 8.0 Hz, 1 H), 4.22 (s, 1 H), 2.67 (ddd, *J* = 17.4, 8.7, 6.3 Hz, 1 H), 2.55 (ddd, *J* = 17.3, 8.7, 6.5 Hz, 1 H), 2.20 (ddd, *J* = 14.5, 8.7, 6.5 Hz, 1 H), 2.09 (ddd, *J* = 14.5, 8.7, 6.3 Hz, 1 H), 1.60 (s, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, DEPT) δ C 164.8, 145.4, 119.6, 113.9, 69.4; CH 134.4, 128.2, 119.3, 114.9; CH<sub>2</sub> 37.3, 12.3; CH<sub>3</sub> 28.5; HRMS (ESI) calcd for C<sub>12</sub>H<sub>14</sub>N<sub>3</sub>O [M+H]: 216.1137, found 216.1129.

### **methyl 3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl) propanoate 51c.**

Following the general reductive alkylation procedure, 2-methylquinazolin-4(3H)-one (0.0211 g, 0.130 mmol), CSA (0.0333 g, 0.143 mmol), methyl acrylate (0.04 mL, 0.65 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (4.9 mL, 0.33 mmol) to give **51c** (0.0179 g, 0.115 mmol, 55%).

### **tert-butyl 3-(2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 51b.**

Following the general reductive alkylation procedure, 2-methylquinazolin-4(3H)-one (0.0220 g, 0.136 mmol), CSA (0.0348 g, 0.150 mmol), *tert*-butyl acrylate (0.10 mL, 0.68 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.3 mL, 0.34 mmol) to give **51b** (0.0227 g, 0.0782 mmol, 58%) as a white solid after purification by FCC (1:1 hexanes:EtOAc).

Data for **51b**: R<sub>f</sub> 0.53 (1:2 hexanes:EtOAc); mp = 116–117 °C; IR (thin film) 2976, 2929, 1709, 1656, 1486, 1368, 1155, 753 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.86 (dd, *J* = 7.9, 1.2 Hz, 1 H), 7.27 (td, *J* = 7.7, 1.4 Hz, 1 H), 6.79 (t, *J* = 7.6 Hz, 1 H),



6.57 (d,  $J = 8.0$  Hz, 1 H), 6.30 (s, 1 H), 4.23 (s, 1 H), 2.55 (dt,  $J = 16.9, 7.1$  Hz, 1 H), 2.44 (dt,  $J = 16.9, 6.8$  Hz, 1 H), 2.11 (dt,  $J = 14.7, 6.9$  Hz, 1 H), 1.99 (dt,  $J = 14.8, 6.9$  Hz, 1 H), 1.53 (s, 3 H), 1.42 (s, 9 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 173.2, 164.4, 145.9, 114.0, 80.9, 70.0; CH 134.0, 128.3, 118.5, 114.5; CH<sub>2</sub> 36.4, 30.0; CH<sub>3</sub> 29.1, 28.0; HRMS (ESI) calcd for  $\text{C}_{16}\text{H}_{23}\text{N}_2\text{O}_3$   $[\text{M}+\text{H}]^+$ : 291.1709, found 291.1697.

### **3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 52a.**

Following the general reductive alkylation procedure, 3-benzyl-2-methylquinazolin-4(3H)-one (0.0356 g, 0.142 mmol),  $\text{NH}_4\text{Cl}$  (0.0093 g, 0.174 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (4.7 mL, 0.36 mmol) to give **52a** (0.0416 g, 0.136 mmol, 96%) as a white solid.

Data for **52a**:  $R_f$  0.45 (1:1 hexanes:EtOAc); mp = 148–149 °C; IR (thin film) 3013, 2249, 1625, 1489, 1397, 1158, 754  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.98 (dd,  $J = 8.0, 1.2$  Hz, 1 H), 7.36–7.25 (m, 6 H), 6.91 (dt,  $J = 7.6, 1.0$  Hz, 1 H), 6.68 (d,  $J = 8.0$  Hz, 1 H), 4.85 (d,  $J = 16.0$  Hz, 1 H), 4.35 (d,  $J = 16.0$  Hz, 1 H), 4.35 (s, 1 H), 2.36 (m, 2 H), 2.12 (m, 1 H), 1.86 (m, 1 H), 1.55 (s, 3 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 163.9, 143.8, 138.7, 119.2, 115.5, 73.4; CH 134.0, 128.9, 128.8, 127.4, 127.3, 119.8, 115.1; CH<sub>2</sub> 45.4, 34.5, 12.3; CH<sub>3</sub> 25.6; HRMS (ESI) calcd for  $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_3$   $[\text{M}+\text{Na}]^+$ : 328.1426, found 328.1415.

### **methyl 3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 52c.**

Following the general reductive alkylation procedure, 3-benzyl-2-methylquinazolin-4(3H)-one (0.0321 g, 0.128 mmol), CSA (0.0328 g, 0.141 mmol), methyl acrylate (0.06 mL, 0.92 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (4.2 mL, 0.32 mmol) to give **52c** (0.0199 g, 0.0588 mmol, 46%) as a white solid after purification by FCC (5:1 hexanes:EtOAc).

Data for **52c**:  $R_f$  0.66 (1:1 hexanes:EtOAc); mp = 136–137 °C; IR (thin film) 2950, 1734, 1624, 1489, 1397, 754  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.97 (d,  $J = 7.7$  Hz, 1 H), 7.35–7.20 (m, 6 H), 6.85 (t,  $J = 7.7$  Hz, 1 H), 6.57 (d,  $J = 8.1$  Hz, 1 H), 4.96 (d,  $J = 15.8$  Hz, 1 H), 4.60 (d,  $J = 15.8$  Hz, 1 H), 4.27 (s, 1 H), 3.59 (s, 3 H), 2.34 (m, 2 H), 2.12 (dt,  $J = 14.7, 5.2$  Hz, 1 H), 2.02 (td,  $J = 10.0, 5.1$  Hz, 1 H), 1.46 (s, 3 H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , DEPT)  $\delta$  C 173.8, 164.2, 144.5, 139.1, 115.2, 74.1; CH 133.6, 128.9, 128.5, 127.4, 127.0, 119.0, 114.4; CH<sub>2</sub> 45.3, 34.0, 28.9; CH<sub>3</sub> 51.8, 26.4; HRMS (ESI) calcd for  $\text{C}_{20}\text{H}_{23}\text{N}_2\text{O}_3$   $[\text{M}+\text{H}]^+$ : 339.1709, found 339.1693.

### ***tert*-butyl 3-(3-benzyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanoate 52b.**

Following the general reductive alkylation procedure, 3-benzyl-2-methylquinazolin-4(3H)-one (0.0331 g, 0.132 mmol),  $\text{NH}_4\text{Cl}$  (0.0080 g, 0.145 mmol), *tert*-butyl acrylate (0.10 mL, 0.66 mmol) in THF (0.50 mL, 0.3 M) were reacted with a THF solution of  $\text{SmI}_2$  (3.4 mL, 0.33 mmol) to give **52b** (0.0322 g, 0.0847 mmol, 64%) as a white solid.

Data for **52b**: *R<sub>f</sub>* 0.40 (3:1 hexanes:EtOAc); mp = 142–143 °C; IR (thin film) 2977, 2930, 1726, 1625, 1489, 1394, 1154, 754 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.96 (d, *J* = 7.7 Hz, 1 H), 7.33–7.20 (m, 5 H), 7.22 (t, *J* = 7.3 Hz, 1 H), 6.83 (t, *J* = 7.5 Hz, 1 H), 6.56 (d, *J* = 7.7 Hz, 1 H), 5.00 (d, *J* = 15.8 Hz, 1 H), 4.54 (d, *J* = 15.9 Hz, 1 H), 4.40 (s, 1 H), 2.27 (m, 2 H), 2.10–1.99 (m, 1 H), 1.42 (s, 3 H), 1.38 (s, 9 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>, DEPT) δ C 172.7, 164.2, 144.6, 139.0, 115.0, 80.8, 74.1; CH 133.6, 128.8, 128.5, 127.3, 126.9, 118.7, 114.2; CH<sub>2</sub> 45.2, 33.8, 30.2; CH<sub>3</sub> 27.9, 26.4; HRMS (ESI) calcd for C<sub>20</sub>H<sub>23</sub>N<sub>2</sub>O<sub>3</sub> [M+H]: 339.1709, found 339.1693.

### **3-(2-(*tert*-butyl)-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 53.**

Following the general reductive alkylation procedure, 2-(*tert*-butyl)quinazolin-4(3H)-one (0.0280 g, 0.138 mmol), CSA (0.0366 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.46 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.7 mL, 0.35 mmol) to give **53** (0.0124 g, 0.0482 mmol, 35%) as a white solid along with 0.0099g of 2-(*tert*-butyl)quinazolin-4(3H)-one after purification by FCC (1:1 hexanes:EtOAc).

Data for **53**: *R<sub>f</sub>* 0.65 (1:2 EtOAc: Hexanes); IR (thin film) 3356, 2921, 2246, 1655 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.79 (dd, *J* = 8.4, 1.4 Hz, 1 H), 6.73 (t, *J* = 7.7 Hz, 1 H), 6.55 (d, *J* = 8.4 Hz, 1 H), 6.10 (s, 1 H), 4.09 (s, 1 H), 2.61–2.66 (m, 1 H), 2.53–2.58 (m, 1 H), 2.03–2.11 (m, 2 H), 1.03 (s, 9 H); <sup>13</sup>C (176 MHz, CDCl<sub>3</sub>) δ C 164.1, 146.5, 134.9, 128.3, 120.0, 118.2, 12.8, 111.6, 43.2, 33.5, 29.9, 24.6, 12.8; HRMS (TOF MS ES<sup>+</sup>) calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O [M+H]: 258.1606, found 258.1599.

### **3-(3-cyclopropyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 54a.**

Following the general reductive alkylation procedure, 3-cyclopropylquinazolin-4(3H)-one (0.0261 g, 0.140 mmol), NH<sub>4</sub>Cl (0.0086 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.7 mL, 0.35 mmol) to give **54a** (0.0340 g, 0.140 mmol, 99%) as a colorless oil.

Data for **54a**: *R<sub>f</sub>* 0.24 (1:1 EtOAc: Hexanes); IR (thin film) 3294, 2929, 2246, 1636 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (dd, *J* = 8.0, 1.6 Hz, 1 H), 7.32 (td, *J* = 8.0, 1.6 Hz, 1 H), 6.90 (ddd, *J* = 8.0, 8.0, 0.8 Hz, 1 H), 6.73 (d, *J* = 8.0 Hz, 1 H), 4.81 (dd, *J* = 9.6, 4.0 Hz, 1 H), 2.69 (ddd, *J* = 9.6, 6.8, 4.0 Hz, 1 H), 2.46 (ddd, *J* = 8.0, 6.4, 4.4 Hz, 2 H), 2.15–2.24 (m, 1 H) 2.01–2.10 (m, 1 H), 1.09–1.17 (m, 1 H), 0.79–0.89 (m, 2 H), 0.61–0.68 (m, 2 H); <sup>13</sup>C (100 MHz, CDCl<sub>3</sub>) δ C 164.4, 143.4, 134.0, 128.6, 120.3, 118.9, 117.4, 116.4, 68.9, 28.5, 27.9, 13.8, 10.2, 6.0; HRMS (EI<sup>+</sup>) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O [M+]: 241.12152, found 241.12128.

### **3-(3-cyclohexyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile 54b**

Following the general reductive alkylation procedure, 3-cyclohexylquinazolin-4(3H)-one (0.0338 g, 0.148 mmol), NH<sub>4</sub>Cl (0.0089 g, 0.166 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.49 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub>

(4.9 mL, 0.37 mmol) to give **54b** (0.0409 g, 0.144 mmol, 97%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **54b**: Rf 0.38 (1:1 EtOAc: Hexanes); IR (thin film) 3284, 2932, 2856, 2245, 1622 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.94 (dd, *J* = 7.7, 1.4 Hz, 1 H), 7.32 (td, *J* = 8.4, 1.4 Hz, 1 H), 6.95 (ddd, *J* = 8.4, 8.4, 1.4 Hz, 1 H), 6.77 (d, *J* = 7.7 Hz, 1 H), 4.82 (dd, *J* = 10.5, 2.8 Hz, 1 H), 4.46 (tt, *J* = 11.9, 3.5 Hz, 1 H), 2.34-2.44 (m, 2 H), 2.23-2.29 (m, 1 H) 1.78-1.92 (m, 6 H), 1.69 (d, *J* = 13.3 Hz, 1 H), 1.54 (qd, *J* = 11.9, 3.5 Hz, 1 H), 1.37-1.45 (m, 3 H), 1.14 (qt, *J* = 9.1, 4.2 Hz, 1 H); <sup>13</sup>C (176 MHz, CDCl<sub>3</sub>) δ C 161.8, 142.9, 133.4, 128.9, 120.8, 119.6, 118.9, 117.1, 63.2, 53.4, 31.8, 31.6, 30.2, 26.1, 25.9, 25.5, 14.0; HRMS (EI+) calcd for C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O [M<sup>+</sup>]: 283.16847, found 283.16723.

### **3-(3-cyclopropyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (54a).**

Following the general reductive alkylation procedure, 3-cyclopropylquinazolin-4(3H)-one (0.0261 g, 0.140 mmol), NH<sub>4</sub>Cl (0.0086 g, 0.158 mmol), acrylonitrile (0.05 mL, 0.76 mmol) in THF (0.47 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (3.7 mL, 0.35 mmol) to give **54a** (0.0340 g, 0.140 mmol, 99%) as a colorless oil.

Data for **54a**: Rf 0.24 (1:1 EtOAc: Hexanes); IR (thin film) 3294, 2929, 2246, 1636 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (dd, *J* = 8.0, 1.6 Hz, 1 H), 7.32 (td, *J* = 8.0, 1.6 Hz, 1 H), 6.90 (ddd, *J* = 8.0, 8.0, 0.8 Hz, 1 H), 6.73 (d, *J* = 8.0 Hz, 1 H), 4.81 (dd, *J* = 9.6, 4.0 Hz, 1 H), 2.69 (ddd, *J* = 9.6, 6.8, 4.0 Hz, 1 H), 2.46 (ddd, *J* = 8.0, 6.4, 4.4 Hz, 2 H), 2.15-2.24 (m, 1 H) 2.01-2.10 (m, 1 H), 1.09-1.17 (m, 1 H), 0.79-0.89 (m, 2 H), 0.61-0.68 (m, 2 H); <sup>13</sup>C (100 MHz, CDCl<sub>3</sub>) δ C 164.4, 143.4, 134.0, 128.6, 120.3, 118.9, 117.4, 116.4, 68.9, 28.5, 27.9, 13.8, 10.2, 6.0; HRMS (EI+) calcd for C<sub>14</sub>H<sub>15</sub>N<sub>3</sub>O [M<sup>+</sup>]: 241.12152, found 241.12128.

### **3-(3-cyclohexyl-4-oxo-1,2,3,4-tetrahydroquinazolin-2-yl)propanenitrile (54b).**

Following the general reductive alkylation procedure, 3-cyclohexylquinazolin-4(3H)-one (0.0338g, 0.148mmol), NH<sub>4</sub>Cl (0.0089g, 0.166mmol), acrylonitrile (0.05mL, 0.76 mmol) in THF (0.49 mL, 0.3 M) were reacted with a THF solution of SmI<sub>2</sub> (4.9 mL, 0.37 mmol) to give **54b** (0.0409 g, 0.144 mmol, 97%) as a colorless oil after purification by FCC (3:1 hexanes:EtOAc).

Data for **54b**: Rf 0.38 (1:1 EtOAc: Hexanes); IR (thin film) 3284, 2932, 2856, 2245, 1622 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.94 (dd, *J* = 7.7, 1.4 Hz, 1 H), 7.32 (td, *J* = 8.4, 1.4 Hz, 1 H), 6.95 (ddd, *J* = 8.4, 8.4, 1.4 Hz, 1 H), 6.77 (d, *J* = 7.7 Hz, 1 H), 4.82 (dd, *J* = 10.5, 2.8 Hz, 1 H), 4.46 (tt, *J* = 11.9, 3.5 Hz, 1 H), 2.34-2.44 (m, 2 H), 2.23- 2.29 (m, 1 H) 1.78-1.92 (m, 6 H), 1.69 (d, *J* = 13.3 Hz, 1 H), 1.54 (qd, *J* = 11.9, 3.5 Hz, 1 H), 1.37-1.45 (m, 3 H), 1.14 (qt, *J* = 9.1, 4.2 Hz, 1 H); <sup>13</sup>C (176 MHz, CDCl<sub>3</sub>) δ C 161.8, 142.9, 133.4, 128.9, 120.8, 119.6, 118.9, 117.1, 63.2, 53.4, 31.8, 31.6, 30.2, 26.1, 25.9, 25.5, 14.0; HRMS (EI+) calcd for C<sub>17</sub>H<sub>21</sub>N<sub>3</sub>O [M<sup>+</sup>]: 283.16847, found 283.16723.

### **General procedure for synthesizing pyridinium oxide:**

To a solution of the corresponding alcohol(1eq) in DCM (0.2M) at 0 °C was added Et<sub>3</sub>N (1.5eq) and then methanesulfonyl chloride (1.5eq). The mixture was stirred for 1 h at 0 °C and slowly warming up to room temperature for 3hr before saturated aqueous NH<sub>4</sub>Cl solution was added. This mixture was extracted with DCM three times. The combined extracts were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The mixture of the crude corresponding methylate (1eq), 3-hydroxypyridine (2eq) in BuCN(20M) were heated up to 130 °C for 6 hr in sealed tube to give pyridinium oxide after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.08 to 1:0.15).

**1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (74)** *Following the general reductive alkylation procedure*, hex-5-en-2-ol<sup>40</sup> (1g, 10 mmol) in DCM (20 mL) at 0 °C was added Et<sub>3</sub>N (2.07 mL, 15 mmol) and then methanesulfonyl chloride (1.17 mL, 15 mmol). The mixture of the crude methylate (89mg, 0.5 mmol), 3-hydroxypyridine (95mg, 1 mmol) in BuCN(2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **74**(68mg, 67% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.06 to 1:0.12).

Data for **74**: R<sub>f</sub> 0.20 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3368, 3077, 2931, 1588, 1507, 1379 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.75 (t, *J* = 2.1, 1 H), 7.15 (dd, *J* = 8.8, 1.8 Hz, 1 H), 7.12 (dd, *J* = 8.8, 5.3 Hz, 1 H), 7.00 (d, *J* = 5.3 Hz, 1 H), 5.60 (ddt, *J* = 16.7, 10.5, 6.7 Hz, 1 H), 4.92 (d, *J* = 10.5 Hz, 1 H), 4.89 (d, *J* = 16.7 Hz, 1 H), 4.06 (dq, *J* = 8.8, 6.8 Hz, 1 H), 1.79–1.91 (m, 4 H), 1.48 (d, *J* = 6.8 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 170.1, 135.7, 134.5, 131.5, 126.8, 119.8, 116.7, 66.6, 35.6, 29.7, 21.8; HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>NO [M<sup>+</sup>]: 178.1232, found 277.1238.

**1-(3-methylpent-4-en-1-yl)pyridin-1-ium-3-olate (76)** *Following the general reductive alkylation procedure*, 3-methylpent-4-en-1-ol<sup>41</sup> (500 mg, 5 mmol) in DCM (25 mL) at 0 °C was added Et<sub>3</sub>N ( 1.05mL, 7.5 mmol) and then methanesulfonyl chloride (0.6 mL, 75 mmol). The mixture of the crude methylate (165mg, 1 mmol), 3-hydroxypyridine (340mg, 4 mmol) in ACN(2 ml) were heated up to 100 °C for 10 hr in sealed tube to give **76** (165mg, 75% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.1 to 1:0.12).

Data for **76**: R<sub>f</sub> 0.20 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3367, 3072, 2966, 1566, 1506 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.43 (s, 1 H), 7.30 (d, *J* = 9.3 Hz, 1 H), 7.23 (dd, *J* = 8.9, 4.9 Hz, 1 H), 7.00 (d, *J* = 4.9 Hz, 1 H), 5.67 (ddd, *J* = 17.3, 10.9, 7.7 Hz, 1 H), 5.12 (d, *J* = 11.1 Hz, 1 H), 5.01 (d, *J* = 17.3 Hz, 1 H), 4.11 (ddd, *J* = 13.3, 8.5, 5.2 Hz, 1 H), 4.02 (dd, *J* = 13.3, 7.9 Hz, 1 H), 2.20 (brs, 1 H), 2.00 (dtd, *J* = 16.3, 8.8, 5.2 Hz, 1 H), 1.92–1.85 (m, 4 H), 1.10 (d, *J* = 6.9 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 160.0, 141.0, 133.0, 131.8, 130.5, 128.0, 115.5, 68.4, 43.8, 36.0, 21.5, 21.2; HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>NO [M<sup>+</sup>]: 178.1232, found 277.1236.

**1-(cyclohex-3-en-1-ylmethyl)pyridin-1-ium-3-olate (78)** *Following the general reductive alkylation procedure*, cyclohex-3-en-1-ylmethanol<sup>42</sup> (1g, 10 mmol) in DCM (20 mL) at 0 °C was added Et<sub>3</sub>N (2.07 mL, 15 mmol) and then methanesulfonyl chloride (1.17 mL, 15 mmol). The mixture of the crude methylate (89mg, 0.5 mmol), 3-hydroxypyridine (95mg, 1 mmol) in BuCN (2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **78**(68mg, 67% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.06 to 1:0.12).

Data for **78**: R<sub>f</sub> 0.20 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3368, 3077, 2931, 1588, 1563, 1507, 1379 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.75 (t, *J* = 2.1, 1 H), 7.15 (dd, *J* = 8.8, 1.8 Hz, 1 H), 7.12 (dd, *J* = 8.8, 5.3 Hz, 1 H), 7.00 (d, *J* = 5.3 Hz, 1 H), 5.60 (ddt, *J* = 16.7, 10.5, 6.7 Hz, 1 H), 4.92 (d, *J* = 10.5 Hz, 1 H), 4.89 (d, *J* = 16.7 Hz, 1 H), 4.06 (dq, *J* = 8.8, 6.8 Hz, 1 H), 1.79–1.91 (m, 4 H), 1.48 (d, *J* = 6.8 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 170.1, 135.7, 134.5, 131.5, 126.8, 119.8, 116.7, 66.6, 35.6, 29.7, 21.8; HRMS (EI) calcd for C<sub>11</sub>H<sub>15</sub>NOCl [M<sup>+</sup>]: 178.1232, found 177.1238.

**6-chloro-1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (80)** *Following the general reductive alkylation procedure*, hex-5-en-2-ol<sup>40</sup> (1g, 10 mmol) in DCM (20 mL) at 0 °C was added Et<sub>3</sub>N (2.07 mL, 15 mmol) and then methanesulfonyl chloride (1.17 mL, 15 mmol). The mixture of the crude methylate (60mg, 0.34 mmol), 6-chloropyridin-3-ol (88mg, 0.68 mmol) in BuCN(2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **80**(49mg, 48% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.06 to 1:0.08).

Data for **80** in acid: R<sub>f</sub> 0.28 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3390, 3076, 2934, 1581, 1499, 1374 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 9.47 (d, *J* = 2.3, 1 H), 8.07 (dd, *J* = 8.6, 2.3 Hz, 1 H), 7.72 (d, *J* = 8.6 Hz, 1 H), 7.00 (d, *J* = 5.3 Hz, 1 H), 5.71 (ddt, *J* = 16.4, 10.4, 6.4 Hz, 1 H), 5.30 (tq, *J* = 6.8, 6.3 Hz, 1 H), 5.03 (d, *J* = 11.6 Hz, 1 H), 5.01 (d, *J* = 16.9 Hz, 1 H), 2.07–2.22 (m, 4 H), 1.73 (d, *J* = 6.3 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 158.9, 135.0, 134.9, 133.6, 132.1, 129.6, 117.3, 65.2, 35.4, 29.9, 21.0; HRMS (EI) calcd for C<sub>11</sub>H<sub>15</sub>NOCl [M<sup>+</sup>]: 212.0842, found 212.0832.

**6-bromo-1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (82)** *Following the general reductive alkylation procedure*, hex-5-en-2-ol<sup>40</sup> (1g, 10 mmol) in DCM (20 mL) at 0 °C was added Et<sub>3</sub>N (2.07 mL, 15 mmol) and then methanesulfonyl chloride (1.17 mL, 15 mmol). The mixture of the crude methylate (45mg, 0.25 mmol), 6-bromopyridin-3-ol (89mg, 0.51 mmol) in BuCN(2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **82**(mg, 46% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.08 to 1:0.15).

Data for **82** in acid: R<sub>f</sub> 0.22 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3404, 2978, 1578, 1494, 1374 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.76 (d, *J* = 2.5, 1 H), 7.43 (d, *J* = 9.3 Hz, 1 H), 7.72 (d, *J* = 8.6 Hz, 1 H), 7.24 (dd, *J* = 9.6, 3.2 Hz, 1 H),

5.72 (ddt,  $J = 16.6, 10.4, 6.3$  Hz, 1 H), 5.03–5.01 (m, 3 H), 1.92–2.10 (m, 4 H), 1.67 (d,  $J = 6.8$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  168.3, 136.5, 135.5, 133.2, 132.4, 116.9, 109.7, 65.6, 35.8, 29.8, 21.3; HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{15}\text{NOBr}$  [ $\text{M}^+$ ]: 256.0337, found 256.0324.

**1-(hex-5-en-2-yl)-4-methylpyridin-1-ium-3-olate (84)** *Following the general reductive alkylation procedure*, hex-5-en-2-ol<sup>40</sup> (1g, 10 mmol) in DCM (20 mL) at 0 °C was added  $\text{Et}_3\text{N}$  (2.07 mL, 15 mmol) and then methanesulfonyl chloride (1.17 mL, 15 mmol). The mixture of the crude methylate (89mg, 0.5 mmol), 4-methylpyridin-3-ol (220mg, 2 mmol) in BuCN(2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **84**(50mg, 48% two steps) after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.08 to 1:0.12).

Data for **84** in acid:  $R_f$  0.22 (1:0.1 DCM:10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 3384, 3079, 2980, 1506, 1361  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  7.26 (s, 1 H), 7.04 (d,  $J = 5.5$  Hz, 1 H), 6.94 (d,  $J = 5.2$  Hz, 1 H), 5.58 (ddt,  $J = 16.6, 10.6, 6.3$  Hz, 1 H), 4.89 (d,  $J = 10.6$  Hz, 1 H), 4.87 (d,  $J = 16.6$  Hz, 1 H), 3.99 (tq,  $J = 7.3, 6.8$ , 1 H), 2.19 (s, 3 H), 1.75–1.87 (m, 4 H), 1.44 (d,  $J = 6.8$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  169.3, 137.5, 135.8, 134.8, 129.3, 120.9, 116.7, 66.6, 35.7, 29.8, 21.8, 18.6; HRMS (EI) calcd for  $\text{C}_{12}\text{H}_{18}\text{NO}$  [ $\text{M}^+$ ]: 192.1388, found 192.1378.

**(E)-6-chloro-1-(7-ethoxy-7-oxohept-5-en-2-yl)pyridin-1-ium-3-olate (86)**

*Following the general reductive alkylation procedure*, ethyl (E)-6-hydroxyhept-2-enoate<sup>43</sup> (1g, 5.8 mmol) in DCM (11.6 mL) at 0 °C was added  $\text{Et}_3\text{N}$  (1.21 mL, 8.7 mmol) and then methanesulfonyl chloride (0.68 mL, 8.7 mmol). The mixture of the crude methylate (511 mg, 2.04 mmol), 6-chloropyridin-3-ol (531 mg, 4.09 mmol) in BuCN(0.1 mL) were heated up to 130 °C for 6 hr in sealed tube to give **86** (55mg, 44% two steps) after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.06 to 1:0.012).

Data for **86** in acid:  $R_f$  0.36 (1:0.1 DCM:10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 3388, 2983, 1713, 1588, 1506, 1371  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  9.53 (s, 1 H), 8.05 (d,  $J = 8.6$  Hz, 1 H), 7.73 (d,  $J = 8.6$  Hz, 1 H), 6.82 (dt,  $J = 14.4, 6.5$  Hz, 1 H), 5.80 (d,  $J = 15.5$  Hz, 1 H), 5.27 (quint,  $J = 6.7$  Hz, 1 H), 4.17 (q,  $J = 7.0$  Hz, 2 H), 2.33 (quint,  $J = 7.3$  Hz, 1 H), 2.27 (q,  $J = 6.4$  Hz, 2 H), 2.21 (quint,  $J = 7.3$  Hz, 1 H), 1.76 (d,  $J = 6.8$  Hz, 3 H), 1.27 (d,  $J = 7.4$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  165.8, 158.8, 144.5, 135.1, 133.6, 132.1, 129.7, 123.7, 65.0, 60.6, 34.7, 28.3, 21.0, 14.2; HRMS (EI) calcd for  $\text{C}_{14}\text{H}_{19}\text{NO}_3\text{Cl}$  [ $\text{M}^+$ ]: 284.1053, found 284.1048.

**(E)-6-bromo-1-(7-ethoxy-7-oxohept-5-en-2-yl)pyridin-1-ium-3-olate (88)**

*Following the general reductive alkylation procedure*, ethyl (E)-6-hydroxyhept-2-enoate<sup>43</sup> (1g, 5.8 mmol) in DCM (11.6 mL) at 0 °C was added  $\text{Et}_3\text{N}$  (1.21 mL, 8.7 mmol) and then methanesulfonyl chloride (0.68 mL, 8.7 mmol). The mixture of the crude methylate (25 mg, 0.1 mmol), 6-bromopyridin-3-ol (34 mg, 0.2 mmol) in BuCN(0.2 mL) were heated up to 130 °C for 6 hr in sealed tube to give **88** (14.4 mg, 37% two steps) after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.06).

Data for **88** in acid:  $R_f$  0.36 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3396, 3056, 2981, 1711, 1493, 1369 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>)  $\delta$  9.62 (s, 1 H), 7.96 (d,  $J$  = 8.7 Hz, 1 H), 7.90 (d,  $J$  = 8.7 Hz, 1 H), 6.83 (dt,  $J$  = 15.7, 6.8 Hz, 1 H), 5.80 (d,  $J$  = 15.9 Hz, 1 H), 5.25 (quint,  $J$  = 7.0 Hz, 1 H), 4.17 (q,  $J$  = 7.0 Hz, 2 H), 2.35 (quint,  $J$  = 7.3 Hz, 1 H), 2.27 (q,  $J$  = 6.4 Hz, 2 H), 2.21 (quint,  $J$  = 7.3 Hz, 1 H), 1.76 (d,  $J$  = 6.8 Hz, 3 H), 1.27 (d,  $J$  = 7.4 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>)  $\delta$  165.7, 159.2, 144.5, 134.6, 133.7, 133.2, 123.6, 123.3, 68.2, 60.5, 34.8, 28.2, 21.1, 14.2; HRMS (EI) calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>3</sub>Br [M<sup>+</sup>]: 328.5048, found 328.5055.

**1-((2S,4R)-4-methylhex-5-en-2-yl)pyridin-1-ium-3-olate (92)** *Following the general reductive alkylation procedure*, (4R)-4-methylhex-5-en-2-ol<sup>44</sup> (120 mg, 1.05 mmol) in DCM (5mL) at 0 °C was added Et<sub>3</sub>N (0.22 mL, 1.58 mmol) and then methanesulfonyl chloride (0.13 mL, 1.58 mmol). The mixture of the crude methylate (165 mg, 0.86 mmol), 3-hydroxypyridine (164 mg, 1.72 mmol) in BuCN (2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **92** (105mg, 55% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.06 to 1:0.1).

Data for **92**:  $R_f$  0.25 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3388, 2979, 2935, 1728, 1579, 1496, 1374 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>)  $\delta$  8.95 (s,  $J$  = 1 H), 8.39 (d,  $J$  = 5.0 Hz 1 H), 7.80 (d,  $J$  = 6.8 Hz, 1 H), 7.99 (d,  $J$  = 5.3 Hz, 1 H), 5.36 (m 1 H), 5.26 (m, 1 H), 4.72 (quint,  $J$  = 7.6 Hz, 1 H), 4.10 (quint,  $J$  = 7.2 Hz, 1 H), 1.98–2.05 (m, 2 H), 1.95–1.89 (m, 2 H), 1.67 (d,  $J$  = 6.4 Hz, 3 H), 1.57 (d,  $J$  = 6.6 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>)  $\delta$  160.0, 141.0, 133.0, 131.9, 130.5, 128.0, 115.5, 68.4, 43.8, 36.0, 21.5, 21.2; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1384.

**(E)-1-(hept-5-en-2-yl)pyridin-1-ium-3-olate (101)** *Following the general reductive alkylation procedure*, (E)-hept-5-en-2-ol<sup>45</sup> (400mg, 3.5 mmol) in DCM (17mL) at 0 °C was added Et<sub>3</sub>N (0.74 mL, 5.3 mmol) and then methanesulfonyl chloride (0.41 mL, 5.3 mmol). The mixture of the crude methylate (38 mg, 0.2 mmol), 3-hydroxypyridine (38 mg, 0.4 mmol) in BuCN (2 drops) were heated up to 130 °C for 6 hr in sealed tube to give **101** (27.5mg, 55% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.08 to 1:0.15).

Data for **101**:  $R_f$  0.20 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3390, 3059, 2936, 1586, 1493, 1384 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>)  $\delta$  8.95 (s,  $J$  = 1 H), 8.39 (d,  $J$  = 5.0 Hz 1 H), 7.80 (d,  $J$  = 6.8 Hz, 1 H), 7.99 (d,  $J$  = 5.3 Hz, 1 H), 5.36 (m 1 H), 5.26 (m, 1 H), 4.72 (quint,  $J$  = 7.6 Hz, 1 H), 4.10 (quint,  $J$  = 7.2 Hz, 1 H), 1.98–2.05 (m, 2 H), 1.95–1.89 (m, 2 H), 1.67 (d,  $J$  = 6.4 Hz, 3 H), 1.57 (d,  $J$  = 6.6 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>)  $\delta$  159.1, 132.9, 132.6, 130.7, 128.5, 127.8, 127.7, 69.0, 36.5, 28.8, 21.8, 12.9; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1384.

**(Z)-1-(hept-5-en-2-yl)pyridin-1-ium-3-olate (103)** *Following the general reductive alkylation procedure*, (Z)-hept-5-en-2-ol<sup>46</sup> (140mg, 1.23 mmol) in DCM (6.2 mL) at 0 °C was added Et<sub>3</sub>N (0.26 mL, 1.84 mmol) and then methanesulfonyl chloride (0.145 mL, 1.84 mmol). The mixture of the crude methylate (100 mg, 0.52 mmol), 3-hydroxypyridine (99 mg, 1.04 mmol) in BuCN (3 drops) were heated up to 130 °C for 6 hr in sealed tube to give **103** (75mg, 62% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.06 to 1:0.12).

Data for **103**: R<sub>f</sub> 0.20 (1:0.1 DCM:10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3382, 3024, 2919, 1567, 1505, 1507, 1372 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.44 (s, *J* = 1 H), 7.27 (m, 1 H), 7.20 (d, *J* = 8.8 Hz, 1 H), 7.99 (d, *J* = 5.3 Hz, 1 H), 5.52 (dq, *J* = 13.3, 7.0 Hz, 1 H), 5.27 (m, 1 H), 4.89 (d, *J* = 16.7 Hz, 1 H), 4.10 (quint, *J* = 7.2 Hz, 1 H), 1.83–1.98 (m, 4 H), 1.58 (d, *J* = 6.8 Hz, 3 H), 1.50 (d, *J* = 7.2 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 170.3, 134.6, 134.6, 131.9, 127.3, 126.7, 126.5, 119.3, 66.8, 36.4, 23.0, 21.9, 12.9; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1386.

#### General procedure for the pyridinium oxide cycloaddition:

**Procedure A:** The mixture of the corresponding pyridinium oxide (1eq) and Ag<sub>2</sub>CO<sub>3</sub> (1.1eq) in BuCN (0.1mL) was heated up to 130 °C for 36 hr in sealed tube and filtered by celite to give cycloaddition product after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.04).

**Procedure B:** The mixture of the corresponding pyridinium oxide (1eq) and Ag<sub>2</sub>CO<sub>3</sub> (1.1eq) in ACN (0.1M) was heated up to 130 °C for 24 hr in sealed tube and filtered by celite to give cycloaddition product after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.04).

\* Unstable compound, directly to next step.

\*\* assigned by 2D-NMR (COSY, HSQC, HMBC).

**(1S,4S,5S,6R,9aS)-4-methyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (75)** *Following the general reductive alkylation procedure A*, 1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (35.4mg, 0.2 mmol) and Ag<sub>2</sub>CO<sub>3</sub> (83mg, 0.22mmol) in BuCN (2 mL) was heated up to 130 °C for 36 hr in sealed tube to give **75** (30.8 mg, 87% product ratio=7:1) after purification by FCC (pure EtOAc).

Data for **75**: R<sub>f</sub> 0.50 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2933, 2860, 1694, 1507, 1386 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.10 (dd, *J* = 9.5, 5.7 1 H), 5.87 (d, *J* = 9.5 Hz, 1 H), 3.75 (d, *J* = 7.4Hz, 1 H), 3.55 (d, *J* = 5.6 Hz, 1 H), 2.92 (tq, *J* = 11.6, 6.4 Hz, 1 H), 2.35 (t, *J* = 3.4 Hz, 1 H), 1.83 (dd, *J* = 13.5, 7.5 1 H), 1.77–1.71 (m, 2 H), 1.59 (ddd, *J* = 13.8, 6.7, 1.5 1 H), 1.47 (dt, *J* = 13.8, 5.3 1 H), 1.18–1.13 (m, 1 H), 1.04 (d, *J* = 6.4 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 199.4, 151.2,



126.8, 69.1, 64.4, 34.8, 30.4, 30.2, 25.9, 20.0; HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>NO [M<sup>+</sup>]: 178.1232, found 178.1223.

**(1R,2R,5S,6R,9aR)-2-methyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (77)** *Following the general reductive alkylation procedure B*, 1-(3-methylpent-4-en-1-yl)pyridin-1-ium-3-olate (60 mg, 0.34 mmol) and Ag<sub>2</sub>CO<sub>3</sub> (103 mg, 0.37 mmol) in BuCN (3.4 mL) was heated up to 130 °C for 36 hr in sealed tube to give **77** (50 mg, 84% product ratio=10:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.02 to 0.04).

Data for **77**: R<sub>f</sub> 0.4 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2954, 2924, 1695, 1381 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.10 (dd, *J* = 9.9, 6.1 1 H), 5.88 (d, *J* = 9.9 1 H), 3.54 (d, *J* = 7.6 Hz, 1 H), 3.51 (d, *J* = 6.1 Hz 1 H), 2.92-2.88 (m, 2 H), 2.12 (d, *J* = 6.8 Hz, 1 H), 1.92 (dd, *J* = 13.7, 7.6 Hz, 1 H), 1.87 (dt, *J* = 11.8, 5.7 Hz, 1 H), 1.41 (dd, *J* = 13.6, 6.8 Hz, 1 H), 1.37-1.33 (m, 1 H), 1.12-1.07 (m, 1 H), 0.88 (d, *J* = 6.5 1 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 199.3, 151.5, 126.3, 69.8, 68.6, 53.4, 42.1, 35.0, 26.7, 26.2, 20.9; HRMS (EI) calcd for C<sub>11</sub>H<sub>16</sub>NO [M<sup>+</sup>]: 178.1232, found 178.1224.

**(2S,5R,9R,9aS,10S)-1,2,3,4,4a,5,9,9a-octahydro-6H-5,9,2-(epinitrilomethano)benzo[7]annulen-6-one (79)** *Following the general reductive alkylation procedure B*, (S)-1-(cyclohex-3-en-1-ylmethyl)pyridin-1-ium-3-olate (19 mg, 0.1 mmol) and Ag<sub>2</sub>CO<sub>3</sub> (30 mg, 0.11 mmol) in ACN (1 mL) was heated up to 130 °C for 24 hr in sealed tube to give **79** (11 mg, 58% product ratio=10:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.03 to 0.1).

Data for **79**: R<sub>f</sub> 0.45 (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.1); IR (thin film) 2960, 2922, 1696 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.17 (dd, *J* = 9.7, 6.2 1 H), 5.96 (d, *J* = 9.7 1 H), 3.60 (s, 1 H), 3.58 (d, *J* = 6.2 Hz, 1 H), 3.35 (s, 1 H), 3.22 (dd, *J* = 14.4, 4.0 Hz, 1 H), 2.79 (d, *J* = 14.0 Hz, 1 H), 2.32 (t, *J* = 6.3 Hz, 1 H), 2.25 (m, 1 H), 1.97 (dt, *J* = 13.1, 7.7 1 H), 1.86-1.81 (m, 2 H), 1.74-1.69 (m, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 199.5, 152.3, 126.2, 76.2, 69.0, 61.9, 38.8, 37.0, 30.4, 27.8, 27.2, 20.8; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 190.1230, found 190.1232.

**(1S,4S,5R,6R,9aR)-9a-chloro-4-methyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (81)** *Following the general reductive alkylation procedure A*, 6-chloro-1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (27 mg, 0.13 mmol) and Ag<sub>2</sub>CO<sub>3</sub> (39 mg, 0.14 mmol) in BuCN (1.3 mL) was heated up to 130 °C for 12 hr in sealed tube to give **81** (21.9 mg, 80% product ratio=4:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.04 to 1:0.06).

Data for **81**: R<sub>f</sub> 0.48 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2940, 1710, 1606 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.11 (d, *J* = 9.7 1 H), 5.92 (dd, *J* = 9.3, 1.4 Hz, 1 H), 3.80 (d, *J* = 8.6 Hz, 1 H), 3.38 (dq, *J* = 13.5, 6.5 Hz, 1 H), 2.48 (brs, 1 H), 2.34 (td, *J* = 13.2, 5.2 Hz, 1 H), 2.05 (dd, *J* = 13.6, 8.6 1 H), 1.80 (ddd, *J* = 13.6, 6.6,

2.2 1 H), 1.62 (dt,  $J = 13.6$ , 5.2 1 H), 1.49 (dt,  $J = 14.8$ , 5.5 1 H), 1.19 (dd,  $J = 14.4$ , 6.0 1 H), 1.08 (d,  $J = 6.7$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  197.4, 153.8, 125.8, 89.9, 62.3, 51.0, 38.8, 30.8, 25.2, 24.5, 19.7; HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{15}\text{NOCl}$   $[\text{M}^+]$ : 212.0842, found 212.0842.

**(1*S*,4*S*,5*R*,6*R*,9*aR*)-9a-bromo-4-methyl-1,3,4,9a-tetrahydro-2*H*-1,6-methanoquinolizin-7(6*H*)-one (83)** *Following the general reductive alkylation procedure B*, 6-bromo-1-(hex-5-en-2-yl)pyridin-1-ium-3-olate (9.5 mg, 0.037 mmol) and  $\text{Ag}_2\text{CO}_3$  (11.5 mg, 0.041 mmol) in ACN (0.4 mL) was heated up to 110 °C for 24 hr in sealed tube to give **82** (5.3 mg, 56% product ratio=3:1) after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.03).

Data for **83**:  $R_f$  0.42 (1:0.075 DCM: 10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 2934, 2870, 1707, 1378  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  7.29 (d,  $J = 9.8$  1 H), 5.82 (d,  $J = 9.5$  Hz, 1 H), 3.73 (d,  $J = 8.5$  Hz, 1 H), 3.92 (tq,  $J = 13.1$ , 6.2 Hz, 1 H), 3.48 (q,  $J = 7$  Hz, 1 H), 2.52 (t,  $J = 3.7$  Hz, 1 H), 2.34 (td,  $J = 13.5$ , 7.5 1 H), 1.98 (dd,  $J = 14.7$ , 9.2 1 H), 1.78 (dd,  $J = 13.5$ , 7.0 1 H), 1.67 (dt,  $J = 13.8$ , 4.6 1 H), 1.56 (dt,  $J = 14.6$ , 5.4 1 H), 1.16 (dd,  $J = 13.2$ , 6.2 1 H), 1.07 (d,  $J = 6.8$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  198.0, 154.8, 125.3, 62.4, 53.4, 39.2, 30.3, 29.7, 26.9, 24.5, 20.0; HRMS (EI) calcd for  $\text{C}_{11}\text{H}_{15}\text{NOBr}$   $[\text{M}^+]$ : 254.0337, found 256.0341.

**(1*S*,4*S*,5*S*,6*R*,9*aS*)-4,8-dimethyl-1,3,4,9a-tetrahydro-2*H*-1,6-methanoquinolizin-7(6*H*)-one (85)** *Following the general reductive alkylation procedure A*, 1-(hex-5-en-2-yl)-4-methylpyridin-1-ium-3-olate (19 mg, 0.1 mmol) and  $\text{Ag}_2\text{CO}_3$  (31 mg, 0.11 mmol) in BuCN (1 mL) was heated up to 130 °C for 36 hr in sealed tube to give **85** (16.8 mg, 88% product ratio=8:1) after purification by FCC (pure EtOAc).

Data for **85**:  $R_f$  0.23 (pure EtOAc); IR (thin film) 2931, 1789, 1380  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  6.82 (d,  $J = 6.2$  1 H), 3.78 (d,  $J = 7.6$  Hz, 1 H), 3.51 (d,  $J = 6.0$  Hz, 1 H), 2.90 (dt,  $J = 12.3$ , 7.0 1 H), 2.30 (t,  $J = 3.1$  Hz, 1 H), 1.81 (dd,  $J = 13.2$ , 7.2 1 H), 1.73 (s, 3 H), 1.51 (dd,  $J = 13.7$ , 6.8 1 H), 1.43 (dt,  $J = 14.0$ , 4.5 1 H), 1.19-1.12 (m, 1 H), 1.05 (d,  $J = 6.8$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  199.7, 146.7, 133.1, 69.1, 63.4, 57.6, 34.7, 30.4, 30.2, 25.9, 20.0, 14.6; HRMS (EI) calcd for  $\text{C}_{12}\text{H}_{18}\text{NO}$   $[\text{M}^+]$ : 192.1388, found 192.1385.

**ethyl (1*S*,4*S*,5*R*,6*R*,9*aS*,10*S*)-9a-chloro-4-methyl-7-oxo-1,3,4,6,7,9a-hexahydro-2*H*-1,6-methanoquinolizine-10-carboxylate (87)** *Following the general reductive alkylation procedure A*, (*E*)-6-chloro-1-(7-ethoxy-7-oxohept-5-en-2-yl)pyridin-1-ium-3-olate (75mg, 0.017 mmol),  $\text{Ag}_2\text{CO}_3$  (86 mg, 0.019mmol) was heated up to 130 °C for 36 hr in sealed tube to give **87** (64 mg, 85% product ratio=15:1) after purification by FCC (hexanes:EtOAc =1:3).

Data for **87**:  $R_f$  0.55 (1:0.1 DCM: 10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 2966, 2935, 1728, 1370  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  7.04 (d,  $J = 9.6$  1 H), 5.86 (d,  $J = 9.6$  Hz, 1 H), 4.11 (d,  $J = 9.6$  Hz, 1 H), 4.09-4.00 (m, 2H), 3.68 (tq,  $J = 12.8$ , 7.0 Hz,

1 H), 3.23 (d,  $J = 9.0$  Hz, 1 H), 3.13 (s 1 H), 2.36 (td,  $J = 15.5$ , 8.0 Hz, 1 H), 1.68 (dt,  $J = 12.8$ , 4.2 Hz, 1 H), 1.57 (dt,  $J = 14.9$ , 5.3 Hz, 1 H), 1.18 (t,  $J = 7.5$  Hz, 3 H), 1.08 (d,  $J = 6.4$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  193.8, 171.0, 153.6, 126.7, 89.1, 65.3, 61.5, 51.2, 48.4, 42.0, 25.1, 24.8, 19.6, 13.9; HRMS (EI) calcd for  $\text{C}_{14}\text{H}_{19}\text{NO}_3\text{Cl}$   $[\text{M}^+]$ : 284.1053, found 284.1048.

**ethyl (1S,4S,5R,6R,9aS,10S)-9a-bromo-4-methyl-7-oxo-1,3,4,6,7,9a-hexahydro-2H-1,6-methanoquinolizine-10-carboxylate (89)** Following the general reductive alkylation procedure A, (*E*)-6-bromo-1-(7-ethoxy-7-oxohept-5-en-2-yl)pyridin-1-ium-3-olate (23mg, 0.07 mmol),  $\text{Ag}_2\text{CO}_3$  (21 mg, 0.077mmol) was heated up to 130 °C for 4 hr in sealed tube to give **89** (18.6 mg, 82% product ratio=7:1) after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.02 to 0.04).

Data for **89**:  $R_f$  0.52 (1:0.1 DCM: 10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 2969, 2939, 1730, 1372  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  7.23 (d,  $J = 9.6$  1 H), 5.76 (d,  $J = 9.6$  Hz, 1 H), 4.09-4.00 (m, 3H), 3.66 (tq,  $J = 12.9$ , 6.6 Hz, 1 H), 3.20-3.17 (m, 2H), 2.40 (td,  $J = 13.9$ , 5.8 Hz, 1 H), 1.75 (dt,  $J = 13.8$ , 5.3 Hz, 1 H), 1.58-1.56 (m, 1 H), 1.18 (t,  $J = 7.5$  Hz, 3 H), 1.09 (d,  $J = 6.4$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  193.6, 170.9, 154.6, 126.0, 85.3, 65.3, 61.5, 53.4, 48.9, 42.5, 26.5, 25.1, 19.9, 13.8; HRMS (EI) calcd for  $\text{C}_{14}\text{H}_{19}\text{NO}_3\text{Br}$   $[\text{M}^+]$ :328.5048, found 328.5037.

**ethyl (1S,4S,5S,6R,9aS,10S)-4,9-dimethyl-7-oxo-1,3,4,6,7,9a-hexahydro-2H-1,6-methanoquinolizine-10-carboxylate (91)** To a solution of the ethyl (*E*)-6-hydroxyhept-2-enoate<sup>43</sup> (1g, 5.8 mmol) in DCM (11.6 mL) at 0 °C was added  $\text{Et}_3\text{N}$  (1.21 mL, 8.7 mmol) and then methanesulfonyl chloride (0.68 mL, 8.7 mmol). The mixture was stirred for 1 h at 0 °C and slowly warming up to room temperature for 3hr before saturated aqueous  $\text{NH}_4\text{Cl}$  solution was added. This mixture was extracted with DCM three times. The combined extracts were washed with brine and dried over  $\text{Na}_2\text{SO}_4$  and concentrated. The mixture of the crude corresponding methylate (50mg, 0.2 mmol), 5-methylpyridin-3-ol (48mg, 0.4 mmol) in BuCN(2drops) were heated up to 130 °C for 6 hr in sealed tube to give pyridinium oxide after purification by FCC (DCM:10% $\text{NH}_4\text{OH}$  in MeOH=1:0.06 to 0.12). The corresponding pyridinium oxide (13.2 mg, 0.05 mmol),  $\text{Ag}_2\text{CO}_3$  (15 mg, 0.055 mmol) was heated up to 130 °C for 12 hr in sealed tube to give **90** (18.6 mg, 75% product ratio>20:1) after purification by FCC (hexanes:EtOAc =1:3).

Data for **91**:  $R_f$  0.55 (1:0.1 DCM: 10% $\text{NH}_4\text{OH}$  in MeOH); IR (thin film) 2966, 2931, 1723, 1699, 1371  $\text{cm}^{-1}$ ;  $^1\text{H}$  NMR (700 MHz,  $\text{CDCl}_3$ )  $\delta$  5.65 (s, 1 H), 4.09 (d,  $J = 8.2$  Hz, 1 H), 4.05-4.00 (m, 2H), 3.34 (s, 1 H), 3.07 (d,  $J = 7.9$  Hz, 1 H), 3.01-2.97 (m, 2H), 2.00 (s, 1H), 1.86-1.82 (m, 2 H), 1.58-1.57 (m, 1 H), 1.18 (t,  $J = 7.1$  Hz, 3 H), 1.10 (d,  $J = 6.4$  Hz, 3 H);  $^{13}\text{C}$  NMR (175 MHz,  $\text{CDCl}_3$ )  $\delta$  195.1, 171.8, 164.3, 124.3, 67.0, 61.1, 57.6, 49.3, 38.1, 30.1, 26.7, 20.9, 20.0, 13.9; HRMS (EI) calcd for  $\text{C}_{15}\text{H}_{22}\text{NO}_3$   $[\text{M}^+]$ :264.1600, found 264.1589.

**(1R,2R,4S,5S,6R,9aR)-2,4-dimethyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (93)** Following the general reductive alkylation procedure A, 1-((2S,4R)-4-methylhex-5-en-2-yl)pyridin-1-ium-3-olate (10mg, 0.052 mmol) and Ag<sub>2</sub>CO<sub>3</sub> (16 mg, 0.059mmol) in BuCN (0.4 mL) was heated up to 130 °C for 36 hr in sealed tube to give **93** (7.9 mg, 79% product ratio>20:1) after purification by FCC (pure EtOAc).

Data for **93**: R<sub>f</sub> 0.50 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2954, 2927, 2871, 1699, 1507, 1386 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.11 (dd, *J* = 9.5, 6.0 1 H), 5.90 (d, *J* = 9.5 Hz, 1 H), 3.66 (d, *J* = 7.8 Hz, 1 H), 3.54 (d, *J* = 5.6 Hz, 1 H), 2.92 (tq, *J* = 11.9, 6.6 Hz, 1 H), 2.11 (d, *J* = 7.0 Hz, 1 H), 1.90 (tq, *J* = 12.0, 6.7 Hz, 1 H), 1.78 (dd, *J* = 13.4, 7.4 1 H), 1.46 (dt, *J* = 13.8, 4.2 1 H), 1.40 (ddd, *J* = 13.4, 6.7, 1.5 1 H), 1.06 (d, *J* = 6.7 Hz, 3 H), 0.88 (d, *J* = 6.7 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 199.4, 151.6, 126.6, 69.6, 64.1, 57.2, 41.3, 35.0, 34.8, 25.9, 20.5, 19.6; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1389.

**(1R,2S,4S,5S,6R,9aR)-2,4-dimethyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (95)** To a solution of the (4S)-4-methylhex-5-en-2-ol<sup>44</sup> (62.6 mg, 0.55 mmol) in DCM (1.1 mL) at 0 °C was added Et<sub>3</sub>N (0.12 mL, 0.83 mmol) and then methanesulfonyl chloride (0.06 mL, 0.83 mmol). The mixture was stirred for 1 h at 0 °C and slowly warming up to room temperature for 1hr before saturated aqueous NH<sub>4</sub>Cl solution was added. This mixture was extracted with DCM three times. The combined extracts were washed with brine and dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated. The mixture of the crude corresponding methylate (90mg, 0.47 mmol), 3-hydroxypyridine (94 mg, 0.94 mmol) in BuCN(2drops) were heated up to 130 °C for 6 hr in sealed tube to give pyridinium oxide **94**<sup>\*</sup> (53 mg, 53% two steps) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.08 to 0.15). The corresponding pyridinium oxide (45 mg, 0.24 mmol), Ag<sub>2</sub>CO<sub>3</sub> (72 mg, 0.26 mmol) was heated up to 130 °C for 36 hr in sealed tube to give **95** (32.3 mg, 72% product ratio=3:1:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH =1:0.05)

Data for **95**: R<sub>f</sub> 0.48 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2955, 2922, 1694, 1381 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>) δ 7.08 (dd, *J* = 9.6, 5.9 1 H), 5.90 (dd, *J* = 9.5, 1.1 Hz, 1 H), 3.81 (d, *J* = 6.2 Hz, 1 H), 3.56 (d, *J* = 8.0 Hz, 1 H), 2.99 (tq, *J* = 14.2, 7.4 Hz, 1 H), 2.06 (d, *J* = 7.0 Hz, 1 H), 1.96 (dd, *J* = 14.0, 7.9 Hz, 1 H), 1.37 (ddd, *J* = 13.6, 6.7, 2.0 1 H), 1.21 (d, *J* = 7.1 Hz, 3 H), 0.86 (d, *J* = 6.7 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>) δ 199.4, 151.4, 126.7, 71.3, 61.8, 55.8, 41.9, 31.4, 31.3, 24.8, 20.8, 20.0; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1384.

**ethyl (1S,4S,5S,6R,9aS,10R)-6-chloro-4-methyl-9-oxo-1,3,4,6,9,9a-hexahydro-2H-1,6-methanoquinolizine-10-carboxylate (100)** Following the general reductive alkylation procedure A, (*E*)-6-chloro-1-(7-ethoxy-7-oxohept-5-en-2-yl)pyridin-1-ium-3-olate (75mg, 0.017 mmol), Ag<sub>2</sub>CO<sub>3</sub> (86 mg, 0.019mmol) was heated up to 130 °C for 36 hr in sealed tube to give **100** (48 mg, 64% product ratio=2:1) after purification by FCC (hexanes:EtOAc =1:3).


Data for **100**:  $R_f$  0.55 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 3039, 1714, 1601, 1369 cm<sup>-1</sup>; <sup>1</sup>H NMR (700 MHz, CDCl<sub>3</sub>)  $\delta$  7.37 (d,  $J$  = 9.8 1 H), 5.88 (d,  $J$  = 9.8 Hz, 1 H), 4.14-4.09 (m, 2H), 3.92 (s, 1 H), 3.75 (dq,  $J$  = 13.0, 6.7 Hz, 1 H), 3.46 (dq,  $J$  = 14.4 Hz, 1 H), 2.84 (s, 1 H), 2.05 (ddd,  $J$  = 13.0, 5.8, 2.0 Hz, 1 H), 1.86-1.75 (m, 5H), 1.30 (dd,  $J$  = 14.4, 5.9 Hz, 1 H), 1.25 (t,  $J$  = 6.8 Hz, 3 H), 1.23 (d,  $J$  = 7.2 Hz, 3 H); <sup>13</sup>C NMR (175 MHz, CDCl<sub>3</sub>)  $\delta$  195.8, 169.9, 157.8, 126.9, 87.3, 72.4, 62.7, 61.5, 51.2, 39.0, 27.1, 22.2, 19.6, 14.1; HRMS (EI) calcd for C<sub>14</sub>H<sub>19</sub>NO<sub>3</sub>Cl [M<sup>+</sup>]: 284.1053, found 284.1048.

**(1S,4S,5S,6R,9aR,10S)-4,10-dimethyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (102)** Following the general reductive alkylation procedure A, (*E*)-1-(hept-5-en-2-yl)pyridin-1-ium-3-olate (9mg, 0.05 mmol), Ag<sub>2</sub>CO<sub>3</sub> (15 mg, 0.055mmol), and trace of BHT in BuCN (0.5 mL) was heated up to 130 °C for 24 hr, then 150 °C for 24 hr in sealed tube to give **102** (4.6 mg, 51% product ratio=15:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.04 to 0.06).

Data for **102**:  $R_f$  0.55 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2966, 2931, 2862, 1693, 1507, 1383 cm<sup>-1</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.17 (dd,  $J$  = 9.6, 5.9 1 H), 5.99 (dd,  $J$  = 9.8, 1.0 Hz, 1 H), 3.86 (d,  $J$  = 7.9 Hz, 1 H), 3.42 (d,  $J$  = 6.2 Hz, 1 H), 2.99 (tq,  $J$  = 12.4, 7.0 Hz, 1 H), 2.34 (dq,  $J$  = 15.5, 8.0 Hz, 1 H), 2.03 (s, 1 H), 1.78 (dd,  $J$  = 13.4, 7.4 1 H), 1.83-1.72 (m, 1H), 1.51 (dtd,  $J$  = 13.8, 5.7, 1.2 1 H), 1.24-1.19 (m, 1H), 1.09 (d,  $J$  = 6.4 Hz, 3 H), 0.96 (d,  $J$  = 7.7 Hz, 3 H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  198.5, 152.1, 129.2, 69.9, 69.4, 57.5, 42.0, 37.1, 30.9, 27.0, 20.0, 17.5; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1382.

**(1S,4S,5S,6R,9aR,10R)-4,10-dimethyl-1,3,4,9a-tetrahydro-2H-1,6-methanoquinolizin-7(6H)-one (104)** Following the general reductive alkylation procedure A, (*Z*)-1-(hept-5-en-2-yl)pyridin-1-ium-3-olate (9mg, 0.05 mmol), Ag<sub>2</sub>CO<sub>3</sub> (15 mg, 0.055mmol), and trace of BHT in BuCN (0.5 mL) was heated up to 130 °C for 24 hr, then 150 °C for 24 hr in sealed tube to give **104** (2.1 mg, 23% product ratio=8:1) after purification by FCC (DCM:10%NH<sub>4</sub>OH in MeOH=1:0.04 to 0.06).

Data for **104**:  $R_f$  0.55 (1:0.1 DCM: 10%NH<sub>4</sub>OH in MeOH); IR (thin film) 2964, 2927, 2862, 1715, 1370 cm<sup>-1</sup>; <sup>1</sup>H NMR (800 MHz, CDCl<sub>3</sub>)  $\delta$  7.03 (dd,  $J$  = 9.6, 5.8 1 H), 5.90 (d,  $J$  = 9.4 Hz, 1 H), 3.62 (d,  $J$  = 5.6 Hz, 1 H), 3.26 (brs, 1 H), 3.06 (tq,  $J$  = 13.4, 6.8 Hz, 1 H), 2.27 (m, 1 H), 2.04 (brs, 1H), 1.91-1.79 (m, 2H), 1.52 (m, 1H), 1.14 (m, 1H), 1.28 (d,  $J$  = 7.4 Hz, 3 H), 1.06 (d,  $J$  = 6.8 Hz, 3 H); <sup>13</sup>C NMR\*\* (200 MHz, CDCl<sub>3</sub>)  $\delta$  199.5, 150.4, 127.0, 70.5, 70.1, 57.3, 36.4, 35.6, 30.9, 27.2, 26.4, 20.1, 11.2; HRMS (EI) calcd for C<sub>12</sub>H<sub>18</sub>NO [M<sup>+</sup>]: 192.1388, found 192.1384.



```

NAME          LU1043
EXPNO         1
PROCNO        1
Date_         20130412
Time         23.57
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            32
DS            2
SWH           7183.908 Hz
FIDRES       0.219235 Hz
AQ           2.2807028 s
RG           228.1
DE           69.600 us
TE           298.4 K
D1           2.00000000 s
TD0          1

===== CHANNEL f1 =====
NUC1          1H
P1           14.00 us
PL1          0.00 dB
SFO1         400.142610 MHz
SI           32768
SF           400.140070 MHz
WDW          EM
SSB          0
GB           0.30 Hz
PC           1.00


```

C13 LU1043

(P)

161.75  
143.57  
140.07  
134.02  
129.54  
129.17  
127.41  
126.99  
120.98  
118.54  
118.22  
116.97

70.81  
29.69  
28.51  
13.47



50a

200 180 160 140 120 100 80 60 40 20 ppm

```


NAME          LU1043
EXPNO         3
PROCNO        1
Date_         20130413
Time_         4.36
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            4000
DS            4
SWH           23980.814 Hz
FIDRES       0.365918 Hz
AQ           1.3664756 sec
RG           32768
DE           20.850 use
TE           300.3 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0          1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1          -2.00 dB
SFO1         100.6253446 MHz


===== CHANNEL f2 =====
CPDPRG2      waltz16
NUC2          1H
PCPD2        90.00 use
PL2          0.00 dB
PL12         16.16 dB
PL13         17.00 dB
SFO2         400.1416006 MHz
SI           32768
SF           100.6152841 MHz
WDW          EM
SSB          0
LB           3.00 Hz
GB           0
PC           1.40
  
```

(a)

H	8.001
	7.981
	7.450
	7.429
	7.411
	7.407
	7.389
	7.364
	7.344
	7.326
	7.324
	7.310
	7.293
	7.275
	7.265
	6.933
	6.914
	6.895
	6.729
	6.708
	5.205
	5.196
	5.184
	5.175
	3.604
	2.406
	2.388
	2.369
	2.360
	2.344
	2.328
	2.303
	2.287
	2.281
	2.264
	2.245
	2.229
	2.209
	2.159
	2.150
	2.142
	2.132
	2.123
	2.114



50c




```

NAME          LD1044
EXPNO         2
PROCNO        1
Date_         20130709
Time          23.33
INSTRUM       robbins
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            2
DS            2
SWH           7183.908 Hz
FIDRES       0.219235 Hz
AQ           2.2607028 sec
RG           18
RG2           18
DS2           69.600 us
DE           6.50 us
TE           298.2 K
D1            2.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            14.00 us
PL1           0.00 dB
SFO1          400.1428010 MHz
SI            32768
SF            400.1400070 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00

```






```


NAME          LU1044
EXPNO         3
PROCNO        1
Date_         20130710
Time          22.24
INSTRUM       robinn
PROBHD        5 mm PABBO
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
DS            800
NS            4
SWH           23980.814 Hz
FIDRES        0.365918 Hz
AQ            1.3664756 sec
RG            20642.5
DW            20.850 use
DE            6.50 use
TE            299.8 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz

===== CHANNEL f2 =====
CEPDERG2     waltz16
NUC2          1H
PCPD2        90.00 use
PL2          0.00 dB
PL12         16.16 dB
PL13         17.00 dB
SFO2         400.1416006 MHz
SF          100.6152857 MHz
SP           EX
WDM          0
SSB          0
LB           3.00 Hz
GB           0
PC           1.40
  
```





50b



```

NAME          L01045x
EXPNO         1
PROCNO        1
Date_         20130708
Time_         22.15
INSTRUM       robbins
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            4
DS            2
SWH           7183.902 Hz
FIDRES       0.24235 Hz
AQ           2.2807028 sec
RG           69.600 us
WDW           6.50 us
SSB           298.2 K
GB            1
PC            2.00000000 sec
===== CHANNEL f1 =====
NUC1          1H
P1            14.00 us
PL1           0.00 dB
SFO1          400.1428010 MHz
SI            32768
SF            400.1400071 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
  
```







```

NAME          LU1011
EXPNO         1
PROCNO        1
Date_         20130723
Time         11.21
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zg30
SOLVENT       CDCl3
NS            8
DS           2
SWH           7183.908 Hz
FIDRES        0.219235 Hz
AQ            2.2807028 sec
RG            161.3
DW           69.600 usec
DE           6.50 usec
TE           298.2 K
D1            2.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            14.00 usec
PL1           0.00 dB
SFO1          400.1426018 MHz
SI            32768
SF            400.1400000 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00
  
```

C 113/



```



NAME          LU1011
EXPNO         3
PROCNO        1
Date_         20130723
Time         2.10
INSTRUM       robinson
PROBHD        5 mm PABO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1200
DS            4
SWH           23980.814 Hz
FIDRES       0.365918 Hz
AQ           1.3664756 sec
RG           8192
DW           20.850 use
DE           6.50 use
TE           299.5 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0          1

===== CHANNEL f1 =====
NUC1          13C
P1           9.00 use
PL1          -2.00 dB
SFO1         100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12         16.16 dB
PL13         17.00 dB
SFO2         400.1416006 MHz
SI           32768
SF           100.6152847 MHz
WDW           EM
SSB           0
LB           3.00 Hz
GB           0
PC           1.40
  
```


NAME LU1012  
 EXPNO 1  
 PROCNO 1  
 Date\_ 20130413  
 Time 21.41  
 INSTRUM robbinsch  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 32768  
 SOLVENT CDCl3  
 NS 32  
 DS 2  
 SWH 7183.928 Hz  
 FIDRES 0.212295 Hz  
 AQ 2.2807028 sec  
 RQ 1.84  
 DWT 69.600 us  
 DE 6.50 us  
 TE 298.7 K  
 D1 2.00000000 sec  
 TDO 1

===== CHANNEL f1 =====  
 NUC1 1H  
 P1 14.00 us  
 PL1 0.00 dB  
 SFO1 400.1428010 MHz  
 SI 32768  
 SF 400.1400070 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00




C13 LU1012 (14)

172.81
165.53
147.41
133.76
128.42
119.08
115.54
114.70
81.10
64.79
29.92
29.60
28.03



48b



```



NAME          LU1012
EXPNO         3
PROCNO        1
Date_         20130413
Time          22.06
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            600
DS            4
SWH           23980.814 Hz
FIDRES       0.365928 Hz
AQ           1.368756 sec
RG           1158.82
DM           20.00 use
DE           6.50 use
TE           300.3 K
D1           1.00000000 sec
D11          0.03000000 sec
TD0          1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1          -2.00 dB
SFO1         100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2      waltz16
NUC2          1H
PCPD2        90.00 use
PL2           0.00 dB
PL12         16.16 dB
PL13         17.00 dB
SFO2         400.1416006 MHz
SI           32768
SF           100.6152874 MHz
WDW          EX
SSB           0
LB           3.00 Hz
GB           0
PC           1.40

```

49a



LU1016 (16)

7.931
7.928
7.912
7.909
7.346
7.343
7.326
7.325
7.308
7.304
7.265
6.950
6.948
6.930
6.912
6.910
6.780
6.760
5.844
5.827
5.802
5.146
5.142
5.103
5.099
5.085
5.060
4.763
4.754
4.739
4.730
4.233
4.216
4.199
4.182
4.164
2.933
2.916
2.899
2.163
2.159
2.148
2.124
1.952

```

NAME          LU1016
EXPNO         1
PROCNO        1
Date_         20130108
Time          13.23
INSTRUM       robbins
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            2
DS            4
SWH           7183.908 Hz
FIDRES       0.21923 Hz
AQ           2.2807028 sec
RG           90.0
DM           69.000 us
DE           6.550 us
TE           300.0 K
D1           2.00000000 sec
TD0          1

===== CHANNEL f1 =====
NUC1          1H
P1           14.00 us
PL1          0.00 dB
SFO1         400.1428010 MHz
SI           32768
SF           400.1400070 MHz
WDW          EM
SSB          0
LB           0.30 Hz
GB           0
PC           1.00


```



C13 LU1016

(6)

161.96  
143.15  
134.83  
133.51  
128.60  
120.87  
117.46  
117.06  
67.78  
44.94  
32.85  
28.52  
13.63



49a

200  
180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm



```

NAME          LU1016x
EXPNO         3
PROCNO        1
Date_         20130404
Time          22.58
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            2000
DS            4
SWH           23980.814 Hz
FIDRES        0.365918 Hz
AQ            1.3664756 sec
RG            18390.4
DE            20.850 use
TE            300.3 K
D1            1.0000000 sec
D11           0.0300000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12          16.16 dB
PL13          17.00 dB
SFO2          400.1416006 MHz
SI            32768
SF            100.6152835 MHz
WDW            EM
SSB            0
LB            3.00 Hz
GB            0
PC            1.40

```






```

NAME          LU1017
EXPNO         1
PROCNO        1
Date_         20130528
Time          0.24
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            16
DS            2
SWH           7183.908 Hz
FIDRES       0.219235 Hz
AQ           2.2807028 sec
RG           90.5
RW           69.600 us
DE           26.30 us
TE           293.8 K
D1           2.0000000 sec
TD0          1

===== CHANNEL f1 =====
NUC1          1H
P1           14.00 us
PL1          0.00 dB
SFO1         400.1428010 MHz
SI           32768
SF           400.1400069 MHz
WDW          EM
SSB          0
LB           0.30 Hz
GB           0
PC           1.00

```





```



NAME          LU1018
EXPNO         1
PROCNO        1
Date_         20130108
Time          13.37
INSTRUM       zg30
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            32768
SOLVENT       CDCl3
NS            4
DS            2
SWH           7183.908 Hz
FIDRES       0.219235 Hz
AQ           2.2807028 sec
RG           90.5
DE           69.600 us
TE           300.2 K
D1           2.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            14.00 us
PL1           0.00 dB
SFO1         400.1428010 MHz
SI           32768
SF           400.1400070 MHz
WDW           EM
SSB           0
LB           0.30 Hz
GB           0
PC           1.00
  
```

C13 LU1018

(18)

171.99	—
162.23	—
144.51	—
135.06	
133.16	
128.43	
119.38	
116.99	
115.41	
81.01	
77.29	
76.97	
76.65	
44.71	—
32.70	
31.01	
28.55	
28.03	



```


NAME          LU1018
EXPNO         3
PROCNO        1
Date_         20130227
Time          2.48
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
FIDRES        0.365918 Hz
AQ            1.3664756 sec
RG            18390.4
DE            20.850 use
TE            299.1 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz


===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12          16.16 dB
PL13          17.00 dB
SFO2          400.1416006 MHz
SI            32768
SF            100.6152893 MHz
WDW           EM
SSB           0
LB            3.00 Hz
GB            0
PC            1.40

```

LU1020  
 129  
 7.875  
 7.872  
 7.856  
 7.852  
 7.664  
 7.346  
 7.342  
 7.326  
 7.308  
 7.304  
 7.265  
 6.871  
 6.852  
 6.834  
 6.669  
 6.649  
 4.218  
 2.688  
 2.666  
 2.660  
 2.644  
 2.639  
 2.623  
 2.591  
 2.575  
 2.570  
 2.553  
 2.549  
 2.527  
 2.510  
 2.239  
 2.223  
 2.217  
 2.202  
 2.186  
 2.181  
 2.164  
 2.129  
 2.113  
 2.107  
 2.092  
 2.077  
 2.071  
 1.599



51a





NAME LU1020  
 EXPNO 1  
 PROCNO 1  
 Date\_ 20130413  
 Time 18.02  
 INSTRUM robinson  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 32768  
 SOLVENT CDCl3  
 NS 32  
 DS 2  
 SWH 7183.908 Hz  
 FIDRES 0.219235 Hz  
 AQ 2.2807028 sec  
 RG 128  
 DW 69.600 usec  
 DE 6.50 usec  
 TE 298.7 K  
 D1 2.00000000 sec  
 TDO 1  
 ===== CHANNEL f1 =====  
 NUC1 1H  
 P1 14.00 usec  
 PL1 0.00 dB  
 SFO1 400.1428010 MHz  
 SI 32768  
 SF 400.1400070 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

C13 LUI020

129

164.83  
145.41  
134.38  
128.23  
119.63  
119.25  
114.90  
113.92




```

NAME          LUI020
EXPNO         3
PROCNO        1
Date_         20130413
Time          19.07
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1600
DS            4
SWH           23980.814 Hz
FIDRES        0.365218 Hz
AQ            1.3664256 sec
RG            319.812
DE            20.850 use
DS            300.6 K
TE            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1         100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12         16.16 dB
PL13         17.00 dB
SFO2         400.1416006 MHz
SI            32768
SF           100.6152855 MHz
WDW           EM
SSB           0
LB            3.00 Hz
GB            0
PC            1.40
  
```



```

NAME          LU1019
EXPNO         1
PROCNO        1
Date_         20130403
Time          21.54
INSTRUM       rosinson
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            32
DS            2
SWH           7183.908 Hz
FIDRES       0.219235 Hz
AQ           2.2807028 sec
RG            18
DE           69.600 us
TE           298.7 K
D1            2.0000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1           14.00 us
PL1          -0.00 dB
SFO1         400.1428010 MHz
SF           32768
WDW          EM
SSB           0
GB            0
PC            1.00
  
```




C13 LU1019

(22)

173.15  
164.42  
145.88  
133.97  
128.30  
118.50  
114.49  
113.95

80.93  
69.95

36.36  
29.99  
29.14  
28.04



51b

200  
180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm


```

NAME          LU1019
EXPNO         3
PROCNO        1
Date_         20130403
Time_         22.42
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1000
DS            4
SWH           23980.814 Hz
FIDRES        0.365918 Hz
AQ            1.3664756 sec
RG            16384
DW            20.850 use
DE            6.50 use
TE            300.4 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12          16.16 dB
PL13          17.00 dB
SFO2          400.1416006 MHz
SI            32768
SF            100.6152848 MHz
WDW           EM
SSB           0
LB            3.00 Hz
GB            0
PC            1.40

```





NAME LU1035  
EXPNO 1  
PROCNO 1  
Date\_ 20130411  
Time 21.53  
INSTRUM robinson  
PROBHD zg30  
PULPROG 5 mm PABBO BB-  
TD 32768  
SOLVENT CPC13  
NS 32  
DS 2  
SWH 7183.908 Hz  
FIDRES 0.219235 Hz  
AQ 2.2807028 sec  
RG 114  
DW 69.600 usec  
DE 6.50 usec  
TE 283.2 K  
D1 2.00000000 sec  
TD0 1

===== CHANNEL f1 =====  
NUC1 1H  
P1 14.00 usec  
PL1 0.00 dB  
SFO1 400.1428010 MHz  
SI 32768  
SF 400.1400070 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

C13 LU1035

(24)

163.90	
143.78	
138.67	
133.97	
128.91	
128.77	
127.34	
127.26	
119.81	
119.21	
115.51	
115.09	
73.41	
45.35	
34.46	
25.56	
12.34	

**52a**

```

NAME          LU1035
EXPNO         3
PROCNO        1
Date_         20130412
Time          0.48
INSTRUM       robinson
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1000
DS            4
SWH           23980.814 Hz
FIDRES        0.365918 Hz
AQ            1.3664756 sec
RG            11585.2
DE            20.850 use
TE            300.2 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz


===== CHANNEL f2 =====
CPOPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12          16.16 dB
PL13          17.00 dB
SFO2          400.1416006 MHz
SI            32768
SF            100.6152863 MHz
WDW           EM
SSB           0
LB            3.00 Hz
GB            0
PC            1.40

```


LU1036

(25)

7.976  
7.957  
7.335  
7.318  
7.311  
7.292  
7.272  
7.265  
7.241  
7.224  
6.871  
6.851  
6.833  
6.584  
6.564  
4.975  
4.936  
4.618  
4.579  
4.273  
3.590  
2.406  
2.388  
2.371  
2.348  
2.343  
2.322  
2.307  
2.289  
2.164  
2.153  
2.131  
2.125  
2.107  
2.084  
2.060  
2.048  
2.035  
2.016  
1.998  
1.992  
1.981



52c



```

NAME          LU1036
EXPNO         1
PROCNO        1
Date_         20130410
Time          22.20
INSTRUM       robbins
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            32768
SOLVENT       CDCl3
NS            32
DS            2
SWH            7183.908 Hz
FIDRES        0.219235 Hz
AQ            2.2807028 sec
RG            128
DE            69.600 us
TE            300.0 K
D1            2.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            14.00 us
PL1           0.00 dB
SFO1          400.142800 MHz
SI            32768
SF            400.140071 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            0
PC            1.00


```

C13 LU1036

(25)

173.82  
164.20  
144.47  
139.06  
133.62  
128.93  
128.52  
127.37  
127.00  
118.99  
115.22  
114.35

74.06  
51.82  
45.32  
33.95  
28.92  
26.36



52c

200  
180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm



```

NAME          LU1036
EXPNO         3
PROCNO        1
Date_         20130410
Time          23.03
INSTRUM       robbins
PROBHD        5 mm PABBO BB-
PULPROG       zgpg30
TD            65536
SOLVENT       CDCl3
NS            1000
DS            4
SWH           23980.814 Hz
FIDRES        0.365218 Hz
AQ            1.3664756 sec
RG            18390.4
DQ            20.850 use
DE            6.50 use
TE            300.8 K
D1            1.00000000 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1           -2.00 dB
SFO1          100.6253446 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12          16.16 dB
PL13          17.00 dB
SFO2          400.1416008 MHz
SI            32068
SF            100.6132652 MHz
WDW           EM
SSB           0
GB            3.00 Hz
PC            1.40
  
```

LU1037129



```

NAME          LU1037
EXPNO         10002
PROCNO        20130328
Date_         2.35
Time          2.35
INSTRUM       spect
PROBHD        5 mm CPDCH 130
PULPROG       zgpg30
TD0           95236
SOLVENT       CDCl3
NS            8
DS            2
SWH           11904.762 Hz
FIDRES        0.125003 Hz
AQ            3.9999621 sec
RG            203
DW            42.000 usec
DE            6.50 usec
TE            298.1 K
D1            2.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1            9.40 usec
PL1           -3.20 dB
P1LW          33.59817505 W
SFO1          700.1516910 MHz
SI            131072
SF            700.1471560 MHz
WDW           EM
SSB           0
LB            0.30 Hz
GB            1.00
PC

```


C13 LU1037 **26**

172.65  
164.22  
144.60  
139.03  
133.58  
128.81  
128.45  
127.31  
126.90  
118.70  
115.00  
114.24

80.76  
74.09

45.24

33.84  
30.20  
27.94  
26.38

**52b**

200 180 160 140 120 100 80 60 40 20 ppm

**BRUKER**

NAME LU1037  
EXPNO 3  
PROCNO 1  
Date\_ 20130327  
Time 22.19  
INSTRUM spect  
PROBHD 5 mm CPDCH 13C  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 500  
DS 4  
SWH 41666.668 Hz  
FIDRES 0.635783 Hz  
AQ 0.7864820 sec  
RG 203  
DW 12.000 usec  
DE 11.50 usec  
TE 293.1 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1



===== CHANNEL f1 =====  
NUC1 13C  
P1 9.00 usec  
PL1 4.50 dB  
PL1W 38.1453833 W  
SFO1 176.067436 MHz

===== CHANNEL f2 =====  
CPDPRG2 waltz16  
NUC2 1H  
PCPD2 65.00 usec  
PL2 -3.20 dB  
PL12 13.60 dB  
PL13 120.00 dB  
PL12W 33.59817505 W  
PL13W 0.70196527 W  
SFO2 0.00000000 W  
SF02 700.1499406 MHz  
SI 32768  
WDW EM  
SSB 0  
LB 3.00 Hz  
GB 1.40

DAS50202

NAME DAS50202  
 EXPRNO 1  
 PROCNO 1  
 Date\_ 20131120  
 Time\_ 13:33  
 INSTRUM spect  
 PROBRD 5 mm CPDCH 130  
 PULPROG zgpg30  
 TD 65536  
 SOVENT CDCl3  
 NS 2  
 DS 2  
 SWH 11904.762 Hz  
 FIDRES 0.125063 Hz  
 AQ 3.999621 sec  
 RG 22.6  
 DW 42.000 usec  
 DE 6.50 usec  
 TE 298.2 K  
 D1 2.00000000 sec  
 TDO 1



7.797  
 7.795  
 7.785  
 7.784  
 7.303  
 7.283  
 7.281  
 7.271  
 7.260  
 6.736  
 6.725  
 6.714  
 6.560  
 6.548  
 6.102  
 4.093  
 2.650  
 2.647  
 2.637  
 2.635  
 2.625  
 2.622  
 2.613  
 2.576  
 2.567  
 2.563  
 2.554  
 2.551  
 2.543  
 2.538  
 2.171  
 2.097  
 2.093  
 2.085  
 2.076  
 2.071  
 2.062  
 2.058  
 2.049  
 2.045  
 1.605  
 1.259  
 1.253  
 1.027



===== CHANNEL f1 =====  
 NUCL 1H  
 P1 9.40 usec  
 PL1 -3.20 dB  
 PL1W 33.59817505 W  
 SFO1 700.1516910 MHz  
 SI 131072  
 SF 700.1471600 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



DAS50202




```

NAME      DAS50202
EXPNO     2
PROCNO    1
PROBHD    5 mm CPDCH 13C
PULPROG   zgpg30
SOLVENT    CDCl3
NS         194
DS         4
SWH        41666.668 Hz
FIDRES     0.635783 Hz
AQ         0.7864820 sec
RG         203
DE         12.000 usec
TE         298.2 K
D1         2.00000000 sec
D11        0.03000000 sec
TD0        1

===== CHANNEL f1 =====
NUC1       13C
P1         9.00 usec
PL1        0.00 dB
PL1W       38.1453433 W
SFO1       176.0697436 MHz

===== CHANNEL f2 =====
CPDPRG2    waltz16
NUC2       1H
PCPD2      65.00 usec
PL2        -3.20 dB
PL12       13.60 dB
PL13       120.00 dB
PL1W       33.59817505 W
PL12W      0.70196527 W
PL13W      0.00000000 W
SFO2       700.1499406 MHz
SI         32768
SF         176.0521140 MHz
WDW        EM
SSB        0
LB         1.50 Hz
GB         0
PC         1.40
  
```



Current Data Parameters

NAME	DAS43011
EXPNO	1
PROCNO	1

F2 - Acquisition Parameters

Date_	20131119
Time	14.31
INSTRUM	DPX400
PROBHD	5 mm Multinucl
PULPROG	zg30
TD	32768
SOLVENT	CDCl3
NS	32
DS	2
SWH	6410.256 Hz
FIDRES	0.195625 Hz
AQ	2.555940 sec
RG	406.4
DM	78.000 usec
DE	6.00 usec
TE	298.2 K
D1	2.0000000 sec
TD0	1



===== CHANNEL f1 =====

NUC1	1H
PL1	15.00 usec
PL1	-1.40 dB
SFO1	400.2628018 MHz

F2 - Processing parameters

SI	32768
SF	400.2600108 MHz
WDW	EM
SSB	0
IB	0.30 Hz
GB	0
PC	1.00

DAS43011




Current Data Parameters  
 NAME DAS43011  
 EXPNO 2  
 PROCNO 1

F2 - Acquisition Parameters:  
 Date\_ 20131119  
 Time 14.38  
 INSTRUM DPX400  
 PROBHD 5 mm Multinuc1  
 PULPROG zgpg30  
 TD 65536  
 FIDRES 0.03000000  
 SOLVENT CDCl3  
 NS 300  
 DS 4  
 SMH 23980.814 Hz  
 FIDRES 0.03000000 Hz  
 AQ 1.384475 sec  
 RG 18425  
 DD 20.850 usec  
 DE 6.00 usec  
 TE 298.2 K  
 D1 1.00000000 sec  
 d11 0.03000000 sec  
 DELTA 0.89999998 sec  
 TD0 1

==== CHANNEL f1 =====  
 NUC1 13C  
 P1 8.30 usec  
 PL1 -3.00 dB  
 SFO1 100.6555216 MHz

==== CHANNEL f2 =====  
 CPDPRG2 waltz16  
 NUC2 1H  
 PCPD2 90.00 usec  
 PL2 -3.00 dB  
 PL12 13.00 dB  
 PL13 13.00 dB  
 SFO2 400.2620013 MHz

F2 - Processing parameters  
 SI 32768  
 SF 100.6454458 MHz  
 WDM 0  
 SSB 0  
 LB 3.00 Hz  
 GB 0  
 PC 1.40





```

NAME      DAS50301
EXPNO     1
PROCNO    1
Date_     20131119
Time      13.26
INSTRUM   spect
PROBHD    5 mm CPDCH 13C
PULPROG   zg30
TD         95236
SOLVENT   CDCl3
NS         32
DS         2
SWH        11904.762 Hz
FIDRES     0.172503 Hz
AQ         3.9999621 sec
RG         325.4
DE         42.000 usec
TE         6.50 usec
TD0        298.2 K
D1         2.00000000 sec
===== CHANNEL f1 =====
NUC1       1H
P1         9.40 usec
PL1        -3.20 dB
PL1W       33.59817505 W
SFO1       700.1516910 MHz
SI         131072
SF         700.1471608 MHz
WDW        EM
SSB        0
GB         0.30 Hz
LB         0
PC         1.00

```

DAS50301





```

NAME      DAS50301
EXPNO     2
PROCNO    1
Date_     20131119
Time      13.32
INSTRUM   spect
PROBHD    5 mm CPDCH 13C
PULPROG   zgpg30
TD         65536
SOLVENT   CDCl3
NS         135
DS         4
SWH        41666.668 Hz
FIDRES     0.635783 Hz
AQ         0.7864820 sec
RG         200
WDW         12.000 usec
SSB         116.50 usec
LB          298.2 K
GB          0.00000000 sec
PC          0.03000000 sec
===== CHANNEL f1 =====
NUC1       13C
P1         9.00 usec
PL1        4.50 dB
PL1W       38.1453833 W
SFO1       176.0697436 MHz
===== CHANNEL f2 =====
CPDPRG2    waltz16
NUC2       1H
PCPD2      65.00 usec
PL2        -3.20 dB
PL12       13.60 dB
PL13       120.00 dB
PL1W       33.59817505 W
PL12W      0.70196527 W
PL13W      0.00000000 W
SFO2       700.1499406 MHz
SI         32768
SF         176.0521203 MHz
WDW         EM
SSB         0
PC         1.40
  
```




7.345
7.342
7.265
7.160
7.157
7.147
7.145
7.131
7.123
7.118
7.110
7.010
7.003
5.617
5.612
5.608
5.602
5.593
5.587
5.584
5.578
4.925
4.911
4.902
4.878
4.877
4.072
4.065
4.055
4.052
4.045
4.042
1.893
1.890
1.879
1.873
1.869
1.863
1.852
1.842
1.805
1.489
1.479



Current Data Parameters  
NAME LU5036\_OX\_mono\_0  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180102  
Time 8.17 h  
INSTRUM spect  
PROBHD Z151340\_0001 (zg30)  
PULPROG 65536  
TD CDC13  
SOLVENT 16  
NS 2  
DS 10504.202 Hz  
SWH 0.320563 Hz  
FIDRES 3.1195135 sec  
AQ 11.3  
RG 47.600 usec  
DE 20.00 usec  
TE 298.2 K  
D1 1.00000000 sec  
TD0 1  
SF01 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00



170.05  
135.73  
134.47  
131.50  
126.76  
119.77  
116.72  
77.39  
77.21  
77.03  
66.60  
35.61  
29.72  
21.77



Current Data Parameters  
NAME LU5036\_OX\_mono\_0  
EXPNO 3  
PROCNO 1

### F2 - Acquisition Parameters

Date\_ 20180102  
Time 8.18 h  
INSTRUM spect  
PROBHD Z151340\_0001 (zgp930)  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 8  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 298.2 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.0000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.0000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

### F2 - Processing parameters

SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

220  
200  
180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm



Current Data Parameters  
 NAME check4  
 EXPNO 50391  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20180818  
 Time 17.42 h


INSTRUM spect  
 PROBD 2566801\_0015 (zg30)  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 14  
 DS 2

SWH 10504.202 Hz  
 FIDRES 0.320563 Hz  
 AQ 3.1195135 sec  
 RG 203


DM 47.600 usec  
 DE 6.50 usec  
 TE 294.6 K  
 DI 1.00000000 sec  
 TDO 1

SFO1 700.0115500 MHz  
 NUCL 1H  
 P1 12.88 usec  
 PLW1 40.00000000 W



F2 - Processing parameters  
 SI 131072  
 SF 700.0070132 MHz  
 WDN EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00







Current Data Parameters  
NAME LU5039\_mono\_0  
EXPNO 3  
PROCNO 1



F2 - Acquisition Parameters

Date\_ 20180104  
Time 13.17 h  
INSTRUM spect  
PROBHD Z151340\_0001 ( zpg30  
PULPROG 65536  
TD 11  
SOLVENT CDCl3  
NS 4  
DS 1  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 298.2 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SFO1 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.00000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40








Current Data Parameters  
NAME PURE\_eqme\_OX  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters

Date\_ 20180726 7.38 h  
Time\_ 7.38 h  
INSTRUM spect  
PROBHD Z566801\_0015 ( z930  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 203  
DW 47.600 usec  
DE 6.50 usec  
TE 294.2 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 12.88 usec  
PLW1 40.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070000 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





Current Data Parameters  
NAME LU4292\_PURE\_2Me\_ox  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180701  
Time 5.35 h  
INSTRUM spect  
PROBHD z566801\_0015 (zgp930  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 6000  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 6.50 usec  
TE 301.4 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 8.95 usec  
PLW1 100.0000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 40.00000000 W  
PLW12 1.57060003 W  
PLW13 0.79086000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40




Current Data Parameters  
 NAME eqme.cy  
 EXPNO 2  
 PROCNO 1

# F2 - Acquisition Parameters

Date\_ 20180819  
 Time 6.50 h  
 INSTRUM spect  
 PROBD 2566801\_0015 ( zq30  
 PULPROG 65536  
 TD CDCl3  
 SOLVENT 32  
 NS 2  
 DS 2  
 SWH 10504.202 Hz  
 FIDRES 0.320563 Hz  
 AQ 3.1195135 sec  
 RG 203  
 DW 47.600 usec  
 DE 6.50 usec  
 TE 294.4 K  
 DI 1.0000000 sec  
 TD0 1  
 SF01 700.0115500 MHz  
 NUC1 1H  
 P1 12.88 usec  
 P1M1 40.0000000 W

# F2 - Processing Parameters

SI 131072  
 SF 700.0070132 MHz  
 WDN EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00





Current Data Parameters  
NAME LU4001\_Monome\_0\_  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20170328  
Time 13.51 h

INSTRUM spect  
PROBHD Z151340\_0001 (

PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3

NS 44  
DS 4  
SWH 42613.637 Hz

FIDRES 1.300465 Hz  
AQ 0.7689557 sec

RG 203  
DW 11.733 usec  
DE 18.00 usec

TE 298.2 K  
D1 2.00000000 sec

D11 0.03000000 sec  
TD0 1

SFO1 176.0362620 MHz  
NUC1 13C

P1 11.75 usec  
PLW1 29.00000000 W

SFO2 700.0098000 MHz  
NUC2 1H

CPDPRG12 waltz16  
PCPD2 65.00 usec

PLW2 13.00000000 W  
PLW12 0.38942000 W



PLW13 0.19609000 W


F2 - Processing parameters  
SI 131072

SF 176.0169002 MHz  
WDW EM

SSB 0  
LB 1.00 Hz

GB 0  
PC 1.40





7.711  
7.521  
7.515  
7.459  
7.447  
7.387  
7.379  
7.367  
7.265

5.704  
5.692  
5.606

4.204  
4.193

2.215  
2.087  
2.067  
2.038  
2.014  
1.824  
1.810  
1.787  
1.729  
1.712  
1.398  
1.389  
1.372



Current Data Parameters  
NAME IU3246\_Pure\_CyH\_ox  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180607  
Time 14.45 h

INSTRUM spect

PROBHD Z151340\_0001 (

PULPROG zg30

TD 65536

SOLVENT CDCl3

NS 13

DS 2

SWH 10504.202 Hz

FIDRES 0.320563 Hz

AQ 3.1195135 sec

RG 5.6

DW 47.600 usec

DE 10.00 usec

TE 303.2 K

D1 1.00000000 sec

TD0 1

SFO1 700.0115500 MHz

NUC1 1H

P1 11.00 usec

PLWL 13.00000000 W

F2 - Processing parameters

SI 131072

SF 700.0070152 MHz


WDW EM


SSB 0

LB 0.30 Hz

GB 0

PC 1.00





155.97

133.76  
133.69  
127.21  
127.15  
125.46  
124.16

77.24  
77.06  
76.98

66.11

35.40  
28.47  
25.55  
24.02




Current Data Parameters  
NAME IU3246\_Pure\_CyH\_ox  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180607  
Time 14.48 h

INSTRUM spect  
PROBHD Z151340\_0001 (   
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 43  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 303.2 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SFO1 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.0000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.0000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing Parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40

200 180 160 140 120 100 80 60 40 20 ppm




7.284  
7.204  
7.195  
7.190  
7.182  
5.983  
5.969  
3.623  
3.599  
3.590  
3.372  
3.248  
3.242  
3.227  
3.221  
2.817  
2.797  
2.352  
2.344  
2.334  
2.273  
1.995  
1.983  
1.976  
1.965  
1.882  
1.873  
1.866  
1.860  
1.854  
1.849  
1.838  
1.831  
1.766  
1.750  
1.746






Current Data Parameters  
NAME LU3260\_CYH\_0  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20171219  
Time 15.32 h  
INSTRUM spect  
PROBHD Z151340\_0001 (z930  
PULPROG 65536  
TD CDC13  
SOLVENT 13  
NS 2  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 32  
DW 47.600 usec  
DE 20.00 usec  
TE 298.2 K  
D1 1.00000000 sec  
TD0 1  
SF01 700.011500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing Parameters  
SI 131072  
SF 700.0070133 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00







Current Data Parameters  
 NAME check\_cyclohexene\_(  
 EXPNO 3  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20171219  
 Time 15.45 h  
 INSTRUM spect  
 PROBHD Z151340\_0001 ( zgp930  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 256  
 DS 4  
 SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 298.2 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SFO1 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 PLW1 29.00000000 W  
 SFO2 700.0098000 MHz  
 NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.00000000 W  
 PLW12 0.37231001 W  
 PLW13 0.18747000 W

F2 - Processing parameters  
 SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40







Current Data Parameters  
NAME LU5053\_Pure\_Mono\_Cl\_OX  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180531  
Time 19.40 h  
INSTRUM spect  
PROBHD Z151340\_0001 (zq30)  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 10  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 28.5  
DW 47.600 usec  
DE 20.00 usec  
TE 303.2 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

9.476  
9.473  
8.077  
8.073  
8.064  
8.060  
7.725  
7.712  
7.261  
5.737  
5.727  
5.722  
5.713  
5.703  
5.697  
5.689  
5.680  
5.283  
5.273  
5.264  
5.255  
5.034  
5.019  
4.995  
2.225  
2.215  
2.205  
2.138  
2.131  
2.123  
2.116  
2.108  
2.092  
1.730  
1.720





158.69  
135.04  
134.92  
133.58  
132.12  
129.60  
117.31  
77.23  
77.05  
76.87  
65.16  
35.45  
29.90  
20.99



Current Data Parameters  
NAME IU5053\_Pure Mono-Cl\_OX  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180531  
Time 19.44 h  
INSTRUM spect  
PROBHD 2151340\_0001 ( zppg30  
PULPROG 65536  
TD 65536  
SOLVENT CDCl3  
NS 44  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 303.2 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLM1 29.00000000 W  
SF02 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLM12 0.37231001 W  
PLM13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



7.264  
7.100  
7.086

5.916  
5.902

3.799  
3.787  
3.670  
3.663  
3.655  
2.465  
2.343  
2.325  
2.305  
2.046  
2.030  
2.015  
1.799  
1.789  
1.780  
1.770  
1.609  
1.588  
1.487  
1.477  
1.467  
1.185  
1.178  
1.167  
1.159



Current Data Parameters  
NAME Check4  
EXPNO 5238  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180819  
Time 11.22 h


INSTRUM spect  
PROBHD 2566801\_0015 (zg30)  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 32


DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec

RG 203  
DM 47.600 usec  
DE 6.50 usec  
TE 294.6 K

D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 12.88 usec  
PLM1 40.0000000 W

F2 - Processing Parameters  
SI 131072  
SF 700.0070130 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





197.43

153.79

125.77

89.88

77.18  
77.02  
76.86

62.33

51.10

38.81

30.80

25.21  
24.51  
19.70




Current Data Parameters  
NAME LV4246\_PURE\_MONO\_CL  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters

Date\_ 20180626  
Time 11.22 h  
INSTRUM spect  
PROBHD Z161768\_0001 (zgpg30)  
PULPROG zgpg30  
TD 65536  
SOLVENT CDC13  
NS 1165  
DS 4  
SWH 48076.922 Hz  
FIDRES 1.467191 Hz  
AQ 0.6815744 sec  
RG 192.59  
DW 10.400 usec  
DE 18.00 usec  
TE 298.1 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SF01 201.2330858 MHz  
NUC1 13C  
P1 12.00 usec  
PLW1 138.64999390 W  
SF02 800.2132008 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 60.00 usec  
PLW2 9.66049957 W  
PLW12 0.13911000 W

F2 - Processing Parameters

SI 131072  
SF 201.2129645 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40







Current Data Parameters  
 NAME LU5049\_OX\_mono\_Br  
 EXPNO 1  
 PROCNO 1



F2 - Acquisition Parameters  
 Date\_ 20180108  
 Time 14.27 h  
 INSTRUM spect  
 PROBHD Z151340\_0001 ( z930  
 PULPROG 65536  
 TD CDC13  
 SOLVENT 16  
 NS 2  
 DS 10504.202 Hz  
 SWH 0.320563 Hz  
 FIDRES 3.1195135 sec  
 AQ 25.4  
 RG 47.600 usec  
 DW 20.00 usec  
 DE 298.2 K  
 TE 1.00000000 sec  
 D1 1  
 TD0 700.0115500 MHz  
 SFO1 1H  
 NUC1 11.00 usec  
 P1 13.00000000 W  
 PLW1

F2 - Processing Parameters  
 SI 131072  
 SF 700.0070169 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



7.762  
 7.757  
 7.433  
 7.420  
 7.263  
 7.245  
 7.241  
 7.232  
 7.227  
 5.738  
 5.732  
 5.729  
 5.723  
 5.714  
 5.708  
 5.705  
 5.699  
 5.035  
 5.021  
 4.997  
 2.095  
 2.085  
 2.072  
 2.061  
 2.053  
 2.042  
 2.025  
 2.014  
 1.957  
 1.948  
 1.939  
 1.574  
 1.565







Current Data Parameters  
 NAME LU5049\_OX\_mono\_Br  
 EXPNO 3  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20180108  
 Time 14.33 h  
 INSTRUM spect  
 PROBD 2151340\_0001 ( zpg30  
 PULPROG 65536  
 TD CDC13  
 SOLVENT 73  
 NS 4  
 DS 4  
 SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 298.2 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SF01 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 PLW1 29.00000000 W  
 SF02 700.0098000 MHz  
 NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.00000000 W  
 PLW12 0.37231001 W  
 PLW13 0.18747000 W

F2 - Processing parameters  
 SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40



7.287  
5.824  
5.811  
3.739  
3.727  
3.647  
3.639  
3.631  
3.620  
3.493  
3.483  
3.473  
3.463  
2.516  
2.360  
2.348  
2.340  
2.329  
2.322  
2.009  
1.988  
1.976  
1.970  
1.957  
1.790  
1.783  
1.772  
1.764  
1.675  
1.663  
1.656  
1.476  
1.468  
1.459  
1.454  
1.448  
1.441  
1.173  
1.163  
1.153  
1.143  
1.070  
1.060



2.26

1.00

0.94  
0.81  
0.95


0.99  
1.20  
1.20  
1.31  
1.75  
1.47  
1.34  
3.21

Current Data Parameters  
NAME LU5258\_mono\_br  
EXPNO 2  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180521  
Time 2.50 h  
INSTRUM spect  
PROBHD zg30  
PULPROG 2151340\_0001 (   
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 32  
DW 47.600 usec  
DE 20.00 usec  
TE 303.3 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





Current Data Parameters  
NAME LU5258\_mono\_br  
EXPNO 3  
PROCNO 1


F2 - Acquisition Parameters




Date\_ 20180521  
Time 7.38 h  
INSTRUM spect  
PROBHD Z151340\_0001 ( zpg30  
PULPROG 65536  
TD 6000  
SOLVENT CDCl3  
NS 4  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 303.2 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SFO1 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.00000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



83






Current Data Parameters  
 NAME LU5045\_mono\_me4  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20180105  
 Time 18.08 h  
 INSTRUM spect  
 PROBD Z151340\_0001 ( z930  
 PULPROG 65536  
 TD CDC13  
 SOLVENT 11  
 NS 2  
 DS 10504.202 Hz  
 SWH 0.320563 Hz  
 FIDRES 3.1195135 sec  
 AQ 9  
 RG 47.600 usec  
 DW 20.00 usec  
 DE 298.2 K  
 TE 1.00000000 sec  
 D1 1  
 TD0 700.0115500 MHz  
 SFO1 1H  
 NUC1 11.00 usec  
 P1 13.00000000 W  
 PLW1

F2 - Processing parameters  
 SI 131072  
 SF 700.0070169 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



169.26

137.46  
135.83  
134.75  
129.31120.90  
116.6877.33  
77.14  
76.96

66.62

35.65

29.79

21.77  
18.62

Current Data Parameters  
NAME LU5045\_mono\_me4  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameter

Date\_ 20180105  
Time\_ 18.10 h

INSTRUM spect  
PROBHD Z151340\_0001 (

PULPROG zgpg30

TD 65536

SOLVENT CDCl3

NS 6  
DS 4  
SWH 42613.637 Hz

FIDRES 1.300465 Hz  
AQ 0.7689557 sec

RG 203  
DW 11.733 usec

DE 18.00 usec  
TE 298.2 K

D1 2.00000000 sec  
D11 0.03000000 sec

TD0 1  
SFO1 176.0362620 MHz

NUC1 13C  
P1 11.00 usec

PLW1 29.00000000 W  
SFO2 700.0098000 MHz

NUC2 1H  
CPDPRG12 waltz16

PCPD2 65.00 usec  
PLW2 13.00000000 W

PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz


WDW EM  
SSB 0

LB 1.00 Hz  
GB 0

PC 1.00

200 180 160 140 120 100 80 60 40 20 ppm

85



7.262  
6.826  
6.817

3.787  
3.776  
3.511  
3.503  
2.906  
2.896  
2.887  
2.307  
2.303  
2.298  
1.829  
1.818  
1.733  
1.524  
1.515  
1.505  
1.495  
1.441  
1.438  
1.419  
1.204  
1.194  
1.174  
1.164  
1.157



Current Data Parameters  
NAME LU5055\_mono\_Me4  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180112  
Time 9.35 h  
INSTRUM spect  
PROBHD zg30  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 25.4  
DW 47.600 usec  
DE 20.00 usec  
TE 298.2 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

0.94  
0.13

1.09  
0.11  
0.99  
0.12  
1.00  
0.96  
0.12  
0.14  
1.07  
3.21  
1.07  
1.01  
0.43  
1.12  
3.09



ppm



Current Data Parameters  
NAME LU5055\_mono\_Me4  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180112  
Time 9.40 h  
INSTRUM spect  
PROBHD Z151340\_0001 (zpg30  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 53  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 298.2 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.00000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40






Current Data Parameters  
 NAME LU4068\_PURE\_Ester\_Cl\_OX  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters


Date\_ 20180531  
 Time 19.51 h  
 INSTRUM spect  
 PROBD Z151340\_0001 (   
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 13  
 DS 2  
 SWH 10504.202 Hz  
 FIDRES 0.320563 Hz  
 AQ 3.1195135 sec  
 RG 28.5  
 DW 47.600 usec  
 DE 20.00 usec  
 TE 303.2 K  
 D1 1.00000000 sec  
 TD0 1  
 SF01 700.0115500 MHz  
 NUCL 1H  
 P1 11.00 usec  
 PLW1 13.00000000 W


F2 - Processing parameters

SI 131072  
 SF 700.0070169 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



- 9.522
- 8.059
- 8.047
- 7.735
- 7.722
- 7.262
- 6.839
- 6.829
- 6.818
- 6.807
- 6.797
- 5.810
- 5.788
- 5.279
- 5.270
- 5.260
- 5.250
- 4.181
- 4.171
- 4.161
- 4.150
- 2.341
- 2.331
- 2.322
- 2.288
- 2.278
- 2.269
- 2.259
- 2.221
- 2.211
- 2.202
- 2.192
- 1.762
- 1.753
- 1.282
- 1.272
- 1.262





165.78
158.76
144.51
135.06
133.57
132.12
129.74
123.66
77.23
77.05
76.87
60.59
34.69
28.26
20.96
14.24



Current Data Parameters  
 NAME LU4068\_PURE\_Ester\_Cl\_OX  
 EXPNO 3  
 PROCNO 1



F2 - Acquisition Parameters  
 Date\_ 20180531  
 Time 19.56 h  
 INSTRUM spect  
 PROBD Z151340\_0001 (   
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 96  
 DS 4  
 SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 303.2 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SFO1 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 PLW1 29.00000000 W  
 SFO2 700.0098000 MHz  
 NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.00000000 W  
 PLM12 0.37231001 W  
 PLM13 0.18747000 W

F2 - Processing parameters  
 SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40

200 180 160 140 120 100 80 60 40 20 ppm



7.048  
7.034  
5.861  
5.848  
4.116  
4.103  
4.065  
4.054  
4.037  
4.027  
3.699  
3.691  
3.682  
3.673  
3.665  
3.482  
3.472  
3.232  
3.220  
3.124  
2.385  
2.377  
2.366  
2.358  
2.347  
2.340  
1.694  
1.687  
1.679  
1.675  
1.667  
1.660  
1.585  
1.577  
1.571  
1.564  
1.557  
1.205  
1.188  
1.178  
1.168  
1.086  
1.076



Current Data Parameters  
NAME LU43762\_pure\_ester\_C1  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20171106  
Time 17.35 h  
INSTRUM spect  
PROBHD Z151340\_0001 (PULPROG zg30)  
TD 65536  
SOLVENT CDCl3  
NS 6  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 25.4  
DW 47.600 usec  
DE 20.00 usec  
TE 299.4 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070142 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00







Current Data Parameters  
NAME IU43762\_pure\_ester\_C1  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters

Date\_ 20171106  
Time\_ 17.37 h  
INSTRUM spect  
PROBHD Z151340\_0001 ( zppg30  
PULPROG TD zppg30  
TD 65536  
SOLVENT CDCl3  
NS 32  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 298.5 K  
D1 2.0000000 sec  
D11 0.0300000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.0000000 W  
SF02 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.0000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40









Current Data Parameters  
NAME LU4255\_Pure\_Esther\_Br\_OX  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180528  
Time 18.02 h  
INSTRUM spect  
PROBHD zg30  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 25.4  
DW 47.600 usec  
DE 20.00 usec  
TE 303.2 K  
D1 1.00000000 sec  
TDO 1  
SF01 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070140 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00






Current Data Parameters  
 NAME Lu4255\_Pure\_Estrer\_Br\_OX  
 EXPNO 3  
 PROCNO 1


# F2 - Acquisition Parameters

Date\_ 20180528  
 Time 18.06 h  
 INSTRUM spect  
 PROBHD Z151340\_0001 (PULPROG zgpg30)  
 TD 65536  
 SOLVENT CDCl3  
 NS 37  
 DS 4  
 SMH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 303.2 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SFO1 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 PLW1 29.00000000 W  
 SFO2 700.0098000 MHz  
 NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.00000000 W  
 PLW12 0.37231001 W  
 PLW13 0.18747000 W

# F2 - Processing parameters

SI 131072  
 SF 176.0169099 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40






7.261  
7.242  
7.228  
5.773  
5.770  
5.759  
5.757  
4.083  
4.073  
4.068  
4.061  
4.057  
4.048  
4.041  
4.031  
4.026  
4.020  
4.015  
3.677  
3.668  
3.660  
3.651  
3.644  
3.192  
3.180  
2.418  
2.410  
2.400  
2.392  
2.380  
2.372  
1.768  
1.761  
1.754  
1.749  
1.741  
1.734  
1.192




Current Data Parameters  
NAME LU4288\_PURE\_Ester\_Br  
EXPNO 2  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20180530  
Time 23.34 h  
INSTRUM spect  
PROBHD Z151340\_0001 ( 2930  
PULPROG zg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 28.5  
DW 47.600 usec  
DE 20.00 usec  
TE 303.2 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.011500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00





89




Current Data Parameters  
 NAME L04288\_PURE\_Ester\_Br  
 EXPNO 3  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20180530  
 Time 23.42 h  
 INSTRUM spect  
 PROBD Z151340\_0001 (zpg30)  
 PULPROG zgpg30  
 TD 65536  
 ID CDC13  
 SOLVENT NS  
 NS 140  
 DS 4  
 SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 303.2 K  
 D1 2.00000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SF01 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 PLW1 29.00000000 W  
 SFO2 700.0098000 MHz  
 NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.00000000 W  
 PLW12 0.37231001 W  
 PLW13 0.18747000 W



F2 - Processing Parameters  
 SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40



Current Data Parameters  
 NAME LU5023\_PURE\_Ester\_me51  
 EXPNO 1  
 PROCNO 1





91



F2 - Acquisition Parameters  
 Date\_ 20171212  
 Time\_ 18.07 h  
 INSTRUM spect  
 PROBHD zg30  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 12  
 DS 2  
 SWH 10504.202 Hz  
 FIDRES 0.320563 Hz  
 AQ 3.1195135 sec  
 RG 22.6  
 DW 47.600 usec  
 DE 20.00 usec  
 TE 298.2 K  
 D1 1.00000000 sec  
 TD0 1  
 SF01 700.011500 MHz  
 NUC1 1H  
 P1 11.00 usec  
 PLW1 13.00000000 W

F2 - Processing parameters  
 SI 131072  
 SF 700.0070131 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



Current Data Parameters  
NAME LU5023\_PURE\_Ester\_me51  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20171212  
Time\_ 18.13 h  
INSTRUM spect  
PROBHD Z151340\_0001 ( zpg30  
PULPROG 65536  
TD 102  
SOLVENT CDC13  
NS 4  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 298.2 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.00000000 W  
SF02 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



Current Data Parameters  
 NAME LU4292\_PURE\_2Me\_o;  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameter  
 Date\_ 20180701  
 Time 0.43 h

INSTRUM spect  
 PROBD Z566801\_0015 ( zq30  
 PULPROG

TD 65536  
 SOLVENT CDCl3  
 NS 32

DS 2  
 SWH 10504.202 Hz  
 FIDRES 0.320563 Hz  
 AQ 3.1195135 sec

RG 203  
 DW 47.600 usec  
 DE 6.50 usec  
 TE 294.3 K



D1 1.00000000 sec  
 TD0 1  
 SFO1 700.0115500 MHz  
 NUC1 <sup>1</sup>H  
 P1 12.88 usec

PLM1 40.00000000 W


F2 - Processing parameters

SI 131072  
 SF 700.0070000 MHz  
 WDW EM  
 SSB 0

LB 0.30 Hz  
 GB 0  
 PC 1.00







Current Data Parameters  
 NAME LV4292\_PURE\_2Me\_o;  
 EXPNO 3  
 PROCNO 1

F2 - Acquisition Parameter  
 Date\_ 20180701  
 Time 5.35 h

INSTRUM spect  
 PROBHD Z566801\_0015 (  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 6000  
 DS 4

SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec


RG 203  
 DW 11.733 usec  
 DE 6.50 usec  
 TE 301.4 K

D1 2.0000000 sec  
 D11 0.03000000 sec  
 TD0 1  
 SF01 176.0362620 MHz  
 NUC1 13C

P1 8.95 usec  
 PLW1 100.0000000 W  
 SF02 700.0098000 MHz

NUC2 1H  
 CPDPRG12 waltz16  
 PCPD2 65.00 usec  
 PLW2 40.0000000 W  
 PLW12 1.57060003 W  
 PLW13 0.79086000 W

F2 - Processing parameters  
 SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40



160.04  
 141.02  
 133.01  
 131.85  
 130.50  
 127.99  
 115.46  
 77.17  
 76.99  
 76.81  
 68.36  
 43.78  
 35.99  
 21.45  
 21.15




200  
180  
160  
140  
120  
100  
80  
60  
40  
20  
ppm




Current Data Parameters  
NAME LU5028\_PURE\_2me\_0  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180531  
Time\_ 9.34 h  
INSTRUM spect  
PROBHD zg30  
PULPROG 2151340\_0001 ( 65536  
TD CDC13  
SOLVENT 16  
NS 2  
DS 10504.202 Hz  
SWH 0.320563 Hz  
FIDRES 3.1195135 sec  
AQ 28.5  
RG 47.600 usec  
DW 20.00 usec  
DE 303.2 K  
TE 1.00000000 sec  
D1 1  
TD0 700.0115500 MHz  
SFO1 1H  
NUC1 11.00 usec  
P1 13.00000000 W  
PLW1

F2 - Processing parameters  
SI 131072  
SF 700.0070143 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00







Current Data Parameters  
NAME LU5028\_PURE\_2me\_0  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20180531  
Time 9.41 h

INSTRUM spect  
PROBHD Z151340\_0001 (zpg30  
PULPROG 65536  
TD CDC13  
SOLVENT 96  
NS 4  
DS 4  
SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203  
DW 11.733 usec  
DE 18.00 usec  
TE 303.2 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TDO 1  
SFO1 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PLW1 29.00000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PLW2 13.00000000 W  
PLW12 0.37231001 W  
PLW13 0.18747000 W

F2 - Processing parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40





Current Data Parameters  
 NAME LU5108\_PURE\_2ME\_RJ  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameter



Date\_ 20180623  
 Time 23.00  
 INSTRUM spect  
 PROBHD 5 mm PABBO BB-  
 PULPROG zg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 13  
 DS 2  
 SWH 8278.146 Hz  
 FIDRES 0.126314 Hz  
 AQ 3.9583745 sec  
 RG 362  
 DW 60.400 usec  
 DE 6.50 usec  
 TE 303.6 K  
 D1 1.00000000 sec  
 TD0 1

===== CHANNEL f1 =====

NUC1 1H  
 P1 14.00 usec  
 PL1 0 dB  
 PL1W 10.27361584 W  
 SFO1 400.1424710 MHz

F2 - Processing parameters

SI 32768  
 SF 400.1400068 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00



This exp uses qsim mode. it has inherent lower S/N  
The SW is 240 ppm



Current Data Parameters  
NAME LU5108\_PURE\_2ME\_RE  
EXPNO 3  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20180624  
Time 0.54  
INSTRUM spect  
PROBHD 5 mm PABBO BB-  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 2429  
DS 4  
SWH 24154.590 Hz  
FIDRES 0.368570 Hz  
AQ 1.3565952 sec  
RG 14596.5  
DW 20.700 usec  
DE 6.50 usec  
TE 303.5 K  
D1 2.70000005 sec  
D11 0.03000000 sec  
TD0 1

===== CHANNEL f1 =====  
NUC1 13C  
P1 9.00 usec  
PL1 -2.00 dB  
PL1W 46.89702606 W  
SFO1 100.6263507 MHz

===== CHANNEL f2 =====  
CPDPRG12 waltz16  
NUC2 1H  
PCPD2 90.00 usec  
PL2 0 dB  
PL12 16.16 dB  
PL13 17.00 dB  
PL12W 10.27361584 W  
PL12W 0.24872722 W  
PL13W 0.20498557 W  
SFO2 400.1416006 MHz

F2 - Processing parameters  
SI 131072  
SE 100.6152830 MHz  
WDW EM  
SSB 0  
GB 0  
PC 1.40






7.372  
7.359  
7.266  
5.885  
5.871  
4.138  
4.134  
4.128  
4.124  
4.118  
4.114  
4.108  
4.104  
3.922  
3.758  
3.748  
3.738  
3.473  
3.453  
3.122  
3.112  
3.101  
2.836  
2.060  
2.058  
2.051  
2.049  
2.042  
2.039  
1.860  
1.850  
1.839  
1.831  
1.821  
1.773  
1.767  
1.410  
1.399  
1.389  
1.261  
1.251  
1.241  
1.237  
1.226



100



Current Data Parameters  
NAME LU43761  
EXPNO 1  
PROCNO 1

F2 - Acquisition Parameters  
Date\_ 20171106  
Time 16.33 h

INSTRUM spect  
PROBHD Z151340\_0001 ( 2g30  
PULPROG zg30

TD 65536  
SOLVENT CDCl3

DS 8  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec

RG 18  
DW 47.600 usec  
DE 20.00 usec

TE 299.5 K  
D1 1.00000000 sec

TD0 1  
SFO1 700.0115500 MHz


NUC1 1H  
P1 11.00 usec

PLM1 13.00000000 W

F2 - Processing parameters  
SI 131072  
SF 700.0070137 MHz  
WDW EM

SSB 0  
LB 0.30 Hz

GB 0  
PC 1.00



Current Data Parameters  
NAME LU43761  
EXPNO 3  
PROCNO 1


F2 - Acquisition Parameters  
Date\_ 20171106  
Time 16.44 h

INSTRUM spect  
PROBHD 2151340\_0001 (PULPROG  
TD 29pg30  
65536  
SOLVENT CDC13  
NS 17  
DS 4

SWH 42613.637 Hz  
FIDRES 1.300465 Hz  
AQ 0.7689557 sec  
RG 203

DW 11.733 usec  
DE 18.00 usec  
TE 298.4 K  
D1 2.00000000 sec  
D11 0.03000000 sec  
TD0 1  
SF01 176.0362620 MHz  
NUC1 13C  
P1 11.00 usec  
PIW1 29.00000000 W  
SFO2 700.0098000 MHz  
NUC2 1H  
CPDPRG12 waltz16  
PCPD2 65.00 usec  
PIW2 13.00000000 W  
PIW12 0.37231001 W  
PIW13 0.18747000 W

F2 - Processing Parameters  
SI 131072  
SF 176.0169002 MHz  
WDW EM  
SSB 0  
LB 1.00 Hz  
GB 0  
PC 1.40



8.943  
8.393  
8.385  
8.096  
8.084  
7.812  
7.802  
7.793  
7.259  
7.258

5.382  
5.372  
5.362  
5.352  
5.267  
5.257  
5.245  
4.733  
4.723  
4.713  
4.704

2.052  
2.042  
2.032  
2.020  
2.009  
2.000  
1.990  
1.979  
1.933  
1.923  
1.913  
1.692  
1.683  
1.575  
1.566



Current Data Parameters  
NAME LU5193\_E\_OX  
EXPNO 1  
PROCNO 1



## F2 - Acquisition Parameters

Date\_ 20180607  
Time 2.52 h  
INSTRUM spect  
PROBHD 2151340\_0001 ( z930  
PULPROG 65536  
TD 15  
SOLVENT CDCl3  
NS 2  
DS 2  
SWH 10504.202 Hz  
FIDRES 0.320563 Hz  
AQ 3.1195135 sec  
RG 5.6  
DW 47.600 usec  
DE 10.00 usec  
TE 303.2 K  
D1 1.00000000 sec  
TD0 1  
SFO1 700.0115500 MHz  
NUC1 1H  
P1 11.00 usec  
PLW1 13.00000000 W


## F2 - Processing Parameters

SI 131072  
SF 700.0070169 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00

101









Current Data Parameters  
 NAME LU5193\_F\_OX  
 EXPNO 3  
 PROCNO 1



### F2 - Acquisition Parameters

Date\_ 20180607  
 Time 2.57 h  
 INSTRUM spect  
 PROBD Z151340\_0001 ( zpg30  
 PULPROG zgpg30  
 TD 65536  
 SOLVENT CDCl3  
 NS 83  
 DS 4  
 SWH 42613.637 Hz  
 FIDRES 1.300465 Hz  
 AQ 0.7689557 sec  
 RG 203  
 DW 11.733 usec  
 DE 18.00 usec  
 TE 303.2 K  
 D1 2.0000000 sec  
 D11 0.0300000 sec  
 TD0 1  
 SFO1 176.0362620 MHz  
 NUC1 13C  
 P1 11.00 usec  
 P1W1 29.0000000 W  
 SFO2 700.0098000 MHz  
 NUC2 1H  
 CPDPRG2 waltz16  
 PCPD2 65.00 usec  
 PLW2 13.0000000 W  
 PLW12 0.37231001 W  
 PLW13 0.18747000 W

### F2 - Processing parameters

SI 131072  
 SF 176.0169002 MHz  
 WDW EM  
 SSB 0  
 LB 1.00 Hz  
 GB 0  
 PC 1.40







```

NAME          LU51761_Pure_E_0
EXPNO         1
PROCNO        1
Date_         20180624
Time          2.20
INSTRUM       spect
PROBHD        5 mm PABBO BB-
PULPROG       zg30
TD            65536
SOLVENT       CDCl3
NS            13
DS            2
SWH           8278.146 Hz
FIDRES       0.126314 Hz
AQ           3.9584243 sec
RG            362
DW           60.400 usec
DE           6.50 usec
TE           303.2 K
D1           1.00000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          1H
P1           14.00 usec
PL1          0.00 dB
PL1W         10.27361584 W
SFO1         400.1424710 MHz
SI           32768
SF           400.1400068 MHz
WDW          EM
SSB           0
LB           0.30 Hz
GB           0
PC           1.00
  
```



```

NAME          LU51761_Pure_E_0
EXPNO          3
PROCNO         1
Date_         20180624
Time          9.14
INSTRUM        spect
PROBHD         5 mm PABBO BB-
PULPROG        zgpg30
TD             65536
SOLVENT        CDCl3
NS             6000
DS             4
SWH            24154.590 Hz
FIDRES        0.368570 Hz
AQ            1.3566452 sec
RG            14596.5
DW            20.700 use
DE            6.50 use
TE            303.2 K
D1            2.70000005 sec
D11           0.03000000 sec
TD0           1

===== CHANNEL f1 =====
NUC1          13C
P1            9.00 use
PL1          -2.00 dB
PL1W         46.89702606 W
SFO1         100.6263507 MHz

===== CHANNEL f2 =====
CPDPRG2       waltz16
NUC2          1H
PCPD2         90.00 use
PL2           0.00 dB
PL12         16.16 dB
PL13         17.00 dB
PL2W         10.27361584 W
PL12W        0.24872722 W
PL13W        0.20498557 W
SFO2         400.1416006 MHz
SI           131072
SF           100.6152830 MHz
WDW           EM
SSB           0
LB           3.00 Hz
GB           0
PC           1.40
  
```



Current Data Parameters  
 NAME LU5179\_oure\_Z\_ox  
 EXPNO 1  
 PROCNO 1


F2 - Acquisition Parameters  
 Date\_ 20180503  
 Time 18.19 h

INSTRUM spect  
 PROBHD Z151340\_0001 ( z930  
 PULPROG 65536  
 TD CDC13  
 SOLVENT 13  
 NS 2  
 DS 10504.202 Hz  
 SWH 0.320563 Hz  
 FIDRES 3.1195135 sec  
 AQ 18

RG 47.600 usec  
 DW 20.00 usec  
 DE 303.2 K  
 TE 1.00000000 sec  
 D1 1


TD0 700.0115500 MHz  
 SF01 1H  
 NUC1 11.00 usec  
 P1 13.00000000 W  
 PLW1

F2 - Processing parameters  
 SI 131072  
 SF 700.0070169 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00




7.438  
 7.274  
 7.261  
 7.204  
 7.196  
 7.184  
 6.993  
 6.985  
 5.544  
 5.534  
 5.519  
 5.510  
 5.500  
 5.294  
 5.277  
 5.263  
 4.118  
 4.108  
 4.099  
 4.090

1.969  
 1.960  
 1.948  
 1.907  
 1.883  
 1.873  
 1.587  
 1.577  
 1.507  
 1.497



103



200 180 160 140 120 100 80 60 40 20 ppm

170.34

134.62  
134.57  
131.89  
127.34  
126.69  
126.51  
119.26

77.22  
77.04  
76.86

66.80

36.42

22.97  
21.89

12.89



Current Data Parameters  
NAME L05179\_pure\_Z\_ox  
EXPNO 3  
PROCNO 1

F2 - Acquisition Parameters

Date\_ 20180503  
Time 18.22 h

INSTRUM spect

PROBHD Z151340\_0001 (

PULPROG zgpg30

TD 65536

SOLVENT CDCl3

NS 40

DS 4

SWH 42613.637 Hz

FIDRES 1.300465 Hz

AO 0.7689557 sec

RG 203

DW 11.733 usec

DE 18.00 usec

TE 303.2 K

D1 2.0000000 sec

D11 0.0300000 sec

TDO 1

SFO1 176.0362620 MHz

NUC1 13C

PI 11.00 usec

PLW1 29.0000000 W

SFO2 700.0098000 MHz

NUC2 1H

CPDPRG12 waltz16

PCPD2 65.00 usec

PLW2 13.0000000 W

PLW12 0.37231001 W

PLW13 0.18747000 W

F2 - Processing parameters

SI 131072

SF 176.0169002 MHz

WDW EM


SSB 0

LB 1.00 Hz


GB 0

PC 1.40

Louis sample  
<sup>1</sup>H zg30  
<sup>25</sup>C



104



Current Data Parameters  
 NAME Louis\_07022018  
 EXPNO 1  
 PROCNO 1

F2 - Acquisition Parameters  
 Date\_ 20180702  
 Time 17.34 h  
 INSTRUM spect  
 PROBHD Z161768-0001 (zg30)  
 PULPROG zg30  
 TD 32768  
 SOLVENT CDCl3  
 NS 32  
 DS 2  
 SWH 12820.513 Hz  
 FIDRES 0.782502 Hz  
 AQ 1.2779520 sec  
 RG 6.3  
 DW 39.000 usec  
 DE 10.00 usec  
 TE 298.2 K  
 D1 2.00000000 sec  
 TD0 1  
 SFO1 800.2137610 MHz  
 NUC1 <sup>1</sup>H  
 P1 7.19 usec  
 PLWL 9.6680022 W

F2 - Processing parameters  
 SI 32768  
 SF 800.2100000 MHz  
 WDW EM  
 SSB 0  
 LB 0.30 Hz  
 GB 0  
 PC 1.00

# The Crystal data of compound 87

cu\_osu41\_0m.res created by SHELXL-2014/7

```

TITL cu_osu41_0m in P2(1)/c
CELL 1.54178 6.4248 10.6067 20.8894 90.000 94.550 90.000
ZERR 4.00 0.0002 0.0003 0.0006 0.000 0.002 0.000
LATT 1
SYMM -x, y+1/2, -z+1/2
SFAC C H N O Cl
UNIT 56 72 4 12 4
L.S. 10
ACTA
BOND $H
FMAP 2
PLAN 20
EQIV $1 -x+1, y+1/2, -z+1/2
HTAB C7 O1_$1
EQIV $2 -x, y-1/2, -z+1/2
HTAB C10 O2_$2
CONF
HTAB
SIZE 0.020 0.040 0.040
TEMP -100.000
WGHT 0.064800 0.430300
FVAR 0.16073
CL1 5 0.232430 0.254902 0.442254 11.00000 0.04015 0.03346 =
0.02804 -0.00749 0.00095 -0.00095
O1 4 0.546234 0.002240 0.237209 11.00000 0.02652 0.03695 =
0.04593 -0.00731 0.01357 0.00183
O2 4 -0.067373 0.205627 0.206522 11.00000 0.03832 0.03492 =
0.03022 0.00618 0.00129 0.00959
O3 4 0.081347 0.024128 0.178154 11.00000 0.04783 0.03549 =
0.02265 0.00212 0.00212 0.00913
N1 3 0.317354 0.046685 0.373198 11.00000 0.01937 0.02449 =
0.02359 0.00043 -0.00010 -0.00030
C1 1 0.213380 0.170698 0.366949 11.00000 0.02305 0.02531 =
0.02347 -0.00319 0.00146 0.00099
C2 1 -0.012580 0.137285 0.341770 11.00000 0.02097 0.02978 =
0.02408 0.00048 0.00214 0.00374
C3 1 -0.119706 0.066302 0.394109 11.00000 0.01859 0.04282 =
0.02607 0.00034 0.00297 -0.00196
C4 1 -0.001422 -0.055019 0.413250 11.00000 0.02883 0.03562 =
0.02399 0.00392 0.00383 -0.00757
C5 1 0.234555 -0.033892 0.423911 11.00000 0.02753 0.03028 =
0.02253 0.00291 -0.00048 -0.00326
C6 1 0.355491 -0.156846 0.429415 11.00000 0.03387 0.03467 =
0.03427 0.00968 -0.00336 0.00116
C7 1 0.323289 0.251050 0.320566 11.00000 0.02398 0.02298 =
0.03265 0.00013 0.00074 -0.00288
C8 1 0.431592 0.199221 0.275925 11.00000 0.02198 0.02826 =
0.03543 0.00384 0.00534 -0.00334
C9 1 0.428854 0.060629 0.268977 11.00000 0.01850 0.02951 =
0.02760 0.00014 0.00154 0.00062
C10 1 0.263787 -0.001021 0.306948 11.00000 0.01923 0.02076 =

```

		0.02588	-0.00003	0.00051	0.00018		
C11	1	0.034603	0.047197	0.286814	11.00000	0.01873	0.02524 =
		0.02467	0.00106	0.00148	-0.00090		
C12	1	0.007619	0.104469	0.220476	11.00000	0.01890	0.03097 =
		0.02582	0.00051	-0.00037	0.00018		
C13	1	0.082967	0.066437	0.111999	11.00000	0.07931	0.05157 =
		0.02343	0.00686	0.00703	0.02118		
C14	1	0.237895	-0.011623	0.080175	11.00000	0.07601	0.06209 =
		0.03644	0.00220	0.01778	0.00900		
H2	2	-0.094570	0.212244	0.325395	11.00000	0.02576	
H3A	2	-0.129425	0.123293	0.430674	11.00000	0.03178	
H3B	2	-0.252887	0.048688	0.380051	11.00000	0.02370	
H4A	2	-0.051138	-0.090565	0.452975	11.00000	0.03571	
H4B	2	-0.032322	-0.114700	0.381345	11.00000	0.02882	
H5	2	0.265526	0.010512	0.464810	11.00000	0.02253	
H6A	2	0.318085	-0.200312	0.466930	11.00000	0.04077	
H6B	2	0.332212	-0.210518	0.391125	11.00000	0.03220	
H6C	2	0.501533	-0.141965	0.434038	11.00000	0.05303	
H7	2	0.308647	0.340351	0.325211	11.00000	0.02943	
H8	2	0.507163	0.248688	0.247729	11.00000	0.03704	
H10	2	0.271308	-0.087640	0.304171	11.00000	0.01921	
H11	2	-0.058661	-0.024372	0.285725	11.00000	0.02442	
H13A	2	-0.054998	0.061897	0.093935	11.00000	0.06948	
H13B	2	0.129278	0.149036	0.110572	11.00000	0.06971	
H14A	2	0.207135	-0.105608	0.083051	11.00000	0.08440	
H14B	2	0.244959	0.021120	0.034066	11.00000	0.08284	
H14C	2	0.371780	0.012693	0.101737	11.00000	0.07268	
HKLF 4 1 1 0 0 0 1 0 0 0 1							

REM cu\_osu41\_0m in P2(1)/c

REM R1 = 0.0371 for 2222 Fo > 4sig(Fo) and 0.0422 for all 2498 data

REM 244 parameters refined using 0 restraints

END

WGHT 0.0632 0.4528

REM Instructions for potential hydrogen bonds

HTAB C7 O1\_\$1

HTAB C10 O2\_\$2

REM Highest difference peak 0.288, deepest hole -0.200, 1-sigma level 0.047

Q1	1	0.1482	0.0245	0.2949	11.00000	0.05	0.29
Q2	1	0.0108	0.0903	0.3131	11.00000	0.05	0.27
Q3	1	0.2776	0.0034	0.3978	11.00000	0.05	0.26
Q4	1	0.2835	0.2129	0.3456	11.00000	0.05	0.25
Q5	1	0.1188	-0.0399	0.4226	11.00000	0.05	0.24
Q6	1	0.2726	0.1125	0.3742	11.00000	0.05	0.24
Q7	1	0.3359	0.0319	0.2890	11.00000	0.05	0.23
Q8	1	0.0936	0.1676	0.3603	11.00000	0.05	0.23
Q9	1	-0.0652	0.1013	0.3657	11.00000	0.05	0.22
Q10	1	0.3133	0.2192	0.2815	11.00000	0.05	0.21
Q11	1	0.4355	0.0504	0.3777	11.00000	0.05	0.20
Q12	1	0.4379	0.1299	0.2780	11.00000	0.05	0.20
Q13	1	0.0181	0.0778	0.2577	11.00000	0.05	0.19



Q14	1	0.2914	0.0232	0.3449	11.00000	0.05	0.19
Q15	1	-0.0662	0.0024	0.3976	11.00000	0.05	0.17
Q16	1	0.2113	0.2081	0.4002	11.00000	0.05	0.16
Q17	1	0.2714	0.0818	0.1012	11.00000	0.05	0.16
Q18	1	0.0075	0.1316	0.1024	11.00000	0.05	0.15
Q19	1	0.2772	-0.0985	0.4211	11.00000	0.05	0.15
Q20	1	0.2973	0.1401	0.1130	11.00000	0.05	0.15